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Summary 
Posterior uveal melanoma is the most common intraocular malignancy in adults. Metastasis occurs 
in approximately 50% of all cases, and spread is primarily to the liver. Very little is known about the 
factors that regulate uveal melanoma metastasis, and it possible that this tumour may follow Paget's 
'seed and soil' hypothesis. Identification of further indicators associated with the metastatic 
phenotype, may aid in detecting patients most at risk. Using a series of short-term cultures, this 
study aimed to further identify factors that may be involved with uveal melanoma metastasis to the 
liver. 
Detachment of cells from the primary tumour mass requires changes to adhesive and degradative 
interactions. Uveal melanomas were shown to ubiquitously express some integrins, degradative 
enzymes and inhibitors, whilst expression of others (a 1, a2, a4, and a6) are more variable, and may 
in part be related to the in vitro stimulation. Once migrated through the surrounding matrix, and 
basement membrane, migration through the endothelium is essential. Using an in vitro model of 
transendothelial invasion, results indicated that for uveal melanoma, invasion seemed to correlate 
with a wider range of prognostic indicators, than through the basement membrane alone. 
Uveal melanoma cells may disseminate widely, but primarily initiate metastatic growth at the liver 
alone. Factors associated with uveal melanomas have been reported to assist in liver targeting, and 
similarly most uveal melanomas in this study responded positively to factors secreted by cells of 
hepatic origin. Cells derived from dermal tissues nevertheless also stimulated invasion. After co-
culture of uveal melanoma cells with dermal or hepatic endothelial cells, notable changes were 
however only observed through interactions with hepatic endothelial cells, suggesting that despite 
attraction to other sites, uveal melanomas may only arrest in the liver. In particular, an increase in 
uveal melanoma a4 expression, accompanied by an increase in hepatic endothelial VCAM-1 
expression may be involved in liver targeting. 
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Chapter 1: Introduction Julia Woodward 
Introduction 
Whilst uveal melanomas are rare in occurrence, they are associated with a poor prognosis and may 
invade and metastasise rapidly, characteristically forming secondary tumours in the liver. This 
feature raises a fundamental question of why tumour cells arrest within the vasculature of specific 
organs. This process of tumour seeding is known to involve changes to the mechanism by which 
primary tumour cells break free of their connective tissue, how they migrate into adjacent vasculature, 
and then how they adhere and invade into organs that support formation of secondary metastasis. 
Identifying the molecules essential to uveal melanoma metastasis will underpin the development of 
improved therapy, targeted at the processes involved in tumour spread. 
Cancer as a cellular disease 
"Every cell is born from another cell" 
Virchow 
Deaths from infectious diseases, such as Small Pox, Influenza and Tuberculosis have declined in the 
last century due to great advances in treatment and prevention of these diseases. Today, malignant 
neoplasms may develop in 25% of the population (reviewed by Underwood, 2000). One of the 
definitions used in the Collins English Dictionary, illustrates cancer as 'an evil influence that spreads 
dangerously', however, despite progress in diagnosis and treatment, many factors important in the 
development of cancers still remain to be discovered. 
Pictorial and written evidence from early civilisations document the effects of cancer, often attributing 
the cause to various gods. In 400BC, Hippocrates first associated the origin of the disease with 
natural causes and described cancer as an imbalance of bodily fluids. Further historical evidence 
was provided by the Greek physician Galen, who first identified breast cancer, observing swollen 
pincer-like outgrowths surrounding the cancer in its later stages, that seized upon adjacent tissue 
(reviewed by Hecht, 1987). This observation ultimately led to the current terminology, where the 
word cancer is derived from the Greek word Karinos related to carcinoma and from the Latin word for 
crab. Sir Percival Pott made one of the most notable observations in 1775, noticing that young men, 
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who had been chimney sweeps in their teenage years, had a high rate of death due to cancer of the 
scrotum (reviewed by Caiman and Paul, 1978). Pott further identified a putative carcinogen, 
observing that the disease may develop years after exposure to such an agent. Later in the 
nineteenth century, with the development of the microscope, cancer was further recognised as a 
cellular disease. More recently, over the past decades research including aspects such as 
biochemistry, genetics, molecular and cellular biology and immunology has sought a greater 
understanding of the processes controlling normal and malignant cellular growth, and collectively, 
rapid progress has been made towards identifying and understanding the underlying mechanisms. 
In normal tissue, homeostasis requires careful regulation of the rates of cell prOliferation and death. 
For a cell to become neoplastic, through an accumulation of mutations in specific genes, the cell 
reproduces uncontrollably, in defiance of the normal restraints and may further invade and colonise 
tissues away from the site of origin (reviewed by Underwood, 2000). The number of mutations and 
specific genes involved further determines the degree of progression. In broad terms, two classes of 
genes are involved: proto-oncogenes and tumour suppressor genes (reviewed by Underwood, 2000). 
Under normal circumstances, these genes are involved in regulating cell proliferation, aging and 
death, differentiation, behaviour, and integrity of the genome but when mutations arise dysfunction 
may result. 
If neoplastic cells remain clustered as a single mass, and only grow locally without invasion of the 
basement membrane, the tumour is known as 'benign' and through surgical removal, no detrimental 
effect may result (reviewed by Underwood, 2000). However, if tumour cells divide uncontrollably, 
growing into and destroying the surrounding tissue, the tumour is known as 'malignant' and may be 
fatal for the patient (reviewed by Underwood, 2000). Invasion of tumours cells into the lymphatic 
system or blood stream allows transport around the body to distant sites, and potentially further 
proliferation in tissues normally reserved for other cells (reviewed by Underwood, 2000). With regard 
to patient survival, one of the most important features of malignancy is this acquisition of a migratory 
and invasive phenotype, causing the tumour to become harder to eradicate (reviewed by Underwood, 
2000). This process is known as 'metastasis' and for uveal melanoma, will be the major focus of this 
investigation. 
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A. Tumour Invasion and Metastasis 
Despite unprecedented advances in tumour therapy, the main cause of treatment failure and death 
from cancer is metastasis (reviewed by Sugarbaker and Ketcham, 1977; reviewed by Underwood, 
2000). Metastasis can be simplified as the detachment of malignant cells from the primary tumour 
mass, followed by dissemination and establishment at a distant site. In a more detailed description 
by Marshall and Hart (1996), the process was described as 'altered cell growth associated with a 
series of adhesion and de-adhesion events which are coupled with regulated tissue degradation'. 
During the progression of the disease, tumour cells undergo a series of changes and may acquire a 
permanent, irreversible, and malignant phenotype. Early work in this field using the 816 cutaneous 
melanoma cell line identified a propensity of specific clones to form colonies in the lung, concluding 
that cells with a highly metastatic potential exist within primary tumours (Fidler, 1973; Fidler and 
Kripe, 1977). With time, it has become evident that the metastatic process is selective for sub-
populations of cells within a heterogeneous malignant neoplasm, and is not a random process (Fidler 
and Hart, 1982). 
For a tumour to establish secondary colonies, metastatic clones must undergo a complex sequence 
of interrelated steps, with each potentially being both dependent on the host responses and intrinsic 
properties of the tumour cell (Fidler and Hart, 1982). Figure 1.a illustrates these sequential steps. 
Each stage will be discussed in further detail in the proceeding sections (1.1-1.6). Due to the hostility 
of these processes, only a very small number of circulating tumour cells initiate metastatic colonies 
(Fidler, 1970). 
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Figure 1.a. Schematic diagram of metastatic spread (normal tissue is represented by the light 
blue areas; tumour cells are shown in ; basement membrane is shown in green; normal 
cells are shown in and endothelial cells are shown in ). Tumour cells from the primary 
tumour mass have been illustrated migrating and invading through the ECM, the basement membrane, and 
the endothelial cell wall. Cells then circulate in the blood stream before under-going to reverse process at the 
secondary site . Metastatic tumour cells further proliferate to form metastases. 
Theories of metastasis 
Tumour cells often appear to exhibit a degree of site-specific metastasis, disseminating to preferred 
organs (e.g. Auerbach, 1988; Muller et al., 2001). Despite spread being facil itated commonly via 
haematogenous, lymphatic or transcoelomic routes , particular organs are frequently involved in 
metastatic growth, relating to the tumour type (e.g. Hart and Fidler, 1980; Muller et al., 2001). In 
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1889, Paget proposed the 'seed and soil' hypothesis after it was observed that certain organs, such 
as the heart, skin and skeletal muscles, despite ample blood flow, are rarely sites of metastases 
(Paget, 1889). This explanation suggested that for each primary tumour there is a colonisation 
pattern determined by the conditions in the endothelium of the microvasculature and the functional 
environment of the target organ. The validity of this concept is becoming increasingly evident. 
Tumour cells are potentially likely to act as 'seeds', expressing particular determinants required for 
specific metastatic progression seen in many cancers. The target organ, or 'soil', may attract 
circulating tumour cells through secreted factors, express necessary receptors required for tumour 
cell attachment, and once cells have established themselves in the secondary environment, promote 
metastatic growth. 
Early advances were made when it was observed that 816 melanoma cells show specific patterns of 
metastatic spread to the pulmonary and ovarian tissue, but not to the renal tissue or at the site of 
surgical stress (Hart and Fidler, 1980). In a later study, different sub-populations of cells from two 
melanoma cell lines and a fibrosarcoma cell line were injected into the internal carotid artery of mice, 
metastases from the different melanoma cell lines formed in either the brain parenchyma or the 
meninges and ventricles (Schackert and Fidler, 1988). In contrast, fibrosarcoma cells were able to 
form lesions throughout the brain and it was concluded that the microenvironment in which the 
tumour cells arrest also appeared to play a significant role in the growth of secondary lesions. 
Further research identified that the surroundings of the secondary organ can also dictate other 
phenotypic effects on metastases (Horak et al., 1986; Nicholson, 1986). For example, amelanotic 
melanoma cell lines can produce melanotic brain metastases in syngeneic mice (Radinsky et al., 
1995). The authors of this study concluded that the microenvironment of the brain might be inducing 
melanocyte-stimulating hormone receptor (MSH-R) expression on the melanoma cells, allowing cells 
to become receptive to the effects of alpha-MSH, and stimulating amongst other effects, cell 
proliferation and melanin production. 
In 1928, a second opposing theory for metastasis was proposed, known as the 'mechanical 
entrapment' theory (Ewing, 1928). This hypothesis suggested that tumour cells arrest in the first 
capillary bed visited in the passage away from the tumour. The first organ therefore encountered by 
circulating venous blood (the lungs) has a high incidence of secondary tumour growth. This premise 
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would seem feasible, as tumour cells are often large in size and consequently, as diameters of the 
tumour cells will often be greater than those of the capillaries, entrapment may result. This theory is 
supported by recent evidence in which using intravital microscopy, colon adenocarcinoma cells were 
shown to arrest in the liver microcirculation, physically lodging in the narrow entrance of the sinusoid 
(Ding et al., 2001). Similar results were however not seen with lymphoma cells, which showed a 
more specific pattern of metastasis, suggesting that simple entrapment is not necessarily the only 
explanation. Pre-treatment of mice with IL-1a has also been shown to facilitate arrest of 816F1 
melanoma cells at the presinusoidal portal vein branches (Scherbarth and Orr, 1997). Without IL-1a 
treatment, melanoma cells adhered at a different site on the sinusoidal endothelium, implicating an 
effect of IL-1a on the site of attachment. 
It is now thought that these theories are not mutually exclusive and each may be partially correct; 
ultimately non-random distribution of metastases may be dependent upon the tumour phenotype 
(Ding at al., 2001). Key dissemination sites are primarily dictated by anatomical conditions but 'seed 
and soil' factors of the site play an important part also. Some tumours disseminate widely and the 
first capillary bed encountered by the circulating tumour cells will be the most common site for 
metastatic growth. Other tumours are far more selective and metastatic growth will only result in 
particular organs, often by-passing several more proximal organs. Both mechanisms nevertheless 
vary with the site of the primary tumour, stage of disease and the metastatic potential of the 
neoplasm under study, and tumour cells circulating in the blood may not inevitably result in metastatic 
growth. There is also recent evidence to suggest that other factors additionally influence metastasis, 
including the time taken for the tumour cells to reach and attach at the site of extravasation (Paku et 
al., 2001) whilst other reports suggest that tumour emboli are more successful at generating 
metastases than single cells (AI-Mehdi et al., 2001). 
1.1. Changes in tumour cell adhesion and cohesion 
For successful invasion, tumour cells must undergo a series of adhesion and de-adhesion steps, to 
facilitate detachment from the primary tumour mass, and penetration through the extra cellular matrix 
(ECM), basement membrane and endothelial cell layer at both the primary and secondary sites 
(Figures 1.i and 1.3.i) (reviewed by Orr at al., 2000). During migration through the ECM, the leading 
edge of the cell adheres to new substrates, requiring altered cell adhesion molecule expression, 
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guiding the cells, and providing the necessary traction required to pull the cell forward. The trailing 
edge of the cell retracts from the matrix proteins, involving dissociation of cell adhesion molecules 
from their ligands. Such external movements are all regulated by internal signals. Cell adhesion 
molecules facilitating these interactions include the integrin family, the selectin family, the 
immunoglobulin (Ig) family and the cadherin family, affecting processes including cell activation, 
proliferation and apoptosis. To enable a potentially metastatic tumour cell to escape from the 
confines of primary tumour mass, the adhesion molecule profile of the cell must suitably alter to allow 
both escape from the confines of the primary tumour, whilst also promoting attachment to the 
surrounding stroma. Typically cadherin molecules, facilitating homophilic cell-cell interactions, are 
involved in these initial stages allowing escape of the tumour cells from the primary site, with loss of 
E-cadherin expression often being correlated with the metastatic phenotype of many epithelial 
tumours (Sommers et al., 1991; Murant et al., 1997). In contrast however, N-cadherin molecules 
may be involved in hetereotypic interactions with cells including both fibroblasts and endothelial cells 
(Sandig et al., 1997; Voura et al., 1998b; Li et al., 2001). Once detached from the primary tumour 
mass, tumour cells must then attach to, and degrade the host ECM and basement membrane before 
adhering to and migrating through, the local endothelium. Tumour cell attachment to the endothelium 
at another site may be further assisted by adhesion molecules that may either be constitutively 
expressed by the target endothelium, expressed in response to tumour and host cell stimuli, or may 
be organ-specific (reviewed by Orr et al., 2000; e.g. Vidal-Vanaclocha et al., 2000; Abdel-Ghany et 
al.,2001). 
Integrins 
The integrin family of adhesion molecules primarily facilitates tumour cell migration and invasion 
through the ECM and basement membrane. In common with inflammatory responses, attachment to 
the endothelium and transendothelial migration may also utilise these receptors, in conjunction with 
other families of adhesion molecules. Integrins form a family of transmembrane cell-cell and cell-
matrix adhesion molecules (reviewed by Hynes, 1987). To date, at least 25 members of the family 
have been identified (reviewed by Humphries, 2000). Each is a heterodimeric complex of an 0.- and 
p-subunit, requiring divalent cation binding for activation (reviewed by Hynes, 1987). In mammals, 
19 a.-chains (120-180kD) and eight p-chains (90-110kD) are to date, known to exist (reviewed by 
Humphries, 2000). Theoretically, numerous permutations could exist, but only certain structures are 
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possible as many a-chains can only associate with particular l3-chains. Classification is based 
accordingly upon the l3-subunits and both chains are required for interaction with the cellular 
cytoskeleton and ECM. Upon binding, the carboxyl-terminal of the l3-chain binds a variety of intra-
cellular complexes, initiating a cascade of responses (e.g. Burridge et a/., 1992; Schaller et a/., 1992). 
During attachment of leucocytes and tumour cells to the endothelium, once cells have initially docked 
(and in some case, rolled) on the endothelium, integrins have also been shown to be responsible for 
tight interactions prior to extravasation and are involved in the transendothelial migration process 
(e.g. Wagner et a/., 1996; Price et a/., 1996). 
Individual integrins will often bind more than one ligand (reviewed by Hynes, 1987). Each ECM 
component potentially is recognised by more than one receptor. Of particular importance in cell-
matrix binding are the 131- and 133- subfamilies; the former are generally involved in adhesion to 
connective tissue macromolecules such as fibronectin, lam in in, and collagen, whereas 133-integrins 
bind vascular ligands such as fibrinogen, von Willebrands factor (Factor VIII), thromospondin, and 
vitronectin (reviewed by Hynes, 1992). In addition, ligand binding is often via particular consensus 
sequences. For example, the first and most common sequence to be elucidated was the Arg-Gly-
Asp (RGD) sequence present in fibrinogen, vitronectin, and other adhesive proteins (Humphries, 
1990). 
Differences in integrin expression between normal and malignant tissue have been well documented 
for many cancers. Loss of laminin and collagen receptors have commonly been reported in lung, 
breast, colon, and pancreatic cancer, suggesting detachment and escape from the basement 
membrane, which is composed principally of these components (e.g. Hall et al., 1991; Koukoulis et 
al., 1991; Pignatelli et al., 1990). Increased expression of these and other integrins has nevertheless, 
also been reported during the metastatic process, allowing adhesion, during migration, to substrates 
not previously encountered, including up-regulation of av133 expression during melanoma 
progression (Albeda et a/., 1990; Voura et a/., 2001b). 
Selectins 
Initial 'loose' interactions of tumour cells to the endothelium are commonly mediated by selectins, 
before firm adhesive interactions are established (Chen et a/., 1997). The selectins are a small family 
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of intercellular adhesion molecules with three members: E-, P- and L-selectin and are differentially 
expressed by endothelial cells and leucocytes (reviewed by Brown, 1997). Of particular importance 
in invasion and metastasis is E-selectin, being transiently expressed on endothelial cells following 
stimulation by inflammatory cytokines such as IL-1, TNFa or bacterial endotoxins (e.g. Ye et al., 
1995; Moss et al., 2000). Much evidence exists implicating a role for E-selectin in neutrophil, 
monocyte, and T lymphocyte rolling during inflammatory responses, faCilitating initial weak 
interactions with the endothelium (reviewed by Springer, 1994). Upon endothelial cell stimulation, E-
selectin is synthesized de novo and translocated to the cell surface, with levels peaking one to four 
hours after the initial stimulus (Ye et al., 1995). 
Ligands for selectins are generally sialylated, glycosylated, or sulphated glycans on glycoproteins, 
glycolipids, or proteoglycans, such as sialyl Lewis X (sLSX) and sialyl Lewis A (sLea). These ligands 
have been identified on leucocytes and a number of tumour cells. For example, colorectal tumour 
cell expression of sLsx has been correlated with increased metastasis to the liver and such tumour 
cells have been shown to adhere to liver sinsusoidal cells via an E-selectin-glycosylated mucin 
interaction (Hoff et aI, 1989; Bresalier et al., 1998). 
Immunoglobulin (Ig) superfamily 
Another family of adhesion molecules implicated in a number of processes of the metastatic cascade 
is the immunoglobulin (Ig) superfamily. The Ig family is the largest group of adhesion molecules, and 
members include the intercellular adhesion molecules (ICAMs), vascular-cell adhesion molecules 
(VCAMs), platelet-endothelial-cell adhesion molecule (PECAM-1), and neural-cell adhesion molecule 
(NCAM). Typically, ligands of this family include ECM components, integrins and other Ig 
superfamily members and interactions may facilitate amongst other functions, flattening of leucocytes 
onto the blood vessel wall prior to extravasation (reviewed by Brown, 1997). Many members may be 
involved in metastatic progression, but ICAM and VCAM are of notable interest with respect to 
tumour and endothelial cell interactions (e.g. Tamaki et al., 1995; Vidal-Vanaclocha et al., 2000). 
ICAM-1 is widely expressed by many cell types and soluble ICAM-1, secreted by both tumour and 
endothelial cells has been implicated in tumour cell evasion of the host immune responses (Fonsatti 
et al., 1999; Zhang and Adachi, 1999). Under normal conditions, resting endothelial cells express 
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low levels of both ICAM-1 and VCAM-1 but expression is increased upon stimulation by inflammatory 
cytokines such as IL-1, IFN-y and TNF-a (reviewed by Meyer and Hart, 1998; e.g. Vidal-Vanaclocha 
et al., 2000). In addition to the association of ICAM and VCAM with metastasis, the involvement of 
endothelial PECAM-1 has also been suggested, binding to av133 (Buckley et al., 1996). Recent 
reports have however indicated a redistribution of this molecule away from the endothelial junction 
during transendothelial cell migration, and thus its precise relevance in invasion remains unclear 
(Voura et al., 2001a). 
1.2. Release of proteolytic enzymes and invasion of local host stroma 
Surrounding all cells is a complex network of a variety of proteins and polysaccharides, secreted 
locally, primarily by fibroblasts, and assembled into an organised meshwork known as the ECM 
(Eyre, 1980; Kleinman et al., 1981; Hay, 1982; Hedman et al., 1982). The basement membrane is a 
similar structure, residing at the interface between the epithelial or endothelial layer and connective 
tissue (Kleinman et al., 1986). For a potentially metastatic tumour cell to invade through the 
surrounding matrix and basement membrane, degradation of the individual components is essential. 
The ligands for many adhesion molecules include ECM and basement membrane proteins, either 
native to the host, or subsequently produced as a result of tumour cell invasion. 
Under normal conditions there is a highly regulated balance between synthesis and degradation of 
the ECM and basement membrane. Net degradation is required for a number of physiological and 
pathological processes, such as tumour cell invasion, leucocyte migration in response to injury or 
infection, and embryogenesis (reviewed by Nagase and Woessner, 1999). For tumour cell migration 
and invasion, degradation of ECM and basement membrane at both the primary and secondary sites 
is therefore imperative. Interactions between tumour and host cells induce the release of proteolytic 
enzymes by both cell groups, facilitating ECM breakdown (e.g. Kataoka et al., 1993; Noel et al., 
1994). The involvement of three families of proteases has been identified in tumour invasion: 
metallo-, seryl- and cysteine-proteases. Of these classes, metalloproteinases and plasminogen 
activators (seryl-proteases) have been most widely implicated in tumour invasion (e.g. Monteagudo 
et al., 1990). ECM breakdown is focused at the invasive front, confining the enzyme cascade to the 
invading pseudopodia ('invadopodia'), and by chemotaxis, migration of the tumour cell will be 
directed through the modified matrix. Much of the degradation initiated at the invasive front, is further 
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orchestrated by the host cells and not the tumour mass (Poulsom et al., 1993; Wolf et al., 1993). 
This process is repeated until the vessel wall may be intravasated and the direction of tumour cell 
migration and invasion will be determined by both locally produced chemoattractants and the 
preferred adhesion pathway (reviewed by Varner and Cheresh, 1996). Proteolytic degradation itself 
can also enhance the process by creating fragments which act as chemoattractants, whilst also 
exposing adhesion binding sites enabling cellular attachment (reviewed by Liotta and Kohn, 2001). 
Extra Cellular Matrix (ECM) composition 
Two main classes of ECM macromolecules exist, which interact to form the network surrounding all 
cells (Eyre, 1980; Kleinman et al., 1981; Hay, 1982). The first group comprises of polysaccharide 
chains, known as glycosaminoglycans, which are often covalently linked to proteins, forming 
proteoglycans. Glycosaminoglycans form hydrated gels within the extra cellular space; 
proteoglycans may also been found on the cell surface as cellular receptors for, for example, cell-
matrix and growth factor binding (reviewed by Alberts et al., 1994). The second group includes 
fibrous and structural proteins, such as collagen and elastin, and adhesive proteins, such as 
fibronectin and laminin. Fibrous proteins are embedded in the hydrated gel-like substance formed by 
the glycosaminoglycans (Eyre, 1980; Kleinman et al., 1981; Hay, 1982). Due to the hydrated state of 
the ECM, diffusion of a variety of substances including nutrients and hormones is facilitated between 
the blood and tissues. Collagen fibres give tissue an extent of tensile strength, whereas elastin fibres 
give a degree of elasticity (Eyre, 1980). Fibronectin enhances the attachment of fibroblasts and other 
cells to the ECM, whereas laminin promotes adhesion of epithelial cells to the basement membrane 
(Hay, 1982; reviewed by Alberts et al., 1994). 
Basement membrane composition 
Both the epithelial and endothelial cell layers are separated from the underlying stroma by basement 
membranes (reviewed by Yurchenco and Schittny, 1990). The basement membrane is secreted and 
assembled largely by the cells that rest on it. The composition can vary between different tissue 
types (Kleinman et al., 1986), and from the ECM and in particular the presence of type IV collagen is 
specific to basement membranes, having a more flexible structure than fibrillar collagens. Other 
components of the basement membrane, such as heparan sulphate proteoglycans, entactin and 
laminin, bind to type IV collagen (Timpl et al., 1979; Durkin et al., 1988). These components 
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co"ectively provide a selective barrier for the movement of specific cells, and in damaged tissue 
provide a structure along which regenerating cells can migrate. 
1.2.1. Matrix Metalloproteinases (MMPs) 
The involvement of MMPs in ECM and basement membrane breakdown has been widely implicated 
in metastasis. MMPs are a family of extra ce"ular endopeptidases, with a physiologica"y optimum 
pH, and are dependent upon the Zn2+ ion for activity (Van Wart and Birkedal-Hansen, 1990; reviewed 
by Nagase and Woessner, 1999). Together, the MMP family (including co"agenases, gelatinases, 
stromelysins and membrane-type MMPs [MT-MMPs)) is capable of degrading most of the ECM 
proteins, successfully disrupting the structural integrity of the connective tissue and consequently 
allowing ce"ular motility through the surrounding stroma. Each member is secreted as a pro-enzyme 
and possesses a conserved sequence in a pro-domain, maintaining latency (Van Wart and Birkedal-
Hansen, 1990). Regulation of these enzymes is controlled by a number of factors including 
transcriptional control by growth factors, inflammatory cytokines and oncogenes, post-translational 
control by activation from the latent form and inhibition by endogenous inhibitors known as tissue 
inhibitors of metalloproteinases (TIMPs) (Werb et al., 1977; Murphy et al., 1989; reviewed by Gomez 
et al., 1997). While most of the MMPs are secreted in a soluble form, MT-MMPs remain bound to the 
cell membrane and these enzymes have been shown to be involved in pro-MMP activation (Sato et 
al., 1994; Hofmann et al., 2000c). 
As described previously, MMP expression is not restricted to tumour cells. Stromal cell expression 
(fibroblasts, inflammatory cells and endothelial cells) of these enzymes is becoming increasingly 
evident (e.g. Poulsom et al., 1993; Wolf et al., 1993; Ito et al., 1995). The precise mechanism by 
which tumour cells activate stromal cell expression is still unclear, but the involvement of direct cell 
contact and the secretion of tumour cell soluble factors have been described (Hofmann et al., 2000b). 
For example, infiltrating endothelial and inflammatory cells produce MMP-2 and MMP-9, aiding both 
tumour and endothelial cell migration (Heppner et al., 1996). MMP-12 expression has also been 
detected in infiltrating macrophages, possibly due to an inflammatory response to the tumour 
(Heppner et al., 1996). Tumour cells may further be responsible for activating secreted stromal cell 
proenzymes. For example, in breast carcinoma, fibroblasts have been shown to express a range of 
MMPs, including MMP-1, -2, -3, -11 and a MT -MMP family member, assisting tumour cell migration 
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(Heppner et al., 1996). MT-MMP mRNA has been identified in fibroblasts, yet the protein is localised 
at the invasive front of the tumour cell, focusing stromal gelatinase A activation by MT-MMP to the 
tumour cell invadopodia (Heppner et al., 1996; Nakahara et al., 1997). 
There is now much evidence implicating increased MMP expression with more advanced stages of 
the disease. For example, in vitro cell lines established from advanced melanomas are almost all 
positive for MMP-9 expression, whereas cell lines derived from early, non-invasive melanomas are 
invariably MMP-9 negative (MacDougall et al., 1995). In vivo, in breast carcinoma and cutaneous 
melanoma, MMP-2 activation rather than expression, has been correlated with disease progression, 
as activation may be localised to the invading pseudopodia of the tumour cells (Azzam et al., 1993; 
Heppner et al., 1996; Nakahara et al., 1997). 
1.2.2. Tissue Inhibitors of Metalloproteinases (TIMPs) 
Endogenous inhibition of MMPs resides at the level of TIMPs; a net loss in TIMP activity may result in 
enhanced MMP activity (Hicks et al., 1984; Tananka et al., 1995). To date, four members of the 
family have been identified and each interacts with their appropriate proenzyme at the region flanking 
the substrate-binding site, blocking activity (e.g. Golberg et al., 1989; Goldberg et al., 1992; reviewed 
by Gomez et al., 1997). TlMP-1 preferentially forms a 1:1 complex with activated MMP-1 and -3 and 
with both pro- and active forms of MMP-9; interaction with latent forms of the enzyme prevents 
proenzyme cleavage whereas interaction with the active form causes protease inhibition (Goldberg et 
al., 1992). TIMP-2 forms a 1:1 complex with both latent and active forms of MMP-2, but also has an 
inhibitory effect against other MMP family members (Butler et al., 1998). These proteins may be 
secreted in an unbound form or complexed to pro-MMP-2 (Goldberg et a/., 1989). Unlike other 
TIMPs, TIMP-3 remains insoluble after secretion, remaining in the stroma and binding to ECM 
components (Leco et al., 1994). TIMP-4 has been most recently isolated and has been found to 
inhibit both invasion and metastasis in breast carcinoma cells (Wang et al., 1997). TIMP expression 
may further be regulated by a number of factors including IL-1 B, TGF-B and EGF (e.g. Ganser et al., 
1991; Overall et al., 1991; reviewed by Gomez et al., 1997). 
Conflicting evidence exists regarding TIMP involvement in the metastatic process and their actions 
often seem paradoxical. TIMP-2 over-expression in metastatic melanoma cells has been seen to 
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decrease invasion, whilst also inhibiting endothelial cell migration (Valente at al., 1998). Conversely, 
in breast carcinoma, TIMP-1 expression has been associated with shortened survival (Ree et al., 
1997), whilst in colon carcinoma, increased TIMP-1 expression has been correlated with tumour 
progression (Hewitt et al., 2000). In malignant melanomas, over-expression of MMP-1 and MMP-3 
has also been shown to be accompanied by an over-expression of TIMP-1 and TIMP-3, again 
inferring a dual function of these regulators in metastasis (Airola et al., 1999). In addition, TIMP-1 
and TIMP-2 have shown to also exhibit growth factor-like functions, and inhibit angiogenesis (Bertaux 
et al., 1991). 
1.2.3. Plasminogen Activators (PAs) and their Inhibitors 
In addition to MMPs, plasminogen activators (PAs) have been shown to playa vital role in the 
metastasis of a number of tumours. These enzymes are responsible for breakdown of plasminogen 
into plasmin. Once in this form, plasmin degrades fibrin clots, activates MMPs and elastases and 
degrades other ECM proteins, such as laminin and fibronectin (e.g. Werb et al., 1977; reviewed by 
Andreasen et al., 2000). Two types of PA have been identified; urokinase PA (u-PA) and tissue-type 
PA (t-PA). Degradation of the ECM has commonly involved u-PA, whilst the action of t-PA has been 
associated with thrombolysis (reviewed by Andreasen at al., 1997). Stationary cells express a 
receptor for both the pro- and active form of u-PA at focal contacts; when stimulated to migrate, 
expression of the u-PA receptor, u-PAR is focused primarily at the leading invasive edge, targeting u-
PA activity to this region (Carriero et al., 1994). u-PAR also binds vitronectin and interacts laterally 
with several ~-chains, coordinating the focus of u-PA activity and paradoxically promotes cell 
adhesion to this substrate (reviewed by Andreasen at al., 2000). Whilst bound, u-PA activates cell-
associated plasminogen, initiating the proteolytic cascade required for local degradation, degrading 
surrounding proteins and also catalysing the conversion of some MMPs from the pro- to the active 
form. Expression of u-PA has consequently been commonly associated with cell invasion and 
metastasis (e.g. Pyke at al., 1991; Bajou et al., 1998). 
To date, four endogenous inhibitors of PAs have been identified, PA inhibitors (PAls)-1, -2 and -3, 
and protease nexin 1 regulating PA activation (reviewed by Meyer and Hart, 1998). Both tumour and 
endothelial cells express high levels of PAI-1, which appears to be a necessity for optimising tumour 
cell invasion; absence of host PAI-1 expression has been shown to inhibit tumour cell invasion and 
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vascularisation (Bajou et al., 1998). PAI-1 has also been shown to bind vitronectin, thus preventing 
u-PAR-expressing cellular adhesion, whilst aiding tumour cell detachment and increasing tumour cell 
invasion (Kanse et al., 1996; Deng et al., 1996). In addition, PAI-1 disrupts u-PAR-vitronectin 
binding, again promoting cell detachment and increasing migration (Kanse et al., 1996; Deng et al., 
1996). It is therefore not surprising that concurrent increases in u-PAR and PAI-1 expression have 
been reported (Liu et al., 1995). 
1.3. Tumour cell dissemination 
Once migrated through the ECM and the basement membrane, tumour cells must further migrate 
through the vessel wall, facilitating dissemination. In order to successfully establish secondary 
colonies, transendothelial cell migration or invasion, must be undergone at both the primary 
(intravasation) and secondary sites (extravasation). These two processes share common features, 
and thus when describing extravasation in this section, a similar (but reverse) process may be 
undergone during intravasation. When considering the former, this process also bears many 
similarities with leucocyte transendothelial migration during inflammatory responses (Voura et al., 
1998a and b). In addition, dissemination is also aided by the process of angiogenesis, which is 
commonly associated with malignant tumour progression, supporting growth of the tumour by 
establishing a blood supply (Folkman et al., 1989). 
1.3.1. Transendothelial cell migration 
Figure 1.3.1.a illustrates the process of extravasation of a tumour cell at the secondary site. Once 
strong adhesive interactions have been made with endothelial cell, tumour cell migration through the 
endothelium is facilitated. 
In common with metastasis, during an inflammatory response, leucocytes must successfully navigate 
the endothelial cell barrier to affect the required response at the site of inflammation (Muller, 1995). 
As with leucocytes, tumour cells may form a series of adhesive interactions with the endothelium 
prior to extravasation (Voura et al., 1998a). For leucocytes, initial contact with the vessel wall is in 
part a random event, perhaps enhanced by local changes in flow characteristics; loose interactions 
are formed mediated by selectins, integrins and CD44 expressed on the leucocyte surface, allowing 
'rolling' along the endothelium (reviewed by Springer, 1994; Degrendele et al., 1996; Chen et al., 
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1997}. These interactions, together with soluble chemoattractants associated with the endothelium 
or the local tissue, trigger the up-regulation of specific leucocyte integrins and induce conformational 
changes in integrin heterodimers, resulting in greater affinity with the vasculature (reviewed by 
Springer, 1994; e.g. Simon et al., 1995; Tsang et al., 1997). Once adhered to the luminal side of the 
endothelium, it only takes a few minutes to reach the sub-endothelial basement membrane. 
Adherent leucocytes initially move towards endothelial cell junctions, followed by diapedesis between 
endothelial cells and finally migration through the sub-endothelial matrix potentially aided by specific 
chemoattractants (Tsang et al., 1997). To date, there is no direct evidence to suggest that 
leucocytes utilise degradative enzymes to migrate, but instead pass along predefined lines of 
weakness between capillary endothelium. 
In contrast, unlike leucocyte migration, the time taken for the extravasation of tumour cells is much 
greater (Voura et al., 1998a). The precise mechanisms by which tumour cells migrate through 
normal vascular endothelium remain unclear, but evidence has suggested that tumour cells penetrate 
the endothelial junction (Voura et al., 1998a and 1998b). In vivo studies have also concluded that the 
time taken for these processes and the mechanisms may further vary between tumour cell types and 
the site of extravasation (Paku et al., 2001). In vitro studies of cutaneous melanoma adhesion to the 
endothelium have identified specific cellular changes occurring in both cell types (Voura et al., 1998a 
and 1998b). In these studies, after initial adhesion melanoma cells were seen to bleb on the 
basolateral surfaces, whilst endothelial cells showed an abundance of microfilaments at contact 
regions. In response, adhesion molecules at endothelial cell junctions redistributed, causing local 
dissolution, allowing melanoma cell pseudopodia to penetrate the endothelial cell layer. Attachment 
of melanoma cells to the underlying matrix facilitated spreading, prior to endothelial cell processes 
reforming the endothelial junction. Interestingly in these studies, unlike leucocytes and other tumour 
cell types, melanoma cells were not seen to roll along the endothelium after initial attachment. More 
recently, as described previously, these authors have also reported a redistribution of PECAM-1 
away from the endothelial junctions during melanoma cell transendothelial cell migration and a vital 
role for melanoma N-cadherin and aVf33 expression during this process (Sandig et al., 1997; Voura 
et al., 1998b; Voura et al., 2001a and b). 
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Tumour cell extravasation potentially also requires endothelial retraction to enable the larger cells to 
migrate through (Voura et al., 1998a). This again differs from leucocyte extravasation, in which cells 
extravasate without much disruption to the endothelial layer due to their smaller size and flexibility. 
Studies on the human pancreatic cancer cell line PSN-1 have identified a soluble, tumour cell-derived 
factor, known as endothelial cell retraction factor (Kusama et al., 1995). This factor stimulated 
endothelial cell retraction, thereby inducing breakdown of intercellular junctions, increasing vascular 
permeability and exposing sub-endothel ial matrix. Further studies have correlated these effects on 
endothelial cell retraction with the down-regulation of endothelial cell focal adhesion kinase pp125FAK 
(Okamoto et al., 1998). Alternative investigations have however shown the involvement of other 
factors such as a lipoxygenase metabolite of arachidonic acid (12[S]-HETE) (Honn et al., 1994) and 
sublethal concentrations of H202 (Bradley et al., 1995). H202 production by tumour cells, as a result 
of endothelial cell damage may also lead to tumour cell attachment to the underlying matrix (Offner et 
al., 1996). 
Intravascular 
Activation 
Firm adhesion 
T ransendothelial ~ ~ migration 
Activation of 
endothelial cell 
Activation of 
tumour cell ./ C!J Extravascular 
Chemoattractant 
Figure 1.3.1.a. Diagrammatic representation of transendothelial cell invasion during 
extravasation. Tumour cells ( ), adhere to the endothelium (, ), migrate between endothelial cells, 
adhere to and degrade underlying basement membrane (green) ECM components and migrate towards a 
stimulus. The dark blue arrow indicates the direction of blood flow. 
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In vivo evidence has however, concluded that there are several other mechanisms by which tumour 
cells may extravasate (Paku et al., 2001). Firstly endothelial cell retraction may be followed by 
fragmentation of the basement membrane by cellular processes, ultimately causing the breakdown of 
the capillary. Alternatively, endothelial cells may completely cover the tumour cells prior to 
penetration of the basement membrane. Finally, destruction of the capillary may be a result of intra-
capillary proliferation. The precise mechanism utilised is therefore potentially dependent upon the 
site of extravasation, and properties of the tumour cells, determining the response of the endothelium 
(Paku et al., 2001). 
1.3.2. Tumour angiogenesis 
Tumour cell dissemination is further assisted by the development of a new blood supply to the 
tumour. In the absence of an adequate blood supply, the diffusion of oxygen and nutrients across 
numerous cell layers limits the size of the tumour. To grow beyond 1-2mm3 most tumours must 
successfully initiate the development of a new vascular bed from pre-existing vessels, which will 
support the expanding malignant cell population (Folkman et al., 1989). This process, known as 
angiogenesis, involves the degradation of the ECM around each vessel and then the migration, 
proliferation and differentiation of endothelial cells to form tubes, and eventual new vessels (reviewed 
by Folkman, 1995). Through the development of a new vascular network, tumour growth is 
stimulated whilst also providing a route for extravasation. The walls of the new vessels often have 
fragmented basement membranes, additionally allowing passive tumour cell leakage (Nagy et al., 
1989). Endothelial cells at the growing tip degrade the surrounding ECM, also passively assisting the 
escape of tumour cells into the tumour neovasculature (Fisher et al., 1994). In many tumours, a 
significant association has been found between vascular density and poor prognosis, both in terms of 
disease free and overall survival. For example, microvessel counts at the margin of the primary 
tumour in breast cancers have been proven to be a predictive marker of metastasis, increasing the 
probability of extravasation and dissemination (Weidner et a/., 1991). 
The switch to the angiogenic phenotype depends upon a change in the net balance of positive and 
negative angiogenic factors, released by both the tumour and host cell populations {Folkman and 
Klagsbrun, 1987}. Properties of the tumour mass, including hypoxia and hypoglycaemia can induce 
this transition by activating pro-angiogenic factors {Tuder at al., 1995}. In response, growth of the 
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tumour will result through an influx of blood through the new vessels and through paracrine 
stimulation of tumour cells by numerous growth factors and matrix proteins produced by, and 
transported via the new capillary endothelium. Recently the presence of 'mosaic vessels' in tumours, 
in which the vessel wall is lined by a heterogeneous layer of endothelial and tumour cells, have also 
been discovered, raising the possibility of tumour cells mimicking endothelial cells (Chang et al., 
2001). 
The angiogenic process 
To date, many pro-angiogenic growth factors have been identified, including VEGF, FGF, IGF-1, 
TGF-J31, TNF-a, and HGF (e.g. Roberts et al., 1986; Frater-Schroder et al., 198?; Connolly et al., 
1989; reviewed by Carmeliet and Jain, 2000). In response, endothelial cells alter their morphology, 
producing finger-like protruSions on the cell surface adjacent to the basal lamina, intercellular gaps 
appear and the endothelial cells retract. Subsequent proteolytic degradation of the basal lamina and 
surrounding ECM permits endothelial cells from post capillary parent venules to migrate and form 
sprouts, employing a variety of proteolytic enzymes, including both MMPs and PAs, moving 
chemotactically towards the aforementioned growth factors (Fisher et al., 1994; reviewed by 
Folkman, 1995). Degradation of the surrounding matrix may cause further activation of additional 
angiogenic growth factors (bFGF, VEGF and IGF-1) bound within the ECM. During migration, as 
gaps between endothelial cells increase, neighbouring endothelial cells follow from the parent vessel. 
Endothelial cells initially travel as solid cords but subsequently develop inter- and intra-cellular 
spaces that form lumen (Folkman and Haundenschild, 1980). Proliferation of endothelial cells allows 
the length of the sprout to increase and blood will flow when the two hollow sprouts join at their tips to 
form a loop (Folkman and Klagsbrun, 198?). 
Angiogenesis, micrometastasis and dormancy 
Angiogeneis is therefore a vital stage of both primary and metastatic tumour development. For 
metastatic colonies to therefore grow to any considerable size at a distant site, further 
neovascularisation is required. Until this occurs the micrometastases are said to be dormant and 
may remain asymptomatic and clinically undetectable for months or years (Demicheli et al., 1994). 
Suppression of angiogenesis retains a balanced, high rate of proliferation and apoptosis in the 
micrometastases (Holmgreen et al., 1995). In more than 50% of cancer patients, metastasis has 
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already occurred at the time of initial diagnosis and when the primary tumour is removed. many die 
within months (reviewed by Fidler and Ellis. 1994). It has therefore been theorised that removal of 
the primary tumour might be responsible for removing circulating angiogenic inhibitors and hence 
initiating angiogenesis of the micrometastases. This principle has been used as the basis for the 
development of anti-angiogenic drugs. inhibiting microvascular proliferation with a consequent 
inhibition of angiogenesis-dependent growth (O'Reilly et al .• 1994; O'Reilly. et al., 1997). Of notable 
interest has been the identification of a group of endogenous proteins that inhibit endothelial cell 
proliferation, suppressing growth of metastases in vivo. Among these proteins, two peptides known 
as angiostatin and endostatin have been shown to be potent angiogenesis inhibitors. These are the 
breakdown products of plasminogen and collagen type XVII. respectively which may be facilitated by 
enzymatic activity accompanying tumour growth. hence possibly explaining induction of metastatic 
growth after the surgical removal of the primary tumour (O'Reilly et al .• 1994; O'Reilly, et al., 1997). 
1.4. Tumour cell survival during dissemination 
Once intravasation has occurred, tumour cells disseminate to the secondary site. As described 
earlier, the pattern of dissemination is likely to be determined by both anatomical conditions and the 
microenvironment of the target organ. Spread is commonly facilitated by either the haematogenous 
or lymphatic system. For a cell to successfully disseminate, the tumour cell must therefore survive 
against host immune responses during the transportation. 
Originally it was hypothesised that tumour cells are capable of evading the host immune responses, 
through resisting immune recognition and attack by host inflammatory cells (reviewed by Pardoll, 
2001). As such, tumour cells would still be seen as foreign, but the immune response is in some way 
avoided. This hypothesis would provide an explanation for the inactivation of tumour cell major 
histocompatibility complex (MHC) molecules often observed, as this may prevent T cell recognition 
(Travers et al .• 1982). Opposing this theory, it has also been suggested that the host immune system 
instead recognises tumour cells as self and not foreign (Ochsenbein et al., 2001; Shankaran et al .• 
2001). In this explanation, the location and properties of the tumour cells during development may 
determine whether an immune response is invoked or tolerated. Tumour cell antigen expression may 
therefore be determined during the early stages of tumour progression such as degradation of the 
surrounding stroma and angiogenic development. which may be suffiCiently disruptive to provoke a 
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pro-inflammatory response {reviewed by Fuchs and Matzinger, 1996}. In such cases, immune 
responses may be initiated, facilitating attack by host cells. Alternatively, if an inflammatory response 
is not induced during this period, tumour cell survival may result. Secretion of soluble ICAM-1 by 
both tumour and endothelial cells has also been reported for a number of cancers, and suggested as 
a mechanism by which tumour cells may escape immune surveillance {Fonsatti et al., 1999; Zhang 
and Adachi, 1999}. In these studies, tumour and host inflammatory mediators such as IL-1a. and 
IFNy induced secretion, and it is thought that soluble ICAM-1 may further block the LFA-1 receptor, 
thereby inhibiting T and natural killer cell attachment and providing a means by which these cells 
prevent immune attack. 
1.5. Arrest at the target organ 
If tumour cells survive dissemination in the circulation, the next step of the metastatic process 
involves arrest at the target organ. Mechanical arrest of single cells in capillaries can account for a 
proportion of these adhesive events during metastasis; whereas more directed adhesive interactions 
of tumour emboli may occur in larger vessels (Scherbarth and Orr, 1997). As predicted by Paget's 
model, evidence exists showing antigenic differences between parts of vascular beds in different 
organs, but it is possible that this is not the only determining factor (Paget, 1889; Auerbach et al., 
1987). 
As briefly described earlier (1.1 and 1.3.1), upon initial contact of the tumour cells with the 
endothelium, weak or transient interactions are formed (a process known as 'docking') facilitated 
primarily by selectins, inducing activation of both cell types through cytokines, growth factor, free 
radicals and bioactive lipids (Chen et al., 1997). To reinforce the interaction, firm attachments are 
made via expression of inducible adhesion molecules (principally integrins). These firm interactions 
consequently initiate a cascade of intracellular responses, ultimately inducing endothelial cell 
retraction, tumour cell motility and transendothelial cell migration (Figure 1.3.1.i) (reviewed by Haier 
and Nicholson, 2001). The influence of fluid flow and local shear forces are however becoming 
increasingly evident (e.g. Mogiri et al., 1995; Yoshida et al., 1999). Once endothelial cells have 
retracted, tumour cells then adhere with stronger interactions to the underlying basement membrane. 
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For the degree of metastatic site-specificity commonly seen, regulators and receptors involved in the 
process may be specifically expressed at the secondary sites promoting tumour cell adhesion, 
migration and invasion (reviewed by Liotta, 2001; e.g. Abdel-Ghany et al., 2001; Muller et al., 2001). 
The importance of the host and tumour-derived growth factors, cytokines and chemokines in tumour 
progression is becoming ever more apparent, affecting various stages including tumour cell migration 
(chemotaxis), leucocyte infiltration, cell adhesion molecule expression, tumour cell proliferation and 
angiogenesis (e.g. Leek et al., 1998; reviewed by Balkwill and Mantovani, 2001; e.g. Muller et al. 
2001). Following Paget's original hypothesis, to affect the required response the tumour cells 
involved must therefore express the necessary receptors (Paget, 1889; Nicolson, 1993; e.g. Wang et 
al., 1998b). Recent advances have reported that both breast cancer and malignant melanoma cells, 
express distinct and non-random patterns of chemokine receptors which may play a critical role in 
determining the metastatic destination of these tumour cells (Muller et al., 2001). Blocking these 
receptors subsequently prevented metastasis, inferring that in general terms, target organs may 
produce soluble factors, which chemotactically attract circulating tumour cells expressing the relevant 
receptors. 
Inflammatory mediators may also enhance adhesive interactions between tumour cells and the 
endothelium. For example, as described previously, B16 melanoma cells have been shown to arrest 
primarily within large pre-sinusoidal hepatic portal vessels after IL-1 a treatment (Scherbarth and Orr, 
1997). Without IL-1a treatment, melanoma cells were seen to attach to sinusoidal vessels, 
suggesting that IL-1a may potentially facilitate adhesion to the endothelium. In agreement with this 
theory, in vivo and in vitro studies similarly using B16 melanoma cells, have shown that adhesion to 
the hepatic sinusoidal endothelium stimulated secretion of endothelial TNF-a, IL-1J3 and IL-18, which 
ultimately increased melanoma adhesion to the endothelium (Vidal-Vanaclocha et al., 2000). 
Site-specific endothelial adhesion molecules on the target endothelium may also promote attachment 
of specific tumour cell types. For example, LuECAM has been localised to endothelium of lung 
vessels only, promoting specific attachment of B16 melanoma cells (Zhu et al., 1991). More recently, 
hCLCA2, a Ca2+-sensitive calcium chloride channel protein, has been found to be expressed on the 
endothelial luminal surface of pulmonary arteries, arterioles, and venules, mediating adhesion of 
breast cancer cells via a6J34 (Abdel-Ghany et al., 2001). 
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1.6. Extravasation into organ parenchyma and growth in the target 
organ 
Once arrested at the secondary site, tumour cells must extravasate through the vessel wall and 
degrade the underlying basement membrane and ECM by the processes described earlier (1.1-1.3). 
As detailed previously (1.3.1), the mechanisms underlying extravasation have been shown to vary 
between tumour cell types and target organs (Paku et al., 2001) and controversy exists regarding the 
specific mechanisms underlying these processes. The authors of this study further concluded that 
the time taken for extravasation and the precise involvement of the endothelium in the process differs 
between different target organs and may be determined by properties of the tumour cells. In organs 
such as the adrenals and the brain, tumour cells were seen to induce endothelial retraction and 
penetrate the basement membrane. In contrast in the liver and lung, the endothelium covered 
tumour cells prior to penetration of the basement membrane. 
It has however also been observed that, using a mouse model, upon intraportal injection of B16F1 
melanoma cells, the majority of tumour cells survive and extravasate at the liver (Luzzi et a/., 1998). 
In contrast to other reports suggesting that few Circulating tumour cells ever form metastases (Fidler, 
1970), these authors suggested that lack of metastatic development is determined by the failure of 
initial growth or the development of microscopic tumour into macroscopic tumours. Further 
contrasting evidence relating to metastatic development was also published recently, in which it was 
reported that tumour cells, once attached to the endothelium, might proliferate intravascularly. 
Metastatic foci consequently developed within the capillary, without the need for extravasation, 
ultimately leading to capillary destruction (AI-Mehdi et al., 2001). 
Infiltrating lymphocytes and local host cells are additionally considered to play a pivotal role in 
producing the inflammatory microenvironment required to support tumour growth, both at the primary 
and secondary sites. Studies on prostate and breast cancer have described the pertinent effect of 
host stromal cells on metastatic development, presenting evidence for the effect on tumour cell 
growth and migration upon interaction with such cells (Brooks et a/., 1997; Lang et al., 1998; Lang et 
al., 1999; Lang et al., 2000; Hall et al., 2002). In breast carcinoma, direct interactions between 
tumour cells and host fibroblasts have been shown to enhance fibroblast MMP synthesis, further 
assisting tumour cell invasion (Ito et al., 1995), whilst using a sophisticated co-culture system, Hall et 
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al., (2002) have more recently shown that the consequence of the stromal cells on prostate 
carcinoma morphology and migration was in part determined by the stromal cell origin, describing 
differential effects of host cells derived from benign or malignant tissue. The host tissue therefore 
potentially plays a vital function in metastatic development at both the primary and secondary sites, 
whereby malignant tumours may further influence host tissue behaviour. 
To conclude, no one mechanism of metastasis may therefore explain the spread of tumours from one 
site in the body to another. The process is highly complex and is likely to vary from one tumour type 
to another. Advances are rapidly being made in the cancer field, and hopefully with time, a wealth of 
targets for prevention and treatment will become evident for all tumour types. 
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B. Posterior Uveal Melanoma 
Ocular melanomas may develop from a variety of ocular tissues, including the uveal tract (iris, ciliary 
body and choroid), conjunctiva, eyelid, orbit and nasolacrimal duct (McCartney, 1995). The tissue 
from which the tumour has been derived may have important implications on the biological behaviour 
and prognosis of the tumour (Rennie, 1991). Some of these major sites are illustrated in Figure 1.a. 
Although ocular melanomas can occur at a number of sites, the most common site is the uveal tract. 
Of these, ciliary body and choroidal tumours are most frequently observed and readily disseminate. 
Conversely iris melanomas are less common and very rarely metastasise (McCartney, 1995; 
reviewed by Singh et al., 2001). 
Posterior uveal melanomas are the most common intra-ocular neoplasms in adults, comprising about 
79% of all non-cutaneous melanomas (Scotto et al., 1976). They still however remain rare in 
comparison with other malignancies, representing an annual incidence of 5-7 cases per million of 
Western populations (Egan et al., 1988). Despite the successful treatment of uveal melanomas by 
various techniques, including enucleation, radiotherapy and local resection, the overall mortality rate 
remains unchanged, with secondary tumours appearing in between 19-35% of patients within five 
years (reviewed by Pyrhonen, 1998). Recurrences have however been recorded up to 42 years after 
the primary tumour was detected (Egan et al., 1988). In such cases, it is therefore possible that 
tumour cells access the bloodstream in the early stages of tumour growth to invade secondary 
organs, where they remain in a dormant state for many years before they progress into metastatic 
disease. Median survival following detection of metastases is 4-6 months, and the liver is the 
principle site of metastasis (Char, 1978; Egan et al., 1988). 
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Figure 1.a. Diagrammatic representation of the cross section through the human eye, adapted 
from Bron et al., 1997. Labels indicating common sites for uveal melanomas are shown in red. 
1.1. Aetiology of Uveal melanoma 
1.1.1. Age and patient gender 
The age incidence of posterior uveal melanoma varies, but commonly the median age at diagnosis is 
approximately 55 years (Egan et al., 1988). Diagnosis is rare in children whilst after 70 years of age; 
incidence appears to decline for both sexes (Blair-Smith and Egan, 1980; Egan et al., 1988; 
Rosenbaum et al., 1988). Distribution patterns have however been shown to vary between the 
sexes, with some studies showing a slight male predilection for uveal melanoma (Scotto et al., 1976; 
Albert et ai, 1980). Females have also shown a slight increase between the ages of 20 and 39 years, 
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possibly being related to hormonal patterns, whilst women who have given birth have a lower 
incidence than nulliparous women (Holly et a/., 1991). This would indicate the involvement of an 
ovarian hormone, but as yet, studies have found no correlations between incidence, oestrogen levels 
and oestrogen receptor expression (Hartge et al., 1989). More recently a study has been published 
in which no correlation was made between patient gender and melanoma-specific mortality (Kroll et 
al., 1998). 
1.1.2. Incidence 
Although few factors have been proven to predispose to uveal melanoma, the most outstanding 
observation is that of the low incidence in non-whites. Several studies have all shown a dramatically 
lower incidence in the black population in comparison to the white population (Scotto et al., 1976; 
Blair-Smith and Egan, 1980; Egan et al., 1988) and as with cutaneous melanoma, fair-skinned, blue-
eyed individuals appear to be at an increased risk (Gallagher et al., 1985; Egan et al., 1988; Casswell 
et al., 1989). In a recent population-based study, it was however reported that eye colour is the 
strongest independent predictor of uveal melanoma, where individuals with grey, hazel and blue eyes 
being at the greatest risk (Vajdic et al., 2001). 
The lower incidence of uveal melanoma in individuals with dark skin and eyes, would suggest that 
this may be related to the protective influence of pigmentation, filtering ultraviolet light (Egan et al., 
1988). Unlike cutaneous melanoma, the incidence of uveal melanoma has nevertheless been 
relatively constant over the past decades and there appears to be no correlation between incidence 
and latitudinal location (Egan et al., 1988). Sufficient evidence does however exist to suggest an 
involvement of sunlight in the aetiology of uveal melanoma (Holly et aI, 1990; Seddon et al., 1990). 
Recent evidence has also documented an association between radiofrequency radiation and uveal 
melanoma, suggesting an increased risk of development of uveal melanoma with higher mobile 
phone usage (Stang et a/., 2001). At present, reports are limited in this area and ongoing research 
could ascertain the importance of this finding. 
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1.2. Treatment and Prognosis 
1.2.1. Prognostic factors 
Julia Woodward 
A number of clinical, histo-pathological and cytological prognostic indicators have been determined 
for patients with uveal melanoma, including tumour size and location, cell type, vascularity and 
cytogenetic abnormalities. 
Tumour size 
The single most important prognostic factor with regard to patient survival is possibly tumour size 
(Shammas and Blodi, 1977). Most pathologists classify these tumours according to their largest 
dimension: small (less than or equal to 10mm), medium (11-15mm) and large (greater than 15mm) 
(reviewed by Parsons and Sahel, 2000). Prognosis has been ascertained by a combined study of 
eight investigations, in which the authors observed five-year mortality rates following enucleation 
(Diener-West et al., 1992). In summary, mortality rates of 16% for small tumours, 32% for medium 
tumours and 53% for large tumours were seen and to date, these figures have remained unchanged 
(Diener-West et al., 1992; reviewed by Singh et al., 2001). 
Tumour location 
Uveal melanomas can arise in the iris, ciliary body and choroid (Figure 1.1.a). Iris melanomas are by 
far the least aggressive of all uveal melanomas, rarely metastasising and comprising 3% of all uveal 
melanomas (reviewed by Singh et al., 2001). Tumours of the iris are also often relatively small upon 
diagnosis and have the lowest mortality rate of about 3-5% in 10 years (reviewed by Shields et al., 
2001; reviewed by Singh et al., 2001). In contrast, melanomas of the choroid and ciliary body are far 
more aggressive and patients have an increased risk of metastasis (McCartney, 1995; reviewed by 
Gragoudas and Egan, 2000). Choroidal melanomas are the most common seen comprising around 
85% of all uveal melanomas; ciliary body tumours are less common, occurring in 10% of patients 
(reviewed by Parsons and Sahel, 2000). In an early study, patients with ciliary body melanomas, 
treated by enucleation were shown to have a five-year mortality rate of 53%; in contrast, again after 
enucleation, patients with choroidal melanomas had a five-year mortality rate of 14% (Seddon et al., 
1983). 
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Figure 1.1.a. Examples of choroidal malignant melanomas. i) An amelanotic (A) and a melanotic 
component (M1) have remained beneath the retina, whilst a second melanotic (M2) lesion has penetrated the 
retina (taken from Parsons and Sahel, 2000). ii) The choroidal melanoma has caused complete retinal 
detachment, and can be seen invading through the sclera (indicated by the white arrow). 
Cell type 
Uveal melanoma can morpholog ically be classified into subtypes, determined by their cell type 
(spindle and epithel ioid), which can further be correlated with mortality (McLean et al., 1983). Two 
types of spindle cells may be observed; spindle A celis, which are long and slender with elongated 
nuclei (Figure 1.1 .b.ii) and spindle B cel ls, which are more oval with a prominent nucleolus. In 
contrast, epithelioid cells are larger, with more cytoplasm containing fewer intermediate filaments 
than spindle cells, large rounded nuclei and prominent large nucleoli Figure 1.1.b.i) . Tumours with 
spindle A cells were found to have similar prognosis as those with spindle B cells; the generic term 
'spindle cell ' is consequently commonly used (reviewed by Parsons and Sahel, 2000). In general 
terms, tumours are therefore classified as spindle cell, epithelioid cell, and mixed cell (comprised of 
both spindle and epithelioid cells) (Spencer, 1986; reviewed by Parsons and Sahel, 2000). 
Disagreement nevertheless exists between pathologists, regarding the permitted number of spindle 
cells in epithel ioid tumours and therefore in reality, uveal melanomas containing epithelioid cells are 
classified as 'mixed' (reviewed by Parsons and Sahel, 2000). 
When considering prognosis, tumours composed of purely spindle cells have a greater survival rate 
than those of a mixed cell population, which in turn have a greater survival rate than purely epithelioid 
tumours (McLean et al., 1983). Increases in the epithelioid content of the tumours have further been 
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correlated with higher mortality rates (Seddon et a/., 1983) and an early study of choroidal and ciliary 
body tumours, observed that 81.2% of patients with purely spindle tumours had a 15 year survival 
rate, contrasting with 28% for patients with purely epithelioid tumours (Paul et a/., 1962). As cell 
characterisation may however often be subjective, other prognostic indicators must always been 
taken into account. 
Figure 1.1.b. Histological sections showing epithelioid (i) and spindle A (ii) cells (Parsons and 
Sahel, 2000). Epithelioid cells are larger, rounded cells with prominent nucleoli. Spindle A cells are 
longitudinal with slender nuclei. 
Microcirculation architecture 
The specific architecture of the vascular networks observed in uveal melanomas has also been 
associated with prognosis. Studies investigating tumour vascularity in uveal melanomas have 
identified a correlation between the presence of closed vascular loops in choroidal and ciliary body 
melanomas and poor survival (Folberg et a/., 1993; Rummelt et a/., 1995). Such vascular patterns 
may be more Significant when considering patient mortality from metastatic disease, than tumour 
location, size and cell type (Folberg et a/., 1993; Rummelt et a/., 1995). 
Cytogenetics 
Over the past decade, specific genetic alterations have been observed in uveal melanomas, and 
associations have been made with prognosis. Cytogenetic analysis of ciliary body and choroidal 
melanomas has shown abnormalities of chromosomes 3, 6 and 8 (Sisley et a/., 1997; White et a/., 
1998). Ciliary body tumours have preferentially presented with chromosomal abnormalities of 
monosomy 3 and an additional 8q and this has further been correlated with a worse prognosis (Sisley 
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et al., 1997; White et al., 1998). In contrast, abnormalities of chromosome 6 have been more 
commonly associated with choroidal melanomas (Sisley et al., 1997). 
Other prognostic indicators 
Other notable prognostic indicators include age of the patient (patients below 60 years of age have a 
better prognosis), extrascleral spread, extent of lymphocytic infiltration, integrity of Bruch's membrane 
and cellular proliferation (reviewed by Singh et al., 2001). With regard to the latter, expression of two 
uveal melanoma associated-antigens (Ki-67 and PCNA) involved in proliferation has been identified 
and decreased cell cycling times has been associated with a worse prognosis (Mooy and de Jong, 
1996; Seregard et al., 1998). More recently, weak expression of ICAM-1 has also been correlated 
with an increased risk of metastatic disease (Anastassiou et al., 2000b). 
1.2.2. Treatment 
A range of techniques are now in practice for the treatment of uveal melanomas, and often the 
preferred treatment will be dependent upon how the patient has presented. These broadly include 
enucleation, surgical resection, radiotherapy, transpupillary thermotherapy, and photocoagulation 
(reviewed by Singh et al., 2001). No one modality is superior for all tumours and often a combination 
of these modalities may be used. Factors that may influence the choice of treatment include patient 
preference, size and location of the tumour, age of the patient and state of the fellow eye. For 
example, small tumours are responsive to transpupillary thermotherapy with fewer complications 
(reviewed by Singh et al., 2001). Brachytherapy employs the use of ruthenium-106 and iodine-125 
episcleral plaques and despite the general lack of sensitivity of melanomas to radiotherapy, have 
been found to be successful for treating small tumours in viable locations (reviewed by Rennie, 
1997). The argon laser has also been valuable for treating small choroidal tumours, but is only 
suitable for tumours less than 3.5-4mm in thickness (Rennie, 1991). 
Despite apparent effective removal, or irradiation of the primary tumour, the survival rate of 15 years, 
still remains unchanged at about 50%, due to the high rate of metastasis (Egan et al., 1988; reviewed 
by Rennie, 1997). The mortality rates after treatment by enucleation, plaque radiotherapy, proton 
beam radiotherapy and helium ion therapy appear to be consistent (reviewed by Singh et al., 2001). 
Only 2-3% of patients present with metastases at the time of initial diagnosis, yet within two to three 
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years, many of these surrender to metastatic disease (Pach and Robertson, 1986). Some clinicians 
have suggested that surgical manipulation of the globe at enucleation promotes dissemination of 
malignant cells and adversely affects survival (Zimmerman et al., 1978). Despite arguments 
supporting this hypothesis, due to the complexity of the metastatic process, it seems unlikely that any 
cells released from the primary tumour at the time of surgery would be able to efficiently metastasise 
to a distant site. At present, due to the nature of the secondary disease, treatment of metastases has 
had little success (reviewed by Pyrhonen, 1998; reviewed by Gragoudas and Egan, 2000), and the 
effectiveness of liver screening tests at the time of diagnosis still remains uncertain. Novel therapies 
for early detection of potentially metastatic tumours are therefore urgently required. 
1.3. Invasion and metastasis of uveal melanoma 
Uveal melanoma most commonly metastasises to the liver (Char, 1978); studies have shown that 
95% of patients with metastasis will develop liver involvement (reviewed by Gragoudas and Egan, 
2000), appearing as multi-foci metastases in 19-35% of patients within five years (reviewed by 
Pyrhonen, 1998). Others sites less frequently colonised include the subcutaneous tissue, bone and 
pulmonary tissue (Char, 1978). Once liver metastases have been observed, prognosis is poor and 
patients usually die within six months (Gragoudas et al., 1991). As metastases still develop after 
adequate treatment of the primary tumour it therefore seems feasible that micrometastases dispersed 
throughout the liver, may have established before any treatment can be offered (Shields, et al., 
1985). 
Despite much evidence implicating the liver as the primary target for metastatic uveal melanoma 
explanations determining this pattern of spread are still unclear. Due to the anatomical structure of 
the liver, it would seem possible that mechanical entrapment of tumour cells is feasible. During 
transportation from the eye, a number of other capillary beds may be encountered; yet secondary 
tumours are rarely seen in these sites (Char, 1978). Unlike, for example colorectal carcinoma for 
which secondary tumours present as a single focus in the liver, as uveal melanoma metastases 
develop as multi foci, this may further imply that the spread is more related to Paget's 'seed and soil' 
hypothesiS (Paget, 1889), than simply due to physical arrest. 
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1.3.1. Adhesion molecule and degradative enzyme expression 
It is therefore possible that specific characteristics of malignant uveal melanoma cells may promote 
invasion and metastasis. There is extensive evidence suggesting the involvement of adhesion 
molecules in cutaneous melanoma progression, yet knowledge is limited regarding their profiles in 
uveal melanoma. Certain reports have suggested that unlike cutaneous melanoma, expression of 
a.vP3 may not be an absolute requirement for uveal melanoma metastasis (Ten Berge et al., 1993; 
Marshall et al., 1998; Seftor et aI, 1999). Expression of a.vP5 by primary uveal melanomas has also 
been reported (Natali et al., 1997; Marshall et al., 1998), and loss of a.vP1 and a.5P1 has also been 
correlated with increased invasiveness in vitro, and the aggressive phenotype, respectively (Marshall 
et al., 1998; Beliveau et al., 2000; Beliveau et al., 2001). Gain of a.6P1 expression has additionally 
been associated with an epithelioid cell type and consequently poor prognosis (Rohrbach et al., 
1994; Elshaw et al., 2001). ICAM-1 expression in uveal melanomas has also been documented 
(Natali et al., 1990; Creyghton et al., 1995) and loss of this receptor has now been seen to be 
associated with an increased risk of metastasis within the first five years after diagnosis (Anastassiou 
et al., 2000b). 
Type IV collagenases have been widely implicated in many types of tumour cell invasion and 
metastasis. Ubiquitous expression of a 72kD gelatinase (MMP-2) has been reported in uveal 
melanoma, whereas expression of a 92kD gelatinase (MMP-9) has been more varied (Cottam et al., 
1992; Beliveau et al., 2000; Elshaw et al., 2001). MMP-2 expression has been further correlated with 
poor prognosis and a higher incidence of metastatic disease in uveal melanoma (Vaisanen et al., 
1998; EI-Shabrawi et al., 2001) whilst secretion of a 117kD MMP has also been associated with cells 
of an epithelioid morphology and an aggressive phenotype in vitro (Beliveau et al., 2000). Besides 
MMPs, reports of the involvement of the PAlplasmin system in ECM degradation are scarcer in uveal 
melanoma (De Vries et al., 1995), but TGF-p2, present in the uvea, has been shown to activate t-PA 
secretion from epithelioid cell lines derived from intraocular tumours, yet inhibits secretion and activity 
of u-PA from cell lines derived from orbital tumours (Park et al., 1996). In addition to the degradative 
enzymes, expression of the PA inhibitor PAI-1 has also been reported in the majority of uveal 
melanoma metastases (Ma et al., 1997). 
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1.3.2. Uveal melanoma dissemination 
Once in the circulation, uveal melanoma cells therefore principally target the liver. Recent research 
has potentially identified the involvement of intermediate filaments in hepatic uveal melanoma 
metastasis, but only limited research has been carried out in this area. A small number of pro-
angiogenic factors have also been reported in uveal melanoma, but again evidence is limited. 
Recently, the potential importance of other vascular networks has been described. 
Intermediate filaments 
Diagnosis of early melanomas originally relied upon the presence of specific intermediate filament 
markers such as vimentin (a mesenchymal marker). As malignancy progresses, other cytokeratins 
(characteristic of an epithelial phenotype) have been identified; the co-expression of which suggests 
a 'dedifferentiated' or 'inter-converted' phenotype (Hendrix et al., 1996). In addition to their roles in 
determining cell shape and spreading, intermediate filaments have been postulated to playa role in a 
number of signal transduction pathways, linking the ECM with the nucleus. Co-transfection of a 
vimentin-positive human melanoma cell line (with a low invasive ability) with cDNAs for keratins 8 and 
18, resulted in a two- to three-fold increase in invasiveness in vitro and an increase in focal 
adhesions between the cytoskeleton and ECM. This suggested that co-expression of vimentin and 
keratin contributed to a more invasive phenotype (Chu et al., 1996). A study using human uveal 
melanoma cell lines demonstrated that cell populations co-expressing vimentin and keratins 8 and 18 
were six-fold more invasive than uveal melanoma cells expressing vimentin only, and eight- to 
thirteen-fold more invasive than normal uveal melanocytes. This work has proposed an association 
between intermediate filament co-expression and uveal melanoma metastasis (Hendrix et al., 
1998a). Expression of the c-met proto-oncogene (hepatocyte growth factor (HGF) receptor) has 
further been correlated with the inter-converted phenotype and increased invasive ability in vitro, by 
uveal melanoma cell lines (Hendrix et al., 1998b). Liver metastases were HGF-positive and hence it 
was postulated the regulation of the inter-converted phenotype by HGF might be involved in spread 
(Hendrix et al., 1998b) of c-met-expressing uveal melanoma cells. 
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Angiogenesis 
In common with other tumours, microvessel configuration has been associated with poor prognosis in 
choroidal and ciliary melanomas (Lane at aI, 1997; Folberg at al., 1997) and due to the lack of 
lymphatic vessels in the eye; haematogenous metastasis is the prime route of spread for uveal 
melanoma. The switch to the angiogenic phenotype depends upon the net balance of positive and 
negative angiogenic factors released by both the tumour cell and host cell populations. VEGF and 
bFGF expression has been observed in uveal melanoma, supporting endothelial growth (Boyd at al., 
2002). Expression of the former has further been shown, in conjunction with the expression 
angiopoietin-2 and absence of angiopoieten-1, and consequently it has postulated that this may be 
responsible for the typical vascular patterns associated with poor prognosis (Ijland et al., 1999). 
Angiopoetin-1 and -2 are involved in regulating maturation and stabilisation of newly formed vessels; 
the latter blocks the function of the former, thus inhibiting the early maturation and stabilization of the 
new vessels, rendering the vessels more prone to a proliferative response to VEGF (Ijland et al., 
1999). Contradictory reports have however correlated VEGF expression by ciliochoroidal 
melanomas with the presence of necrosis but not with metastasis or angiogenesis (Sheidow et al., 
2000). 
Once disseminated, uveal melanoma metastases may remain dormant as micrometastases for many 
years before neovascularisation is induced, allowing growth to a clinically detectable size (Shields et 
al., 1985). It is possible that for uveal melanoma, tumour emboli disseminate at the time of 
enucleation and that by removing the primary tumour, anti-angiogenic peptide levels fall, permitting 
endothelial cell proliferation and subsequent metastatic growth. Evidence supporting this theory is 
however scarce, and recent observations have reported variable expression of angiostatin by uveal 
melanoma cell lines (ljland at al., 1999; Apte et al., 2001). 
Of further importance has been the possible involvement of 'vasculogenic mimcry' in uveal 
melanoma. Whilst angiogenesis involves the recruitment of new vessels into the tumour from pre-
existing vessels, highly aggressive and metastasis uveal melanoma cells (yet not non-aggressive 
tumour cells) are capable of forming highly pattemed vascular channels in vitro (Folberg et al., 2000). 
These channels are devoid of endothelial cells and surround tumour emboli in vitro and in vivo, 
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mimicking the patterned networks seen in aggressive tumours, correlating with poor prognosis 
(Maniotis et al., 1999), but their relevance in in vivo metastasis still remains unclear. 
1.3.4. Uveal melanoma metastatic development in the liver 
Once transported, uveal melanoma cells therefore arrest principally in the hepatic microvasculature, 
although as described earlier, other organs such as the subcutaneous tissue, bone and pulmonary 
tissue may occasionally be involved (Char, 1978). 
Liver structure and secondary disease 
The liver is the primary site of metastasis for some of the most common human malignancies, 
including the entire gastrointestinal tract, the lung and the breast and metastases are frequently 
untreatable and associated with poor prognosis (reviewed by Underwood, 2000; e.g. Miyagawa et al., 
2002; Wu et al., 2002). For many of these malignancies, metastatic tumour cells follow a direct route 
via the hepatic portal vein and establish themselves in the first target organ encountered and often 
metastases are well defined and form solid tumours. In contrast, for uveal melanoma, an explanation 
for the hepatic nature of metastases still remains unclear and micro-metastases are commonly 
dispersed throughout the organ, remaining undetected for many years. 
The human liver is primarily composed of hepatocytes, arranged into structures known as lobules; 
the sub-structure of which allows maximum contact of hepatocytes with blood flowing through the 
liver (reviewed by Underwood, 2000). In cross section, lobules are roughly hexagonal, with larger 
branches of the hepatic portal vein and hepatic artery, running along the angles of the lobular 
margins. From these larger vessels, blood is transported towards a central vein of each lobule via 
sinusoids, and thus, due to the thickness of each hepatocyte plate, each hepatocyte is bathed by 
blood on at least two sides. Each sinusoid is lined by cells analogous to endothelial cells, and as 
such creates the initial barrier to which tumour cells must interact prior to intravasation (reviewed by 
Underwood, 2000). Phagocytic Kupffer cells also line the sinusoids, performing a macrophage-like 
function, removing depleted erythrocytes and other debris from the circulation (reviewed by 
Underwood, 2000). There is much evidence to suggest that Kupffer cells are responsible for the 
secretion of many local cytokines, which may subsequently be required for the metastatic process. 
For example, in response to stimulation, hepatocytes and Kupffer cells of the liver have been also 
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shown to produce a number of factors, including IL-8 and TNF-a. (Mawet et al., 1996; Rowell et al., 
1997). Stellate cells are also present close to the sinusoids and hepatic venules, and are involved in 
collagen synthesis aiding hepatic fibrinolysis (reviewed by Underwood, 2000). 
The initial site of tumour cell arrest is predominantly the liver sinusoids (Vidal-Vanaclocha et al., 
2000). As described previously, pre-treatment of mice with IL-1a. has been shown to affect the site of 
816F1 melanoma cell arrest at the sinusoidal endothelium, promoting adhesion to the pre-capillary 
vessels (Scherbarth and Orr, 1997). More recent evidence has suggested that arrested cells suffer 
extreme deformations, suggesting that tumour cells do not roll on the endothelium and instead arrest 
in the capillary bed (Paku et al., 2001). Due to the intricate nature of the hepatic capillary bed, this 
would seem a feasible explanation (Ding et al., 2001). Whichever mechanism is implicated, 
extravasation involves tumour cell interaction with the sinusoidal endothelium, the subendothelial 
basement membrane and hepatocytes, before proliferating to form secondary colonies. There is still 
nevertheless evidence to suggest that the specificity of spread seen in many cancers cannot be 
explained purely by mechanical arrest and may depend upon the tumour type. For example, a 
component of the sinusoidal basement membrane, heparan sulphate proteoglycan has been shown 
to playa critical role in liver colonisation of lung carcinoma cells (Tovari et al., 1997). In a more 
recent study by this group, as detailed earlier (Section A, 1.3.1) cells preferentially metastasising to 
the liver and lung, were shown to migrate to these organs in a shorter period of time, when compared 
with other organs less commonly colonised (Paku et al., 2001). The mechanism utilised by these 
cells to extravasate in these organs, involved tumour cells becoming covered by the endothelium 
prior to penetration of the basement membrane, differing from extravasation at other sites. Due to an 
iII-defined basement membrane in the liver between the microvilli of the hepatocytes, tumour cells 
were further observed to 'sink' into the hepatic bed leading to a disappearance of the hepatic 
microvilli. 
Further insight into the factors involved in the targeting of uveal melanomas to the liver may therefore 
be of vital importance for elucidating potential sites for therapeutic targets, with an ultimate aim of 
preventing these tumours from establishing secondary disease. 
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c. Study background and aims of the investigation 
1.1. Background 
The use of primary short-term cultures 
Previous reports on uveal melanoma have commonly used established cell lines that may differ both 
genotypcially and phenotypically from the original tumour. Ultimately, the use of primary cultures 
should nevertheless provide a closer representation of responses in vivo. This present study was to 
be carried out in conjunction with the Academic Unit of Ophthalmology and Orthoptics and the 
Institute for Cancer Studies. Using tumour samples collected directly from theatre, this laboratory 
provided the expertise for culturing solid uveal melanoma tumour samples. By culturing solid 
tumours as short-term cultures, effects of long-term culturing would hopefully be avoided, thus more 
closely resembling properties of the tumour in vivo. As no two tumours behave in an identical 
manner, regarding individual tumours, it may also be possible to further correlate the behaviour in 
vitro with known histo-pathological data. As cells were to be cultured directly from solid tumours, cell 
numbers could therefore be a limiting factor, together with the uncertainty of establishment in culture. 
More established uveal melanoma cell lines were available for study also, when high cell numbers 
were required, allowing experimental repetition, and as such could be used to develop methods in 
which short-term cultures could be assessed later. Although uveal melanoma samples typically 
contain a low number of infiltrating cells {de Waard-Siebinga et al., 1995}, it would nevertheless still 
be necessary to ascertain that melanoma cells are actually the cultured cell type selected for. 
In vitro models of tumour cell migration and invasion 
Most studies of uveal melanoma invasion have utilised animal models (e.g. Patz at al., 1959; Bradl et 
al., 1991; Grossniklaus et al., 1995), and as yet, few in vitro assays have been reported. In vitro 
studies of cell migration and invasion of other tumour types have commonly employed methods, such 
as the Boyden chamber and Transwells, with upper and lower compartments separated by a porous 
membrane, often coated with an ECM SUbstrate or a reconstituted basement membrane {Falk et al. 
1980; Albini et al., 1987}. Alternatively, other methods of studying invasion have involved gel 
invasion assays in which cells attach to and invade into three-dimensional matrices over a longer 
period of time (Andresen et al., 2000) whilst for the study of cutaneous melanoma, the use of a 
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sophisticated three-dimensional reconstructed skin model has also recently been reported (Eves et 
al., 2000). Many of these studies have nevertheless, involved the use of established cell lines. 
Previous research by this laboratory, has investigated invasion of uveal melanoma short-term 
cultures through a basic invasion assay in vitro, with the inclusion of a minimal fibronectin barrier 
alone (Elshaw et al., 2001). However as yet, the study of primary uveal melanoma cell invasion in a 
more realistic system has not been studied. 
In vitro models for studying tumour cell adhesion to the endothelium 
Tumour cell adhesion to the endothelium is a vital step during metastasis. In vitro assays to study 
these processes have commonly involved adhering tumour cells to a confluent layer of endothelial 
cells, allowing further investigation into the molecules that facilitate and effect these interactions (Teti 
et al., 1997; Scott et al., 2001). There have been few reports as yet, investigating the adhesive 
interactions between uveal melanoma cells and the endothelium. As uveal melanomas primarily 
target the liver, there is a possibility that site-specific determinants on the liver endothelium, may 
assist in this process. 
1.2. Aims of the investigation 
Limited knowledge exists regarding the mechanisms by which uveal melanomas metastasise to the 
liver. This tumour might potentially follow the theory underlying Paget's 'seed and soil' hypothesis 
suggesting that metastatic uveal melanoma cells express a distinct genotypic and phenotypic profile 
that facilitates arrest and subsequent growth in the liver. Using short-term uveal melanoma cultures, 
the overall aims of this study were to investigate differences between cells with varying invasive 
abilities in vitro and further correlate this information with known histo-pathological data. This may 
provide further information defining the aggressive nature of some uveal melanomas. As little is 
known relating to uveal melanoma invasion and metastasis to the liver, the specific aims of this study 
are described below. 
• As previous studies have commonly used cell lines, differences between in vitro and in vivo 
expression of adhesion molecules, degradative enzymes and their respective inhibitors by 
uveal melanomas, potentially involved in metastasis was assessed. 
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• Past studies have employed basic in vitro invasion molecules to study uveal melanoma 
invasion, and consequently a potentially more representative in vitro model of 
transendothelial uveal melanoma cell invasion was developed. 
• As uveal melanomas primarily target the liver, the effects of hepatic-derived cells and 
secreted factors on uveal melanoma invasion were investigated. 
• As organ-specific adhesion molecules may be involved in site-specific metastasis, potential 
differences in adhesion of uveal melanoma cells to endothelial cells derived from hepatic and 
dermal sites were studied. 
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Chapter 2: Materials and Methods 
A. Materials 
Details of the addresses of all suppliers are listed in Appendix I. 
2.1. General laboratory equipment and reagents 
Water 
Julia Woodward 
All solutions were prepared using water purified by a Purite Select Analyst HP system and the pH 
was measured using a Jenway 3020 pH meter. 
Sterilisation of solutions and equipment 
Where required, solutions and equipment were autoclaved prior to use at 20lb/sq inch for 20 minutes 
(Boxer Laboratory Equipment). Autoclave tape was obtained from Rexam Medical Packaging. 
Centrifugation 
With the exception of endothelial cell, unless otherwise stated, cells for tissue culture procedures 
were pelleted by centrifugation at 200g (1000rpm) at 25°C (Heraeus Sepatech Megafuge 1.0 R 
centifuge) for 5 minutes. Endothelial cells were pelleted at 228g (1100rpm) at 25°C for 5 minutes. 
Safety cabinet 
Standard aseptic technique was applied to all tissue culture procedures in a laminar flow class II 
microbiological safety cabinet (B.S.5726) (Walker Safety Cabinets Ltd.). Fifteen minutes before use, 
the cabinet was switched on and swabbed with 1 % (v/v) Virkon (50% (v/v) potassium 
peroxoxmonosulphate, 5% (v/v) sulphamic acid, 15% (v/v) sodium alkyl benzene sulphonate) (Antec 
Interantional Ltd.) and Azowipes (70% (v/v) isopropyl alcohol) (Vernon carus). All equipment and 
reagent containers were cleansed in a similar way prior to use. Where possible, work with different 
cell lines was kept separate and the cabinet sanitised between different cell lines. 
FACSort 
Samples were analysed using a Beckon Dickenson FACSort Vantage flow cytometer, using 
logarithmiC scale for fluorescence intensity, with technical assistance from Mrs Olivia Smith. The 
data were collected and analysed using Cell Quest software (Beckon Dickinson). 
Incubation 
All cell cultures were maintained at 37°C, 100% humidity and 5% carbon dioxide at ambient oxygen 
concentrations (Sanyo C02, Heto-Holten Cellhouse 170, water jacket C02 incubators). 
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Plate reader 
Plates were analysed using a Wellfluor microplate fluorescence reader (Denley). The data were 
collected and analysed using Wellfluor Data Capture software (Denley). 
Microscopes 
Cell confluency was monitored on a daily basis using an inverted phase contrast microscope 
(Olympus CK2). For fluorescence studies, cells were visualised using an Olympus SX50 and an 
inverted Leica OM IRS fluorescent microscope. For scanning electron microscopy, a Phillips 
SEM501 scanning electron microscope was used, with the assistance of Mr Ian Palmer (Department 
of Pathology, Royal Hallamshire Hospital, Sheffield, UK). 
Liquid Nitrogen 
SOC gases supplied liquid nitrogen. 
Ice machine 
Ice was prepared using an ice machine from Scotsman Ice Systems Ltd. 
Water bath 
For maintaining set temperatures, a Grant water bath was used. 
Glassware and non-disposable equipment 
Pyrex glassware was used and cleaned by washing in a dishwasher, rinsing in distilled water and air-
drying. Volumes of less than and including 1 ml were transferred using Gilson pipettes (Anachem 
Ltd.) with appropriate tips (Sarstedt). For volumes above this, a Pipetboy-ACU (Scientific Laboratory 
Supplies) electronic pipette pump with gamma irradiated disposable plastic pipettes was used. For 
disposal of media, glass Pasteur pipettes (150mm or 230mm) (SLS) were used with a standard 
aspirator (Genetic Research Instrumentation). Glass microscopes slides (25x75mm) and coverslips 
(22x50mm and 13mm diameter) were obtained from SOH. Cell density was estimated by counting 
using an Improved Neubauer haemocytometer slide (Merck/SOH). 
Plastic and disposable laboratory equipment 
All tissue culture flasks (25cm2 and 75cm2) were obtained from Nalge NUNC International. Nalgene 
supplied cryovials (1.2ml) and media filters. Sibby Sterilin supplied plastic centrifuge tubes (13ml), 
petri dishes (60x15 mm and 90x15 mm), universal tubes (20m I} and pipettes (10ml and 25ml). 50ml 
centrifuge tubes, FACS analysis tubes (12mm), 24-well and 96-well cell culture cluster plates were 
obtained from Coming-Costar. Syringes and microlance needles were acquired from Seckton 
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Dickenson. Plastic Pasteur pipettes (1ml) were from SLS, plastic pipette tips and eppendorf tubes 
(1 ml and 2ml) were from Starstedt, and stainless steal surgical blades were from Swann Morton. 
Reagents 
General chemicals and reagents were of analytical grade and purchased from Sigma-Aldrich or 
Merck/BDH unless otherwise stated, and stored according to manufacturer's instructions. All 
quantities were weighed using a Sartorius Basic electronic balance. 
2.2. Biological samples 
Details of all tumours and cell lines used in this study are summarised in Appendices" and 1/1. 
2.2.1. Ocular melanoma samples and cells 
Fresh posterior uveal melanoma samples were col/ected from surgery at the Royal Hallamshire 
Hospital (Sheffield, UK) after enucleation. Ethical approval was obtained prior to study and informed 
patient consent was acquired before collection of tumour samples. Removal was in collaboration with 
an ophthalmic pathologist. For tissue culture, samples were placed into sterile PBS. For 
immunohistochemistry tumour samples were either placed in 10% buffered formalin and 
subsequently processed using a Citadel 2000 Processor (Shandon), or were snap frozen in liquid 
OCT in iso-pentane, and stored at -70°C or in a liquid nitrogen vessel. For classification purposes, 
tumours are identified numerically, and are known as Sheffield Ocular Melanomas (SaM). All histo-
pathological data can be found in Appendix II. 
2.2.2. Endothelial cells 
HDMECAs 
Normal human dermal microvascular endothelial cells (adult) (HDMECA) (TCS Cell Works Ltd.) were 
used as representative endothelial cells for these studies in most experiments. These cells are 
derived from human adult dermis and have a finite useful lifespan of approximately 15 population 
doublings. Generally cells were used up to passage ten. 
HULECs 
Human liver endothelial cells (HULECs) were a gift from Dr Lance Bums (Department of Surgery and 
Anaesthesia, Royal Hallamshire Hospital, Sheffield, UK). Cells were extracted from liver resections 
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for colonic metastases. These cells grow as a monolayer and attain the characteristic cobblestone 
morphology of endothelial cells (Burns et al., 1999). Cells were used within ten passages. 
2.2.3. HepG2 cells 
HepG2 cells (a human hepatoma cell line) were used to represent hepatocytes in these studies and 
were obtained from the European Collection of Animal Cell Cultures (ECACC) (catalogue number 
85011430). Cells were derived from a 15-year-old male Caucasian, are of epithelial morphology and 
produce a wide range of proteins, including factor VIII, prothrombin and antithrombin III. Cells are 
viable for up to 90 passages. 
2.2.4. A375 cells 
A375 cells (a cutaneous melanoma cell line) were used when a comparison with cutaneous 
melanoma was required and were obtained from the European Collection of Animal Cell Cultures 
(ECACC) (catalogue number 88113005). The cells were derived from a 54-year-old female with 
malignant melanoma, and are of epithelial morphology. 
2.2.5. Other cell types 
Alternative cell types used in these studies included A549, JFF and NAK 3.2 and were used in certain 
experiments as controls. 
A549 
A549 cells (a human lung carcinoma cell line) were obtained from the European Collection of Animal 
Cell Cultures (ECACC) (catalogue number 86012804) and are derived from a 58-year-old Caucasian 
male. 
JFF 
JFF cells are primary human dermal fibroblasts and were a gift from Dr 0 Donovan (Department of 
Pathology, Royal Hallamshire Hospital, Sheffield, UK). 
NAK 3.2 
NAK 3.2 cells are primary human dermal keratinocytes and were a gift from Dr SSt-John Smith 
(Department of Dermatology, Royal Hallamshire Hospital, Sheffield, UK). 
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2.3. Tissue culture reagents and solutions 
All tissue culture reagents were purchased from Sigma-Aldrich, unless otherwise stated and stored 
according to manufacturer's instructions. Where required, solutions were autoclaved, as previously 
described. 
2.3.1. General reagents and solutions 
Phosphate-buffered saline (PBS) and phosphate-buffered saline EOTA (PBSe) 
PBS was prepared by dissolving one tablet (Oxoid Ltd.) in 100ml distilled water and was autoclaved 
prior to use. For PBSe 0.2g of ethylenediaminetetra-acetic acid (EOTA) was added per litre of PBS. 
Trypsin 
Trypsin was prepared at 1 :20 2.5% trypsin in 550J.l.M EOTA in sterile PBS and stored at 2-8°C. All 
cells were dissociated from tissue culture flasks using trypsin unless otherwise stated. 
Cell dissociation solution 
For adhesion and FACS assays, cell dissociation solution was used according to the manufacturer's 
instructions. 
Oi-methyl sulphoxide (OMSO) 
For freezing cells, oMSO at 10% (v/v) sterile dimethyl sulphoxide (OM SO) was prepared and used 
immediately. 
Trypan blue 
Cell viability was monitored using sterile trypan blue, prepared at 0.5% w/v in PBS. Viable cells were 
then assessed using a haemocytometer. 
Bovine serum albumen (BSA) 
For preparation of serum free media and buffers for flow cytometry, BSA was added at a 
concentration of 0.1 % and 0.5%, respectively. 
Foetal bovine serum (FBS) 
FBS was obtained from Helena Biosciences, and used at the concentrations noted. Prior to use, 
FBS was stored at -20°C. 
Gill's haematoxylin 
Gill's haematoxylin was prepared by mixing distilled water (750ml) with ethylene glycol (250ml), 
haematoxylin (2g), and sodium iodide (0.2g). After mixing well, glacial acetic acid (20m!) was added 
and the solution was stirred for 1 hour at room temperature. 
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2.3.2. Growth media 
Ocular melanoma Growth Media 
All ocular melanoma cultures were maintained in Roswell Park Memorial Institute (RPMI) 1640 
growth medium (Invitrogen) supplemented with 20% (v/v) FBS, penicillin (100Ulml), streptomycin 
(100~g/ml), fungizone (5~g/ml), glucose solution (0.2%) and epidermal growth factor (EGF) 
(0.2~g/ml). 
Endothelial cell Growth Media 
Endothelial cells were grown in microvascular endothelial cell growth media containing growth 
supplement (heparin, hydrocortisone, human epidermal growth factor, human fibroblast growth factor, 
dibutyryl cyclic AMP and 5% (v/v) FBS) and antibiotic supplement (gentamicin (50~g/ml), 
amphotericin (50~g/ml)) (TCS CeliWorks Ltd.). Prior to seeding cells, tissue culture flasks were 
coated with 3ml of attachment factor (TCS CeliWorks Ltd.). 
HepG2 Growth Media 
HepG2 cells were maintained in RPMI 1640 containing 10% (v/v) FBS, penicillin (100U/ml), 
streptomycin (100~g/ml), fungizone (5~g/ml), glucose solution (0.2%). 
A375 Growth Media 
A375 cells were grown in Dulbecco's minimal medium containing 10% (v/v) FBS, penicillin (100Ulml), 
streptomycin (1 OO~g/ml), fungizone (5~g/ml). 
A549 and JFF Growth Media 
A549 and JFF cells were grown in Dulbecco's minimal medium (Invitrogen) containing 10% (v/v) 
FBS, penicillin (100U/ml), streptomycin (100~g/ml), fungizone (5~g/ml). 
NAK 3.2 Growth Media 
NAK 3.2 cells were maintained in Keratinocyte serum free medium (Invitrogen), supplemented with 
EGF and bovine pituitary extract (25mg) (Invitrogen). 
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2.4. Reagents, solutions and equipment used for visualising cells 
2.4.1. Immunohistochemistry 
APES coating of slides 
Glass slides were coated with 3% (v/v) 3-aminopropyl-triethoxysilane (APES) solution in acetone 
(APES) to aid adherence of sections to the slides. 
Cutting frozen tissue 
Frozen sections were cut using a Kryostat 1720 digital cryostat (Leitz) onto APES-coated glass 
slides. 
Preparation of and cutting paraffin sections 
Tumour samples from surgery were immediately fixed in formalin, processed and further embedded 
in liquid paraffin wax (Merck/SDH). Sections of paraffin-embedded tissue were prepared using a 
Reichert-Jung 2030 microtome. 
Staining cells 
Prior to staining, prepared sections or areas of cells grown on slides were circled using a wax pen 
(Dako Corporation). For all protocols, a standard three-stage immunoperoxidase technique 
(Vectastain Elite ASC kit) (Vector Laboratories Ltd.) was used. Details and dilutions of the primary 
antibodies used in these studies are listed in Table 2.4.1.a. The stain was further visualised with a 
peroxidase substrate solution; 3-amino-9-ethyl carbazole (AEC) (Vector Laboratories Ltd., 
Peterborough, UK), prepared according to the manufacture~s instructions. When desired, cells were 
counterstained with Gill's haematoxylin, and specimens were then cover-slipped using DAKO 
aqueous mounting medium (DAKO Corporation, CA, USA). 
Antigen Antibody Nature of antibody IgG Working dilution Supplier 
code concent CC FS PS 
ration 
a1 MCA1133 Mouse monoclonal 20llg/ml 1:50 1:50 N/A Serotee 
a2 NCL- Mouse monoclonal Not 1:100 1:100 N/A Novocastra 
CD49b given 
a3 NCL- Mouse monoclonal Not 1:100 1:100 N/A Novocastra 
CD49c given 
a4 P4G9 Mouse monoclonal 811lg/ml 1:100 1:100 N/A Dako Corporation 
as P1D6 Mouse monoclonal 211lg/ml 1:50 1:50 N/A Dako Corporation 
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a6 NCL· Mouse monoclonal Not 1:100 1:100 N/A Novocastra 
C049f given 
avp3 MCA757G Mouse monoclonal 1mg/ml 1:150 1:150 N/A Serotec 
P1 MCA532 Mouse monoclonal 1mg/ml 1:100 1:100 N/A Serotec 
MMp·2 42·5011 Mouse monoclonal 2mg/ml 1:500 1:50 1:1000 Chemicon International 
Inc. 
MMP·9 56·2A4 Mouse monoclonal 3mg/ml 1:2000 1:100 1:500 Chemicon International 
Inc. 
TIMP·2 67-4H11 Mouse monoclonal 2mg/ml 1:2000 1:150 1:1000 Chemicon International 
Inc. 
u·PA N/A Goat polyclonal Not 1:200 1:200 1:1000 Chemicon International 
given Inc. 
PAI·1 N/A Sheep polyclonal Not 1:500 1:500 1:500 Chemicon International 
given Inc. 
PAI·2 N/A Sheep polyclonal Not 1:10· 1:103 1:1000 Chemicon International 
given Inc. 
E- P2H3 Mouse monoclonal 1mg/ml 1:50 N/A N/A Chemicon International 
selactin Inc. 
VCAM·1 P3C4 Mouse monoclonal 1mg/ml 1:50 N/A N/A Chemicon International 
Inc. 
ICAM-1 P2A4 Mouse monoclonal 1mg/ml 1:250 N/A N/A Chemicon International 
Inc. 
S·100 NCL-S100 Mouse monoclonal Not 1:30 N/A N/A Novocastra 
given 
Melan-A NCL- Mouse monoclonal Not 1:25 N/A N/A Novocastra 
MelanA given 
HMB45 NCL· Mouse monoclonal Not 1:45 N/A N/A Novocastra 
HMB45 given 
Mouse N/A Mouse monoclonal Not As As As Oako Corporation 
IgGl given appropri appro appropri 
negative ate priate ate 
control 
Table 2.4.1.a. Details of primary antibodies used in immunohistochemical studies. N/A; not 
applicable, CC; cu~ured cells, FS; frozen sections, PS; paraffin sections. 
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2.4.2. Flow cytometry 
FACS buffer was prepared using PBS with 0.5% BSA and refrigerated until required. Details and 
dilutions of the primary and secondary FITC-Iabelled antibodies used in these studies are listed in 
Table 2.4.2.a. 
Antigen Antibody Nature of antibody IgG Working Supplier 
code concentration dilution 
a1 MAB1973 Mouse monoclonal 1mg/ml 1:100 Chemicon International Inc.. CA. 
USA 
a2 MAB1998 Mouse monoclonal 1mg/ml 1:100 Chemicon International Inc.. CA. 
USA 
a3 MAB2056 Mouse monoclonal 1mg/ml 1:100 Chemicon International Inc.. CA. 
USA 
a4 MAB1698 Mouse monoclonal 1mg/ml 1:50 Chemicon International Inc.. CA. 
3 USA 
as MAB1986 Mouse monoclonal 0.2mg/ml 1:20 Chemicon International Inc .• CA. 
USA 
a6 MAB1378 Rat monoclonal 1mg/ml 1:100 Chemicon International Inc.. CA. 
USA 
~4 MAB2058 Rat monoclonal 1mg/ml 1:100 Chemican International Inc.. CA. 
USA 
E- P2H3 Mouse monoclonal 1mg/ml 1:50 Chemicon International Inc .• CA. 
selectin USA 
VCAM-1 P3C4 Mouse monoclonal 1mg/ml 1:50 Chemicon International Inc.. CA. 
USA 
ICAM-1 P2A4 Mouse monoclonal 1mg/ml 1:100 Chemican International Inc.. CA. 
USA 
FITC- AP124F N/A N/A 1: 100 Chemican International Inc.. CA. 
labelled USA 
goat 
anti-
mouse 
IgG 
FITC- AP136F N/A N/A 1: 100 Chemicon International Inc.. CA. 
labelled USA 
mouse 
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anti-rat 
IgG 
Mouse N/A Mouse monoclonal N/A As Oako Corporation, CA, USA 
IgG1 appropriate 
negative 
control 
Table 2,4,2.a, Details and optimum antibody working dilutions of primary antibodies used 
FACS analysis, N/A; not applicable. 
2.4.3. Labelling cells with succinimidyl esters 
For cellular detection and tracking, cells were labelled with succinimidyl esters (Molecular Probes, 
Inc.) prior to use. In all cases, tumour cells were labelled with carboxy-fluorescein diacetate, 
succinimidyl ester (CFDA-SE) and endothelial cells were labelled with SNARF-1 carboxylic acid, 
acetate, succinimidyl ester (SNARF-1). For FACS analysis and invasion assays, endothelial cells 
were labelled at 2j..lM and 20j..lM, respectively. For adhesion assays, tumour cells were labelled at 
5j..lM. These reagents passively diffuse into the cells and are colourless and non-fluorescent until 
their acetate groups are cleaved by intra-cellular esterases to yield highly fluorescent compounds. 
After reacting with intracellular amines, the fluorescent conjugates become stable in the cell and can 
be fixed with aldehyde fixatives. CFDA-SE emits light at a 492-517nm and SNARF-1 emits light at 
580-640nm. 
2.4.4. Scanning electron microscopy 
Mr Ian Palmer carried out all processing for electron microscopy. All reagents and consumables 
used can be obtained from T AAB Laboratories Equipment Limited. For critical point drying, a 
Polaron 300 critical point dryer was used, and an Edwards Sputter coater was used for sputter 
coating. 
2.5. Reagents, solutions and equipment used in Invasion Assays 
To study invasion, Transwell inserts (6.Smm diameter) (Corning/Costar) were used. The base of the 
insert is a polycarbonate membrane, with 8j..lM pores, unless otherwise noted. Each insert was 
coated with an artificial basement membrane of Matrigel (1.Smg/ml) (Beckton Dickenson), unless 
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otherwise stated. Matrigel was made up according to manufacturer's instructions in serum free 
media (RPMI 1640). For optimisation of the transendothelial cell invasion assay, an extra cellular 
matrix (ECM) solution was also used, made up with equal volumes of fibronectin (15Jlg/ml), collagen 
type IV (15Jlg/ml) and laminin (15Jlg/ml), diluted in sterile PBS. Invasion through alternative pore 
sizes of 3JlM and 5JlM was assessed. For removal of non-invaded cells, disposable cotton buds 
were obtained from Boots Company PLC. Other equipment, solutions and reagents required for the 
invasion assays have been previously described (2.1-2.4). 
2.6. Reagents, solutions and equipment used in Adhesion Assays 
Hoescht (33342) for used for counterstaining cells in the adhesion assays. Plates were analysed 
using a Wellfluor microplate fluorescence reader (Denley). The data were collected and analysed 
using Wellfluor Data Capture software (Denley). Other equipment, solutions and reagents required 
for the adhesion assays have been previously described (2.1-2.4). 
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B. Methods 
2.1. General cell culture 
Passaging of cell lines and short term cultures (STCs) 
Cell confluency was monitored on a daily basis and cultures were passaged towards the end of the 
log phase of cell growth (between 60-80% confluency). Cells were grown in either 25cm2 or 75cm2 
tissue culture flasks and were seeded in volumes of 5 or 10ml of culture medium, respectively. All 
cell lines and STCs used grew in an anchorage dependent manner. 
Sub-culturing 
Growth medium was aspirated from the tissue culture flask using sterile glass Pasteur pipettes and a 
standard aspirator. Attached monolayers were washed in 2ml of PBS. 2ml of trypsin-EDTA was 
added to the flask and the flask incubated at 37°C for 3 minutes. The cells were resuspended by 
gentle flushing in 10ml of culture medium containing FBS to neutralise enzyme activity. Cells were 
transferred to a clean 13ml centrifuge tube and pelleted by centrifugation. The supernatant was 
discarded and the pellet resuspended in pre-equilibrated culture medium before transferring to fresh 
flasks at an appropriate dilution. Prior to seeding endothelial cells, culture flasks were coated with 
3ml of attachment factor and incubated for 30 minutes at 37°C. Residual attachment factor was 
discarded before flasks were used. Cultures were monitored regularly and the media replaced with 
fresh pre-equilibrated media every 3 days, to retain cell viability. 
Preparation of frozen cell cultures 
Frozen stocks of all cell lines and STCs were prepared from sub-confluent cell cultures where cells 
were in the log phase of growth. A suspension of cells was prepared and pelleted by centrifugation. 
Cells were resuspended in the appropriate growth medium supplemented with 10% (v/v) sterile 
DMSO. 1 ml aliquots of this cell suspension were rapidly transferred to 1.2ml cryovials and frozen, in 
a polystyrene rack, surrounded in cotton wool, at -70°C for 24 hours, before transfer to a liquid 
nitrogen vessel for long term storage. 
Revival of frozen cell cultures 
Cryovials were removed from liquid nitrogen and thawed rapidly in a water bath at 37°C. Cell 
suspensions were transferred to a 13ml centrifuge tube, diluted in 10ml of the appropriate medium 
and pelleted by centrifugation. The supernatant was discarded and the pellet resuspended in 10ml of 
the appropriate medium. Cells were allowed to recover and plate down for 24 hours, before the 
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medium was removed and replaced with fresh medium. Cells were then cultured and passaged as 
described before. Cells were passaged at least twice before use in assays, to allow full recovery. 
Estimation of cell number and cell viability by trypan blue exclusion 
Cell density for seeding fresh flasks was estimated by counting using a haemocytometer slide. 
Where appropriate, cell viability was tested using trypan blue exclusion. 50J.l1 of dilute cell 
suspension was added to 50J.l1 of trypan blue mixed and left to stand for 2 minutes. 10J.l1 of this 
suspension was then added to a clean counting chamber and examined under a phase contrast 
inverted microscope. Four grids of sixteen squares were counted containing a volume of 1 mm2 each 
and cell number was counted using the following equation: 
Preparation of STCs 
Number of cells/ml = cell count x 10.000 x dilution factor 
4 
Fresh posterior uveal melanoma samples were collected in surgery and placed into sterile PBS in a 
25m I Universal container. Each sample was chopped finely with a scalpel in a plastic petri dish (60 x 
15 mm), washed in PBS and transferred to a clean 13ml centrifuge tube using a glass Pasteur 
pipette. Cells were pelleted by centrifugation at 200g (1000 rpm) for 10 minutes, the supernatant was 
discarded and the cells resuspended in appropriate growth medium for ocular melanomas before 
transferring to 25cm2 tissue culture flasks. Cultures were carefully monitored daily and the media 
changed every 3-5 days, with fresh pre-equilibrated media. Where possible, STCs were used for 
studies between passages 1 and 6. Once STCs appeared to be growing in culture indefinitely, they 
were considered to be more stable cell lines. To establish techniques and for standardisation of 
assays, an invasive (SOM 196B) and a non-invasive uveal melanoma cell line (SOM 157d [Shaif-
Muthana et al., 2000]) were used. Both cell lines were originally established in this laboratory, and 
are of mixed cell morphology. SOM 196B was used between passages 25 and 33 and SOM 157d 
was used between passages 95 and 105 in all assays. 
Characterisation of primary melanoma cultures 
To confirm that STCs were melanoma in origin, cells were grown on sterile glass slides, and 
immunohistochemistry was used to investigate the expression of the melanoma markers S-100, 
HMB45 and Melan-A (2.1.1). 
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2.2. Visualisation of cells 
2.2.1. Immunohistochemistry 
Growing cells on slides 
Julia Woodward 
To study the expression of specific proteins by cells grown in culture, cultured cells were grown on 
sterile glass slides (25x75mm) for 24 hours. Once cells had reached confluency in a 75cm2 tissue 
culture flask, a cell suspension was prepared and cells were pelleted by centrifugation. Cells were 
then resuspended in appropriate growth medium. Glass slides were placed in a clean petri dish 
(90x15mm) using sterile forceps and 1ml of cell suspension was pipetted onto each slide. Cells were 
allowed to plate down (for approximately 1 hour) before 10ml of appropriate growth medium was 
added to the petri dish to cover the glass slides. Slides were incubated for 24 hours. Prior to fixation, 
slides were washed in PBS and allowed to air dry. Cells were fixed in 100% acetone for 10 minutes 
before transferring to a _20DC freezer for storage. For immunohistochemial studies, slides were 
removed from storage 16 hours before use. 
Preparation of glass slides for use with frozen and paraffin sections 
Glass slides were coated with APES solution to aid adherence of sections to the slides. Prior to 
coating, slides were washed thoroughly in detergent and distilled water before air-drying. Slides were 
then coated in APES solution for 30 seconds before being rinsed in acetone and distilled water twice 
and allowed air-drying. 
Preparation of frozen tissue 
Fresh tumour samples were collected in surgery at the Royal Hallamshire Hospital, after enucleation 
and immediately placed into the liquid OCT compound and snap frozen in iso-pentane, covered in 
further OCT compound and stored at -70°C or in a liquid nitrogen vessel. 
Cutting sections from frozen tissue 
8J.lM sections of frozen tissue were mounted on APES-coated glass slides and allowed to thoroughly 
dry-out overnight at room temperature prior to fixation. To fix sections, slides were placed in 100% 
acetone for 10 minutes. Slides were stored at -20°C until required. Sections were removed from 
storage for 10 minutes before use. 
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Processing tissue to paraffin wax 
Tumour samples from surgery were immediately fixed in formalin prior to processing. Samples were 
dehydrated through up-graded ethyl alcohols and then cleared in xylene before being embedded in 
liquid paraffin wax. 
Cutting paraffin-embedded sections 
5/-lM sections were cut and mounted onto APES-coated glass slides to help adherence of sections, 
racked and dried overnight in an oven at 60°C. When required, sections were de-waxed through two 
changes of xylene at 5 minute intervals, and re-hydrated through a series of graded alcohol solutions. 
Initially this involved clearing the sections of xylene by immersing in 100% ethanol for 5 minutes. 
This was followed by 5 minutes in a trough of fresh 100% ethanol, and finally partially re-hydrated in 
70% ethanol for 5 minutes before. Sections were then blocked for endogenous peroxidase activity, 
by immersing sections in 3% hydrogen peroxide solution in methanol for 20 minutes. Sections were 
next rinsed in tap water before antigen retrieval methodology was used. A trough containing 200ml 
of 0.1 % (w/v) calcium chloride was allowed to equilibrate to 37°C in an incubator, before dissolving 
trypsin in the solution to prepare a 0.1 % (w/v) solution. Slides were transferred to the trough of 
enzyme solution and maintained at 37°C before rinsing in water at room temperature, to inhibit 
enzyme action by diluting the enzyme and lowering the temperature. When high levels of melanin 
were present in the tumour, sections were bleached which involved submerging sections in 0.25% 
(v/v) potassium permanganate solution for 2 hours. Sections were then washed in 1 % (vlv) oxalic 
acid for 1 minute and rinsed in PBS. 
Immunohistochemical staining protocols 
Prior to staining, prepared sections or areas of cells grown on slides were circled using a wax pen to 
retain solutions on the sections or cells during the procedures. All antibody and enzyme incubations 
were performed in a humidity chamber at room temperature, and the solutions were diluted in PBS. 
For all protocols, a standard three-stage immunoperoxidase technique was used. The slides were 
initially rinsed in PBS before incubating with 1.5% normal (blocking) horse or rabbit serum 
(dependent on the origin of the primary antibody) for 30 minutes to prevent non-specific binding. 
Normal serum was then removed from the slides, and the primary antibody applied by pipette, at an 
appropriate dilution. Slides were incubated with the primary antibodies for 2 hours at room 
temperature. The primary antibodies were removed from the slides using a pipette before washing 
slides in PBS for 5 minutes. A 0.5% biotinylated secondary link antibody was next applied (diluted in 
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PBS with 1.5% normal serum), prepared from the same species in which the preferred serum for 
blocking is made, and slides were incubated for 30 minutes. Slides were rinsed thoroughly in PBS for 
5 minutes, before incubating with a preformed avidin and biotinylated horseradish peroxidase 
macromolecular complex for 30 minutes. At the end of this period, slides were washed in buffer and 
finally the stain was visualised with AEC, prepared to the manufacture's instructions. After incubating 
with AEC for 30 minutes, a red reaction product developed. Excess AEC was rinsed from slides 
using distilled water. At this point, a counter-stain of Gill's haematoxylin was applied if desired, and 
then 'blued' in tap water. Sections or cells were then cover-slipped with aqueous mounting medium. 
IgG isotype control antibodies were included in each experiment. For use as positive controls and 
titration experiments, antibodies were screened on alternative cell types, to check for specific binding. 
For assessment of integrin antibodies, A375 cells, keratinocytes and fibroblasts were chosen. Breast 
cancer cells (MCF-7) and sections were used for antibodies against degradative enzymes and 
inhibitors, whilst A375 cells were used for melanoma marker antibodies. 
Analysis 
Two independent observers scored the intensity of positive staining semi-quantitatively, as described 
by McCarty et al., 1985 and Vora et al., 1997. The percentage of cells staining was determined and 
staining was considered homogenous if 75% of cells stained and heterogeneous if the percentage of 
cells stained was between 5% and 75%. Staining intensity was scored as + weak, ++ medium, or 
+++ strong. 
2.2.2. Indirect Immunofluorescence Staining of Melanoma and Endothelial Cells 
and Detection of Staining by Flow Cytometry (FACS assay) 
To analyse expression of surface antigens by cultured cells, FACS analysis was also used. 
Staining cells for FACS analysis 
Cells were harvested using cell dissociation solution and resuspended at a concentration of 5x105 
cells/ml in appropriate growth media. When pelleting cells for FACS analysis, cells were centrifuged 
at 4°C. For each antibody to be tested, 200lli of cell suspension was pi petted into 13ml centrifuge 
tubes (100,000 cells) and 5ml of appropriate growth media was added to each tube. Cells were 
further pelleted, the supernatant was discarded and the cells were resuspended in the remaining 
volume of media. Cells were washed twice by adding 5ml ice-cold FACS buffer to each tube and 
pelleted. After the final centrifugation, the buffer was removed and the cells were resuspended in the 
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remaining volume. The primary antibody was diluted in the FACS buffer and 50~1 of the diluted 
antibody was added to the suspended cells (Section A, Table 2.4.2.a). Cells were incubated on ice 
for 30 minutes. After this incubation period, 5ml buffer was added to each tube and the cells were 
pelleted, before washing twice in FACS buffer. After the final centrifugation, the buffer was removed 
and the cells were resuspended in the remaining volume. An appropriate FITC-Iabelled secondary 
antibody, dependent upon the primary antibody, was prepared on ice at a dilution of 1:100 with buffer 
and 1 OO~I was added to each sample. Cells were incubated on ice for a further 30 minutes. After 
this time, cells were again washed twice and resuspended in 300~1 FACS buffer. Samples were 
transferred to 12mm FACS tubes for flow cytometric analysis on the same day. In all cases, test 
samples were run against a control sample, labelling cells with an appropriate IgGl isotype control 
antibody. Results were expressed as the relative median fluorescent intensity (MFI), comparing test 
with control samples. Relative MFI values of greater than two were taken as positive, as expression 
levels were considered to have doubled. Experiments were repeated three times and a mean 
calculated. 
Incubation of endothelial cells with TNF-a or IL-1 ~ 
To stimulate adhesion molecule expression on endothelial cells, cells were pre-incubated with either 
TNF-a (1ng/ml) or IL-1~ (1ng/ml) for a period of 24 hours. After this period, cells were analysed for 
adhesion molecule expression by FACS analysis. 
Generation of tumour cell conditioned media (CM) and its effect on endothelial cell surface antigen 
expression 
To assess the effect of CM from tumour cells on endothelial cell adhesion molecule expression, the 
media was first aspirated from T75 flasks of semi-confluent tumour cells. Cells were washed with 
PBS and 10ml endothelial cell growth media was replaced in the flask. Cells were incubated for 24 
hours. After this period, the media was again aspirated from flasks of endothelial cells, replaced with 
tumour cell CM and incubated for a further 24 hours. FACS analysis was then carried out to assess 
and changes in adhesion molecule expression. 
Co-culturing endothelial and tumour cells for FACS analysis 
The consequence of co-culturing tumour and endothelial cells was also investigated. Endothelial 
cells from confluent flasks (approximately 1.5x106cells) were pre-labelled with SNARF-1 as described 
below (2.2.3). Cells were re-seeded in a T75 flask, pre-coated with attachment factor and allowed to 
plate down for 1 hour. Cells were then checked to ensure coverage of the flask. After this period, 
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5x105 tumour cells were washed in PBS, resuspended in endothelial cell growth media and added to 
the flask. Flasks were incubated for 24 hours. By incubating co-cultures with 3ml cell dissociation 
solution at 37°C, cell types were dissociated selectively from the flask. Tumour cells were incubated 
for 15 minutes with cell dissociation solution before removal and were placed on ice until required. 
Fresh cell dissociation solution was replaced and flasks were incubated for a further 45-60 minutes, 
to remove endothelial cells. FACS analysis was then performed to analyse any changes in adhesion 
molecule expression. 
2.2.3. Labelling cells with succinimidyl esters 
To label cells, cells were dissociated from their culture flasks and resuspended at a concentration of 
5x105ml in serum free media. Cells were pelleted and resuspended in sterile PBS containing the 
probe at the required concentration. Cells were incubated in a water bath at 37°C for 15 minutes. 
Once labelled, cells were pelleted and resuspended in serum-free media and incubated in a water 
bath for 30 minutes at 37°C to ensure complete modification of the probe. Cells were further washed 
in sterile PBS before resuspending in the required volume of serum-free media, supplemented with 
0.1 % BSA for each assay. 
2.2.4. Scanning electron microscopy 
Mr Ian Palmer (Department of Pathology, Royal Hallamshire Hospital) carried out all processing for 
electron microscopy. To assess transendothelial cell invasion, co-cultures of tumour and endothelial 
cells were set up as described below (2.3.2). Non-invaded cells were not removed before fixation, 
whilst membranes were similarly not removed from plastic inserts prior to fixation. For assessing 
adhesion of tumour cells to the endothelium, endothelial cells were grown to confluence (5x105/ml) 
for 24 hours on 13mm glass coverslips, pre-coated with attachment factor in the base of a 24-well 
plate, in endothelial cell growth media. Media was removed by aspiration; monolayers were rinsed 
twice with PBS before tumour cells (2x105/ml) were seeded onto the endothelial cell layer. Co-
cultures were incubated for 24 hours. 
Membranes and covers lips were washed in 0.1 M sodium cacodylate buffer for 1 minute before fixing 
using 2% formaldehyde and 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer for 30 minutes at 
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room temperature. After fixation, samples were washed in 0.1 M sodium cacodylate buffer for 5 
minutes before covering with 1 % osmium tetroxide in 0.1 M sodium cacodylate buffer for 30 minutes 
at room temperature. Samples were further washed in 50% ethanol for 5 minutes. For 'en-bloc' 
staining, samples were covered with 2% uranyl acetate in 50% ethanol for 30 minutes before further 
rinsing in 50% ethanol for 5 minutes and dehydrating through graded ethanols. 
For preparation of the membranes for scanning electron microscopy, samples were removed from the 
plastic insert with a scalpel. Membranes and coverslips were then transferred from 100% ethanol 
into 100% acetone through a graded series. Cells were critical point dried on cover slips using liquid 
carbon dioxide for 30 minutes. Samples were mounted on aluminium scanning electron microscopy 
stubs using double-sided carbon adhesive disks before sputter coating using a gold cathode for 1 
minute at 50mA. Cells could then be observed under scanning electron microscopy. 
2.3. Invasion assays 
To assess the invasive capacities of cell lines and STCs, a modified Boyden Chamber system was 
employed. 
2.3.1. Standard Invasion Assays 
Coating Transwell inserts with Matrigel 
Prior to use, Matrigel was diluted in RPMI 1640, to a concentration of 1.5mg/ml (according to 
manufacturer's instructions), and frozen at -20°C in 100).l1 aliquots. All manipulations were 
performed on ice and plastic ware chilled, to prevent Matrigel polymerisation. For each assay, a 
fresh aliquot of Matrigel was thawed. Each membrane was evenly coated with 10).l1 Matrigel and 
allowed to air dry for 30 minutes in a sterile environment. When alternative substrates have been 
used to coat membranes, these have been noted in the relevant chapter. 
Preparation of cells for invasion assay 
Cell lines or STCs were dissociated from their culture flasks and after centrifugation, were 
resuspended in 10ml PBS, to wash the cells thoroughly. After further centrifugation, cells were 
resuspended in an assay medium of RPMI 1640 medium, supplemented with 0.1% BSA at a 
concentration of 5x105/ml. 200).l1 of cell suspension was pipetted into the upper chamber of the 
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Transwell insert (1x105/well) whilst 600J..l.I of assay medium was pipetted into the lower chamber. 
Cells were incubated at 37°C for 24 hours, unless otherwise noted. 
Removal of invaded cells, fixation and staining of membranes 
After 24 hours, cells in suspension were removed from the upper chamber of the well. Non-invaded 
cells attached to the upper surface of the membrane were removed by gently scraping the membrane 
with a disposable cotton bud. Invaded cells on the under side of the membrane were fixed in 100% 
ethanol for 5 minutes. To stain the nuclei of the cells, membranes were placed in Gill's haematoxylin 
for 10 minutes. Membranes were finally 'blued' in tap water for 3 minutes. To mount membranes, a 
scalpel was used to carefully detach the membrane from the insert. Membranes were mounted and 
cover-slipped using aqueous mounting medium, ensuring that the invaded side was uppermost. 
Counting invaded cells 
Invaded cells were counted under phase contrast microscope at x400 magnification. For each 
membrane, ten random fields of view were counted. All experiments were set up in triplicate and a 
mean value was calculated. Where possible, experiments were also repeated three times and a 
mean value was again calculated. 
Inclusion of cells and CM in the lower chamber of the invasion assay 
To investigate the effects of different cell types on invasion, cells were grown to confluence (5x105 
cells) in appropriate media in a 24-well plate and were then used in Transwell assays. Prior to the 
assay, media was replaced with RPMI 1640 supplemented with 0.1% BSA. Transwell filters pre-
coated with Matrigel were placed in 24-well plates, thus including the different cell types in the lower 
chamber as potential source of chemoattractants. Tumour cells were dissociated from flasks and 
invasion assays were carried out as described above. Alternatively to assess the effect of CM on 
invasion, CM was collected after incubating each cell type to be assessed with RPMI with 0.1% BSA 
for 24 hours. By using CM and by growing the cells on the lower surface of the well of the Transwell 
chamber, it was possible to assess whether factors secreted by cells were still effective in the 
absence of the cellular source. CM was produced as previously described (2.2.2). CM was then 
stored at -20°C until required for further use. Prior to use, CM and was filter sterilised (O.2J..1.M pore 
filter), and added to the lower chambers of test wells. Negative controls were included in which 
neither cells or CM was added to the lower chamber. Assays were incubated at 37°C for 24 hours 
and levels of invasion were assessed as previously described. Each experiment was performed in 
triplicate and where possible, was repeated three times and a mean calculated. 
- 62-
Chapter 2: Materials and Methods Julia Woodward 
2.3.2. Transendothelial Cell Invasion 
To study transendothelial cell invasion, the basic invasion assay method was used, with the addition 
of an endothelial cell monolayer on the membrane. HDMECAs were used for this purpose, unless 
otherwise noted. HDMECAs were stripped from their culture flasks as previously described and 
resuspended in microvascular endothelial cell growth media at a concentration of 5x1 05/ml. 200f.!1 of 
cell suspension was pi petted onto each membrane, previously coated with Matrigel (1 x1 OS/well) . 
Cells were incubated for 24 hours at 37°C, to allow cells to plate down and form a monolayer across 
the membrane. Before tumour cells were added to the assay, the growth medium was removed from 
the upper chamber of the insert, and the cells were washed with PBS, to remove any traces of FBS. 
Tumour cells were added to the upper chamber at the concentration previously described. The 
assay was subsequently set up as described above and incubated for a period of 24 hours (Fig. 
2.3.2.a). Each experiment included appropriate positive and negative controls set up in triplicate, and 
where possible was repeated three times. Negative control wells were endothelial cells alone. 
Tumour cell invasion through basement membrane components only (,standard invasion levels'), 
acted as positive controls for each culture. Levels of transendothelial cell invasion were compared 
with positive controls. Endothelial cells and non-invaded cells were removed as previously described 
and analysis was carried out as described before (2.3.1). 
RPMI-1640 + 0.1% 
BSA 
Artificial basement 
membrane 
811M pore 
polycarbonate 
membrane 
Transwell insert 
Tumour cells 
Endothelial cells 
Figure 2.3.2.a. Schematic Diagram of the Transendothelial Cell Invasion Assay. Endothelial 
cells (shown in ) are grown to confluence on a Matrigel-coated (shown in green) 8J..lM pore Transwell 
membrane. Tumour cells (shown in ) in the upper chamber then invade through the endothelial cell layer, 
artificial basement membrane (Matrigel), and 8J..lM pore membrane, into the lower chamber. 
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Tracking of tumour and endothelial cells in the transendothelial cells assay 
For tracing endothelial and tumour cell movement in the transendothelial cell invasion assay, cells 
were labelled with succinimidyl esters prior to use, as described previously (2.2.3) at the noted 
concentrations and in triplicate. Labelled cells were used as before in the assay. Wells were 
observed under fluorescence before and after removal of endothelial and non-invaded cells, to allow 
both assessment of the endothelial cell layer and cellular interactions between the two cell types, and 
the invaded cells. 
2.4. Adhesion assays 
To study the adhesive interactions between endothelial and tumour cells, HDMECAs or HULECs 
were dissociated from their culture flasks and resuspended in endothelial cell growth medium at a 
concentration of 2x105/ml. 100ml of cell suspension was then pipetted into each well of a sterile 96-
well plate, pre-coated with attachment factor (2x104/well). For each experiment, each condition was 
repeated in six wells. Cells were incubated for 24 hours to allow growth to confluence in the bottom 
of each well. Prior to setting up the adhesion assay, the growth medium was removed from the wells 
and the cells were washed twice with PBS, to remove any traces of FBS. 
Tumour cells were dissociated from their culture flask, using sterile 550J.lM EDTA in PBS. Using the 
method previously described, tumour cells were labelled with CFDA-SE (2.2.3) and resuspended at a 
concentration of 5x105/ml in RPMI 1640 medium supplemented with 0.1% BSA. Prior to adding 
tumour cells to the endothelium, to ascertain that the cell suspension was made up of single cells 
rather than clumps of cells, a drop of the cell suspension was placed on a glass slide, and observed 
under the microscope. Ensuring that the suspension was well dispersed, 50J.l1 of the cell suspension 
(25x103/well) was carefully pipetted into each well containing the endothelial cell layer. Plates were 
incubated at 37°C for 4 hours and were laid separately on the incubator shelf when multiple plates 
were used (ensuring that plates acclimatised to the required temperature at the same time). During 
the incubation period, plates were rotated to overcome any vibrational effects of the incubator. Five 
minutes prior to the end of the incubation period, endothelial cells were counterstained with Hoescht 
(10J.lM) and replaced in the incubator. Positive and negative controls were included in each assay. 
For positive controls, as uveal melanoma cells preferentially adhere to fibronectin (Wagner et al., 
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1997). tumour cell adhesion to fibronectin-coated wells (15J.lg/ml) was assessed; for negative 
controls. no tumour cells were added to endothelial cell monolayers. After the incubation period. 
plates were removed from the incubator and any non-adherent cells were removed by a process of 
'inverting and blotting' the plate and washing with PBS. repeating this three times. Cells were fixed 
with 4% formaldehyde/PBS for 15 minutes. before rinsing in distilled water and allowing air-drying 
overnight in a dark. dry atmosphere before analysing using a microplate fluorescence reader. Six 
wells were analysed for each condition. and a mean calculated. Experiments were further repeated 
three times and a mean of the three experiments calculated. 
2.5. Statistical analysis 
The Analysis of Variance (ANOVA) test was used throughout these investigations to compare 
population means. assessing treatment values against an appropriate control. The test calculates 
the total amount of variation in a set of data. and the degree of variation associated with possible 
causes. In each instance. the underlying assumptions were assessed to check randomness. 
independence. additivity of the treatment effect. homogeneity of variance and normality of the 
residuals. For FACS data, the one-way ANOVA test was used, as the data was non-normally 
distributed. For two sets of data (transendothelial cell invasion and FACS data). due to the presence 
of low counts, the variance was found to be heterogeneous. and consequently a square root 
transformation was applied (--J(x+0.5)). In all cases p values of less than 0.05 were taken as 
significant. 
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C. Health and Safety 
All procedures were carried out in accordance with health and safety requirements by COSHH 
(Control of Substances Hazardous to Health). Laboratory coats and disposable latex gloves (Ansell 
Medical) were worn at all times when handling biological specimens . 
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3.1. Introduction 
As highlighted in the Introduction (Section B, 1.3.1), previous investigations have reported expression 
of a number of integrins, and degradative enzymes in uveal melanoma (Cottam et al., 1992; Ten 
Berge et al., 1993; Creyghton et al., 1995; Vaisanen et al., 1999; Elshaw et al., 2001; EI-Shabrawi et 
al., 2001). These studies have however, used a selection of tissue samples, and as yet, no study 
has looked at expression of a wide range antigens by the same tumour sample. The effect of the in 
vitro environment on expression by uveal melanoma cells in culture when compared with expression 
in vivo, has furthermore, only been investigated in a limited fashion (Marshall et al., 1998). 
Aims of the study 
Primarily, the aim of this current study was therefore to assess expression of a panel of integrins, 
degradative enzymes and inhibitors in a series of ten primary uveal melanomas, with the aim of 
relating expression to known prognostic indicators. Immunohistochemistry was used to compare 
differences in expression between STCs, and frozen and paraffin-embedded sections, and results 
were related to known histe-pathological data (Appendix II). 
To clarify that cultured cells were malignant uveal melanoma in origin, a series of 23 STCs and two 
cell lines were also stained for expression of a panel of melanoma-associated antigens (Melan-A, S-
100 and HMB-45), where sufficient cells were available. 
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3.2. Results 
3.2.1. Immunohistochemical analysis of melanoma marker expression in uveal 
melanoma short-term cultures 
Three melanoma-associated antigens were chosen for assessment of melanoma classification; all of 
which are routinely used in cutaneous melanoma diagnostics {Orchard, 2000} and their application 
has been previously reported in uveal melanoma classification (de Vries et al., 1998; Heegaard et al., 
2000). As choroidal melanomas of mixed cell populations are not 100% sensitive for one antibody 
alone, three different antibodies were used in the hope of maximising the frequency of positive 
results. In most cases cultures were also analysed by cytogenetics by colleagues in this laboratory, 
as characteristic abnormalities in chromosomes 3, 6 and 8 have previously been described in uveal 
melanomas {reviewed by Singh at al., 2001}. 
A panel of 23 STCs and two cell lines {SOM 157d and SOM 196B} were assessed for melanoma 
marker expression; all tumours were derived from either the choroid or ciliary body {Appendix II}. 
Cells were grown on glass slides and stained by immunohistochemistry, as previously described 
(Methods 2.2.1). Tumours were only assessed where sufficient numbers of cells were available 
surplus to experimental requirements, and therefore not all tumours used for further studies were 
screened. Tumours assessed included SOM 200, 238, 239, 250, 253, 256, 267, 275, 277,282,290, 
295, 296, 301, 305, 306, and 307. Tumours that were not investigated for melanoma marker 
expression were SOM 260, 262, 263, 269, 272, 280, and 281. Results are summarised in Table 
3.2.1.a and examples of staining are shown in Figure 3.2.1.a. A375 cells acted as positive controls 
for these studies {Figures 3.2.1.a.iv and 3.2.2.a.iii and iv}. 
S-100 was most ubiquitously expressed, with cytoplasmic and nuclear staining in 23 of the 25 
cultures {Figure 3.2.1.a.ii}. The antibody used detected both S-100A and S-100B proteins, and has 
been reported to be less specific than antibodies against both Melan-A and HMB-45 {Heegaard et al., 
2000} {potentially reflected by these results}. All ciliary body melanomas expressed S-100 {SOM 
253, 282, 295, 296, 305 and 311} whilst expression was not ubiquitous in the choroidal melanomas 
{Appendix II}. No association could be made between epithelioid, mixed or spindle cell tumours and 
S-100 expression (Appendix II). 
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80M Passage MeJan-A 8-100 HMB-45 
157d 101 +25% +++ 35% +++ 55% 
196B 25 +++ +/++ ++ 
200 3 ++ ++ + 
238 <5 - +++ -
239 14 - +++ -
250 2 - +++ -
253 4 - +++ -
256 1 +++ +++ +++ 
266 11 - ++ -
267 7 - - -
274 <5 + +++ -
275 <5 +++ + +++ 
277 2 - + + 
282 4 - ++ -
290 5 - - -
295 5 - +++ -
296 4 - +50% -
301 3 +++ + +++ 
302 4 ++ ++ ++ 
304 1 +++ ++ +++ 80% 
305 1 - ++ -
306 3 +++ ++ +++ 
307 3 - +++ +++5% 
308 2 +++ ++ +++ 
311 1 +++ 40% +++ ++/+++ 
Table 3.2.1.a. Expression of melanoma-associated antigens in a panel of uveal melanoma 
short-term cultures and cell Jines. Uveal melanomas are classified numerically and known as Sheffield 
Ocular Melanomas (SOM). The percentage of cells staining was determined and staining was considered 
homogenous if 75% of cells stained and heterogeneous if the percentage of cells stained were between 5% 
and 75%. Staining intensity was scored as + weak, ++ medium, or +++ strong. With the exception of two 
tumours (SOM 267 and 290), all tumours expressed at least one melanoma-associated antigen. <5, indicates 
that the passage number was below five, but was unknown. 
In contrast, Melan-A and HMB-45 were expressed in fewer cultures, with 12 out of 25 and 13 out of 
25 cultures expressing these proteins, respectively (Figure 3.2.1.a.i and iii). Nine tumours expressing 
S-100, did not express Melan-A or HMB-45. No association could be made between tumour location 
and Melan-A or HMB-45 expression (Appendix II). For HMB-45, high levels of expression were more 
commonly seen in spindle cell tumours (SOM 266, 274, 275, 301 and 304). with mixed and 
epithelioid tumours showing lower levels of expression, whilst Melan-A stained showed no 
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association with cell type (Appendix II). Two tumours did not express any of the antigens studied 
(SOM 267 and SOM 290). 
With the exception of three STCs (SOM 239, 266 and 267) and the two cell lines (SOM 157d and 
SOM 1968), all cultures were assessed before passage five. No direct association could be made 
between passage number and expression of any of the antigens studied. Excluding the two cell lines 
however, it was however generally observed that tumours of a higher passage were more likely to 
lose Melan-A and HMB-45 expression (SOM 238, 239, 250, 253, 266, 267, 277, 282, 290, 295, 296, 
and 305), when compared with cultures of a low passage (SOM 200, 256, 274, 275, 301 , 302, 304, 
306,307,308, and 311). 
Figure 3.2.1.a. Cultured SOM 157d cells, stained for Melan·A (i), 5·100 (ii) and HMB·45 (iii). 
A375 celis, stained for HMB-45 acted as positive controls (iv). SOM 157d cells are of epithelioid 
morphology, and were stained by the standard ABC immunohistochemistry method with an end substrate of 
AEC (visible as a bright magenta stain) (see 2.2.1). The 't ' indicates examples of cells staining positive. 
Nuclei were counter-stained with Gill's haematoxylin (visible as a purple stain) , and cells were viewed under 
x100 magnification. Melan-A and HMB-45 are both cytoplasmic proteins whereas S-100 proteins are present 
in both the cytoplasm and nucleus. Staining was heterogeneous, with the percentage of positive SOM cells 
graded as 25-30% (+) for Melan A (i) , 30-40% (+++) for S-100 (ii), and 50-60% (+++) for HMB-45 (iii). A375 
cells were graded as 30% (+++) for HMB-45 (iv) . 
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3.2.2. Immunohistochemical analysis of integrin expression in cultured cells 
and frozen sections of posterior uveal melanoma 
The results of the immunohistochemical stud ies of integrin expression are summarised in Tables 
3.2.2.a and b and examples of staining are shown in Fig . 3.2.2.a. Melanin pigmentation in paraffin 
sections was bleached, but th is was not feasible for frozen sections; black pigmentation in frozen 
sections did not however interfere with the magenta colour of the AEC substrate. All frozen and 
paraffin sections were stained by J.K.L. Woodward , and were counter-stained with Gill's 
haematoxylin (Figure 3.2.2.a. ii) . STCs were stained by Ms Shona Elshaw to assist speed of analysis, 
and counter-staining was omitted due to personal preference for techniques, but this did not effect 
the true immunological staining (Figures 3.2.2.a.iii and iv). Integrin expression was restricted to 
cultured cells and frozen sections as antibodies used were unsuitable for formalin-fixed tissue. 
Figure 3.2.2.a. Cultured uveal melanoma cells (i ) and frozen sections (ii) stained for a 1 ~1 and 
a2~1. A375 cells were included as positive controls (iii and iv). Cells were stained by the standard 
ABC immunohistochemistry method with the end substrate being AEC (magenta in colour) . Nuclei in ii) and iv) 
were counterstained with Gill's haematoxylin (visible as a purple stain) , and cells were viewed under the 
magnification noted below. The '+' indicates examples of cells staining positive. Areas of black staining 
in plate ii are melanin granules (M) present in the tumour and for sections staining positively, did not obscure 
observation of positive staining. i) Positive heterogeneous staining for a 1 p 1 in cultured cells of SOM 210 
(x200) (no counter-stain). 50-60% of cells stained positively (++) for a 1 p 1. ii) Negative staining for a 1 p 1 in a 
frozen section of SOM 210 (x400) (counter-stained with Gill's haematoxylin) . iii) Positive staining for a 1 p 1 by 
cultured A375 cells (x400) (no counter-stain) (positive control). iv) Positive staining for a 1 p 1 by cultured A375 
cells (x400) (counter-stained with Gill's haematoxylin) (positive control) . Counter-staining did not effect 
positive staining. 
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Variation in integrin expression between frozen sections and STCs 
Expression specifically targeted to the a-subunit showed some variation, with primarily differences in 
levels of expression of 0.1, 0.2, 0.4, and 0.6 found between frozen tissue sections and cultured cells 
from the same tumours (Table 3.2.2.a). Seven of the ten uveal melanomas lacked 0.1 expression, 
yet cultures established from the same tumours were found to express this integrin (Figures 3.2.2.a.i 
and ii). Similarly, four of the ten tumours (SOM 200, 239, 248, 256) did not express 0.2 but the 
respective STCs stained positively. In contrast frozen sections from three tumours (SOM 250, 253 
and 256) stained positively for 0.6, whilst corresponding STCs did not. Inconsistencies in 0.4 
expression were also seen; for two tumours (SOM 238 and 239), expression was present or absent 
in the cultured cells, with the reverse pattern seen in the frozen sections. No associations could be 
made between expression in frozen sections or cultured cells with tumour cell type, location or patient 
survival (Appendix II). In particular, patients SOM 250 and SOM 255 are known to have developed 
metastases, yet no specific associations could be made between integrin expression in these 
patients and the development of secondary disease. 
SOM 
Antibody 200 210 238 239 248 250 253 255 256 260 
0.1 FS - - ++ - - +++ - - - +++ 
50% 10% 
STC +/++ ++ 50- + + + ++ + +70% +/++ ++ 
50% 60% 50% 50% 50% 
a2 FS - +++ + - - + +/++ + - +++ 
STC +++ +/++ ++ ++/+++ +++ ++/+++ +++ +++ ++ +++ 
a4 FS + +60% - +/++ + +++ + ++ + +/++ 
20% 70% 20% 60% 50% 10% 10% 40% 
STC + 5- ++ + - +++ +50% +/++ + + + 
10% 40% 60% 
0.6 FS +/++ + + +/++ ++ - - ++/+++ - ++ 
STC + ++/+++ - - + + 5- +/++ +/++ + + 
50% >50% 10% 60% 60% 
Table 3.2.2.a. Expression of integrins in posterior uveal melanoma (Sheffield Ocular 
Melanomas (SOM)) in which variation was seen between frozen sections (FS) and short-term 
cultures (STC), detected by Immunohistochemistry. The percentage of cells staining was determined 
and staining was considered homogenous if 75% of cells stained and heterogeneous if the percentage of cells 
stained were between 5% and 75%. Staining intensity was scored as + weak, ++ medium, or +++ strong. 
Variation in expression of 0.1, 0.2, 0.4, and 0.6 was shown between cultured cells and frozen sections. 
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Integrins showing no variation in expression between frozen sections and STCs 
Staining for the a3, a5, and 131-subunits and av133 was consistent between frozen tissue and STCs 
(Table 3.2.2.b). Although frozen sections and STCs of all ten tumours were positive for av133 
expression, stronger expression was however observed in cultured cells in nine out of ten cases, but 
it was not possible to quantify these observations. No associations could be made between 
expression in frozen sections or cultured cells with tumour cell type, location or patient survival 
(Appendix II). 
SOM 
Antibody 200 210 238 239 248 250 253 255 256 260 
a3 FS ++ +++ ++/+++ +++ +++ ++/+++ ++ +++ +++ +++ 
30% 
STC ++ ++ ++ ++ +++ +++ +++ +++ +++ +++ 
a5 FS +/++ ++ + ++ + ++ ++ ++/+++ + ++/+++ 
STC ++ +/++ ++ ++ +++ +++ +++ ++ ++/+++ +++ 
131 FS +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ 
STC +++ ++ ++ +++ ++ ++/+++ +++ ++ +++ +++ 
avJ3 FS + +/++ +5% +50% + + + ++ +10% +/++ 
3 5% 10% 10 
% 
STC +/++ ++ ++/+++ + ++ ++ +++ ++/+++ +/++ ++/+++ 
Table 3.2.2.b. Expression of integrins in posterior uveal melanoma (Sheffield Ocular 
Melanomas (SOM)) in which variation was not seen between frozen sections (FS) and short-
term cultures (8TC), detected by immunohistochemistry. Staining was determined as for Table 
3.2.2.a. No variation in expression of a3, a5, P1 and avp3 was shown between cultured cells and frozen 
sections. 
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3.2.3. Immunohistochemical analysis of degradative enzyme expression and the 
expression of their inhibitors in cultured cells, frozen and paraffin·embedded 
sections of posterior uveal melanoma 
The results of the immunohistochemical studies of MMP-2, MMP-9, TIMP-2, u-PA, PAI-1 and PAI-2 
expression are summarised in Tables 3.2.3.a and b. TIMP-1 expression was not investigated, as an 
appropriate antibody was not available at the time of study. Tissue samples (both frozen and 
paraffin-embedded) and cultured cells from all ten uveal melanomas were found to express MMP-2, 
TIMP-2, u-PA, PAI-1 and PAI-2. Variation was only observed in MMP-9 expression. Expression of 
MMP-9 was detected in all STCs and sections of frozen tissue, but only seven out of the ten paraffin-
embedded samples stained positively for MMP-9 (SOM 200, 210, 239, 248, 250, 256 and 260) 
suggesting that the fixation process maybe preventing positive staining in these instances. Slight 
increases in expression of MMP-9 were also seen in cultured cells from three tumours, when 
compared with respective paraffin and frozen sections (SOM 239, 248 and 250). Again, no 
correlation could be made between expression patterns, prognostic indicators, metastatic disease 
and patient survival (Appendix II). 
SOM 
Antibody 200 210 238 239 248 250 253 255 256 260 
MMp· FS + ++ ++ +++ ++ ++ + + + +50% 
2 50% 10% 
PS ++/+++ ++ ++/+++ ++/+++ +/++ ++ ++ ++ ++ ++ 
STC ++ ++ ++ ++ +++ +++ +++ ++ +50% ++ 
50% 
MMP· FS +5% ++ +++ +/++ + + +/++ + + +/++ 
9 50% 
PS ++ ++ - ++/+++ ++/+++ +/++ . . ++ +++ 
STC +++ ++ +++ ++ +++ ++ ++/+++ ++ +++ +++ 
TIMP· FS +++ +++ +++ +++ +++ +++ ++/+++ +++ +++ ++/+++ 
2 PS ++ ++ +++ +++ ++ +++ + ++ + 
STC +/++ +/++ +/++ +/++ +/++ +/++ +/++ +/++ + 
Table 3.2.3.a. Expression of MMp·2, MMP·9 and TIMp·2 in frozen and paraffin sections (FS 
and PS, respectively) and short·term cultures (STC) in posterior uveal melanoma (Sheffield 
Ocular Melanoma (SOM)), detected by immunohistochemistry. The percentage of cells staining 
was determined and staining was considered homogenous if 75% of cells stained and heterogeneous if the 
percentage of cells stained was between 5% and 75%. Staining intenSity was scored as + weak, ++ medium, 
or +++ strong. Slight variation in expression of MMP-9 expression was shown between paraffin sections and 
frozen sections and cultured cells. No variation in MMP-2 and TIMP-2 was seen. 
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SOM 
Antibody 200 210 238 239 248 250 253 255 256 260 
u·PA FS +++ +++ +++ +++ +++ +++ +++ +++ ++/+++ +++ 
PS +++ +++ + +++ ++/+++ ++ +++ + + + 
STC +++ +++ ++/+++ +++ +++ +++ ++/+++ ++/+++ +++ ++ 
PAI·1 FS +++ +++ +++ ++/+++ +++ +++ +++ +++ ++/+++ ++/+++ 
PS ++ ++ + +++ +++ ++ +++ +++ ++ +++ 
STC +++ ++/+++ +++ +++ ++ +++ ++/+++ ++/+++ +++ +++ 
PAI·2 FS +++ +++ +++ ++/+++ +++ +++ ++ +++ ++ +++ 
PS +++ +++ +/++ +++ +++ ++ +++ +++ ++/+++ +/++ 
STC ++ +++ ++ + +/++ +/++ +/++ +/++ +++ 
50% 
Table 3.2.3.b. Expression of u·PA, PAI·1 and PAI·2 in frozen and paraffin sections (FS and PS, 
respectively) and short·term cultures (STC) in posterior uveal melanoma (Sheffield Ocular 
Melanoma (SOM)), detected by immunohistochemistry. The percentage of cells staining was 
determined as for Table 3.2.3.a. No variation in expression of u-PA, PAI-1 or PAI-2 was seen. 
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3.3. Discussion 
Cell culture has been widely used over a number of years, and provides an excellent system for the 
study of cellular responses and behaviour, offering advantages including providing a readily available 
supply of cells with similar phenotypes, often with high proliferation rates. For cells to become 
immortalised as cell lines, genetic alterations may however have occurred to facilitate continuous 
growth, and consequently cells do not fully represent the tissue of origin. When considering in vitro 
results in relation to clinical details of individual patients, the use of cell lines is therefore often 
inappropriate due to the drift from the original phenotype. In support, serial passage of kidney 
glomerular mesangial cells has been shown to result in altered expression of a number of ECM 
components, degradative enzymes and inhibitors (Schnaper et al., 1996). 
3.3.1. Confirmation of STC melanoma status 
Melan-A (MART -1) 
The Melan-A protein is the product of the MART -1 gene and is expressed in the cytoplasm during 
melanocyte differentiation (Chen et a/., 1996). The antibody is particularly useful in diagnostics due 
to its high sensitivity and specificity for melanocytic lesions (Chen et al., 1996; Heegaard et al., 2000) 
and high expression in uveal melanomas is well documented (Mulcahy et al., 1996; de Vries et al., 
1998; Heegaard et al., 2000). No definition has however been made between benign and malignant 
lesions or between spindle and epithelioid cells (Nicotra et al., 1997; Orosz, 1999; Heegaard et al., 
2000). In this present study, only approximately half of the cultures expressed Melan-A (Table 
3.2.1.a) and in agreement with previous reports (Nicotra et al., 1997; Orosz, 1999; Heegaard et al., 
2000) no association could be made between expression and cell type or tumour location. 
S-100 
The S-100 proteins are a family of calcium-binding proteins, including S-100A and S-100B that differ 
in the composition of the alpha and beta chains. Both are expressed in melanocytes and melanoma 
cells in the nucleus and cytoplasm in both benign and malignant melanoma cells (Orosz, 1999; de 
Vries et al., 2001). In this current study the majority of the cultures expressed the S-100 antigen and 
in particular all ciliary body tumours studied expressed the S-100 protein (Table 3.2.1.a). 
Conjunctival and iris melanomas have however also been shown to express S-100, together with 
pigmented and non-pigmented epithelium of the iris and ciliary body, and RPE cells (Heegaard et al., 
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2000). Due to the high levels of expression in this present study, detection of other cell types at this 
stage therefore had to be taken into consideration. As all of the tumours studied were either 
choroidal or ciliary body melanomas, culture of conjunctival or iris melanomas seemed unlikely. 
HMB-45 (gp100) 
The HMB-45 antibody recognises the cytoplasmic gp100 protein (Adem a et al., 1993; de Vries et al., 
2001). The gp100 protein is associated with melanocyte differentiation throughout melanoma 
progression and the HMB-45 antibody has been classically used, together with the S-100 antibody, in 
melanoma diagnostics (de Vries et al., 2001). This antibody has nevertheless reputedly been 
reported to be less sensitive than antibodies against other melanoma-associated markers yet, is 
highly specific (Heegaard et al., 2000; de Vries et al., 2001; Xu et al., 2002). This was reflected in 
this current study where only approximately 50% of the STCs stUdied, expressed gp100 (Table 
3.2.1.a). Tissue and cell lines from both benign and malignant choroidal uveal melanomas have 
been shown to stain positively for gp100, whilst non-melanocytic cells, including RPE cells have not 
(Steuhl et al., 1993; Luyten et al., 1996; Mulcahy et al., 1996; Luyten et al., 1998; de Vries et al., 
1998; Heegaard et al., 2000). When considering uveal melanoma cell types, most studies have 
described strong expression in spindle, mixed cell type and epithelioid melanomas (Steuhl et al., 
1993; de Vries et al., 1998; Heegaard et al., 2000) and this was reflected in this current study. As all 
cell types did not however constitutively express this antigen, no direct conclusions could be drawn. 
No associations could also be made between tumour location and gp100 expression. 
In conclusion, tumours expressing S-100 and either Melan-A or gp100, were most likely to be uveal 
melanoma in origin, due to the high specificity of the latter two antibodies. Nine cultures however 
stained positively for S-100, but did not express Melan-A or gp100 and no association could be made 
between this staining pattern and cell type or tumour location (Table 3.2.1.a). Uveal melanomas are 
relatively free from infiltrating cells (de Waard-Siebinga et al., 1995), and the behaviour of these 
tumours in subsequent assays was not significantly different from other uveal melanomas studied, 
and thus it is probable that these were uveal melanoma in origin. It is entirely possible that the lack 
of staining reflects time in culture, as loss of the differentiation markers (Melan A, gp100, and S-100), 
was more likely at higher passage. Also previous analysis of the long-term cell line SOM 157d has 
shown differences in staining response at earlier and later passage numbers. A number of 
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characteristic chromosomal abnormalities of SOM 157d cells have however remained consistent. 
Cytogenetic analysis of the original tumour sample from SOM 267 detected characteristic markers 
associated with uveal melanomas, whilst the behaviour of both tumours in in vitro assays was again 
not significantly different from other tumours studied. Analysis of further melanoma-associated 
antigens, such as tyrosinase (Mulcahy et al., 1996; de Vries et a/., 1998) could be of further use in 
classification of these cultures in which S-100, Melan-A and gp100 expression was absent. 
3.3.2. Differences between the in vitro and in vivo expression of integrins, 
degradative enzymes and their inhibitors. 
3.3.2.1. Integrin expression 
Expression in response to culture 
f31-subunit expression was ubiquitous throughout frozen sections and cultured cells of all tumours 
studied (Table 3.2.2.b). The f31-subunit is known to associate with all of the a-subunits chosen for 
investigation (reviewed by Gonzalez-Amaro and Sanchez-Madrid, 1999), whilst some of the a-
subunits studied could have also associated with alternative f3-chains. In agreement with published 
data, consistent a3- and a5-subunit and aVf33 expression was also seen in all frozen sections and 
cultured cells of the tumours studied where minimal variation occurred between specimen types (Ten 
Berge et a/., 1993; Elshaw et al., 2001). 
Differences in expression of a1, a2, a4, and a6 were however observed between in vitro and in vivo 
(Table 3.2.2.a), with expression of a1 and a2 being most susceptible to in vitro up-regulation. In a 
previous study examining epithelial and endothelial derived tissues, a reverse pattern has been 
reported for a1 f31, whereby expression was not observed in cultured cells yet this receptor was 
expressed in the corresponding tissue (reviewed by Albeda and Buck, 1990). Differences in the cell 
type studied could however account for the variation observed between studies. It is of interest that 
EGF, a factor present in uveal melanoma growth media, has been shown to enhance expression of 
a1 f31 in PC12 cells (Danker et al., 2000), and a2f31 in squamous cell, and vulvar carcinoma, lung 
adneocarcinoma and corneal epithelial cells (Waleh et al., 1994; Krensel and Lictner, 1999; Smida 
Rezgui et al., 2000; Song et al., 2001), and therefore could have been responsible for the apparent 
up-regulation in certain cases. In addition, TGF-f3 and PDGF-BB up-regulate mesangial cell a1 f31 
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expression (Kagami et al., 1999) whilst TNFa, IL-1~, TGF-~ and FGF-2 increase a2- and ~1-
subunit expression in vitro (Neliari et al., 1999; Kawashima et al., 2001); each of which could have 
been secreted by the melanoma cells in culture, or present as an undefined constituents of the FBS. 
Observations from this present study would also provide an explanation for contradictory evidence in 
the literature, where a2~1 expression was reported absent in frozen uveal melanoma samples (Ten 
Berge et al., 1993), whilst cultured uveal melanoma cells expressed the a2-subunit (Creyghton at al., 
1995; Elshaw at al., 2001). 
For a6, the potential of both up- and down-regulation in vitro was evident. This could be supported 
by reports in which EGF has enhanced expression of ~1, 134, and a6 subunits and the a6134 integrin 
in squamous cell carcinoma, corneal epithelial cells, and colon cancer cells (Waleh et al., 1994; 
Pouliot at al., 2000; Mariotti et al., 2001; Song et al., 2001). Furthermore TNFa, IL-1I3, TGF-I3, FGF-
2 and IL-12 have also been shown to induce the expression of a6 and 131 in hepatocarcinoma and T 
helper cells (Colantonio at al., 1999; Nejjari et al., 1999). Conversely, TGF-I3, TNFa and IL-113 have 
been reported to down-regulate a6 expression in cultured endothelial and melanoma cells (Defilippi 
at al., 1992; Moretti at al., 1997; Teti at al., 1997) and similarly could have affected the responses 
seen in this present study. With regard to a4 expression, for eight out of the ten tumours, 
expression was seen, both in vitro and in vivo. For the remaining two tumours, a vice varsa scenario 
was seen, and it was therefore difficult to draw reliable conclusions. 
Differences in expression may therefore occur in various tissues not only as a result of tissue-
associated phenomena, but also because of cultural conditions (reviewed by Albeda and Buck, 
1990). Two basic mechanisms of integrin activation have been described as signalling can be either 
intracellular ('inside-out signalling') or extracellular ('outside-in signalling') (reviewed by Hynes, 1992). 
For example, EGFR activation causes phosphorylation of a6134 via the tyrosine kinase Fyn, inducing 
cellular migration and invasion (Mariotti et al., 2001). In this current study, exogenous production or 
addition to the growth media of cytokines, growth factors and other matrix proteins is likely to have 
affected integrin expression via such mechanisms, whilst activation of one integrin type could also 
have a significant effect of the expression of a second integrin type. 
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Association of expression with prognosis 
As described previously, differences in expression of a1, a2, a4, and a6 were observed between 
tumours, but few associations could be made between expression of all integrin subunits studied, 
known prognostic indicators and patient survival (Appendix II). In agreement, Anasatassiou and co-
workers (2000a) have also shown that expression of a2, a3, and avj33 in paraffin sections of uveal 
melanomas could not be correlated with prognosis. In the study by Elshaw and colleagues (2001), 
cultured uveal melanoma cells, whilst ubiquitously expressing a number of integrins, variably 
expressed a4j31 and a6j31, and the latter was only seen in cultures with epithelioid morphologies. 
As cultured uveal melanocytes lacked a 1131, a4j31, and a6j31 expression, it was consequently 
hypothesised that in particular, a6j31 expression is associated with worse prognosis. This published 
data is also consistent with the report that pre-metastatic uveal melanoma cells do not express a6j31 
(Rohrbach et al., 1994). The results of this present study do not however reflect these findings and 
no association was made between a6 expression and cell type. 
Expression of the fibronectin receptor a5j31 has been correlated with a less aggressive phenotype; 
highly invasive epithelioid cells lacked expression, whilst primary melanocytes and less invasive 
cultures were positive for a5j31 (Beliveau et al., 2000). Results in this present study were again 
contradictory as no specific association could be made with as expression and epithelioid and 
spindle morphology. Finally, most evidence for cutaneous and uveal melanoma has suggested that 
decreased expression of avj33 is associated with metastatic development (Ten Berge et al., 1993; 
Danen et al., 1995; Settor et al., 1999), but results shown here indicated ubiquitous expression in all 
ten primary tumours studied. As avj33 expression has been reported to be important during early 
stages of malignant uveal melanoma progression, but is reduced during later stages of metastasis 
(Danen et al., 1995; Settor et al., 1999) it is possible that tumours assessed in this present study 
were resected during the early stages of development. This theory would hold true for eight of the 
patients in which no metastatic disease has, as yet, been discovered. 
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3.3.2.2. Degradative enzyme and inhibitor expression 
Expression in response to culture 
Julia Woodward 
Ubiquitous expression of MMP-2, TIMP-2, u-PA, PAI-1 and PAI-2 was shown in both paraffin and 
frozen sections and cultured cells (Tables 3.2.3.a and b). Variation was only seen in paraffin sections 
stained for MMP-9 (Table 3.2.3.a). Such differences are likely to be a result of the processing 
procedure masking the epitope and effectively denaturing the antigens. Previous work using in part, 
other methods of detection, has however found similar variability in MMP-9 expression between 
individual cases (Cottam et al., 1992; Elshaw et al., 2001; EI-Shabrawi et a/., 2001). In this present 
study, there was some variation between in vitro and in vivo expression, but this could not be 
quantified, and more sensitive methods would be required. However, in support of in vitro MMP 
stimulation, in a similar comparative investigation on a series of nine brain tumours, using 
zymography, immunohistochemistry and immunocytochemistry, local micro-environmental conditions 
in vitro were responsible for stimulating MMP expression, including MMP-9 (Rooprai at al., 1998). 
Association of expression with prognosis 
As consistent expression of MMP-2, TIMP-2, u-PA, PAI-1 and PAI-2 was observed, with slight 
variation in MMP-9 most likely to be related to processing, few conclusions relating to histo-
pathological data (Appendix II), prognosis and survival could be drawn. MMP-2 and MMP-9 
expression has been previously associated with extra scleral spread and poor prognosis in uveal 
melanoma (Cottam et al., 1992; Vaisanen at al., 1999; EI-Shabrawi et al., 2001) but in vitro studies 
using zymography and invasion assays, have not been able to correlate MMP-2 expression with 
levels of uveal melanoma invasion or prognosis (Elshaw et al., 2001). As no differences were seen 
between the two metastatic tumours and the remaining tumours in which metastatic disease has not 
been diagnosed, no correlation with invasive behaviour, patient survival and prognostic indicators 
could be made. 
To date, there is little evidence regarding TIMP expression in uveal melanoma. As the antibody used 
would detect bound and unbound forms of this inhibitor, it is feasible that TIMP-2 detected was bound 
to MMP-2, potentially inhibiting its action. TIMP-2 overexpression has however been associated with 
increased cutaneous melanoma invasion (Valente at al., 1998), and thus for the two metastatic 
tumours studied, TIMP-2 could have promoted invasion rather than inhibited it. With regard to the PA 
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system, u-PA and PAI-1 have both been found to be expressed at a higher level in the metastases of 
uveal melanomas in comparison to the primary tumour, whilst uveal melanocytes only weakly 
express u-PA (Tripathi et al., 1990; De Vries et al., 1995; Ma et al., 1997). No association could 
however be made between expression and the metastatic tumours assessed in this study. 
In light of the results presented here and previous studies, differences in expression between in vivo 
and in vitro conditions should be taken into consideration. More sensitive and quantitative methods 
should be enlisted to identify significant changes in response to culture. For example, with regard to 
protease secretion, more definite conclusion may be drawn using functional methods such as 
zymography, or quantitative approaches such as ELiSAs. mRNA studies by Northern blots, RT-PCR 
or in situ hybridisation would also be informative for detection of any of the regulators studied in this 
investigation. 
In summary, these results have highlighted that uveal melanomas ubiquitously express a number of 
integrins, degradative enzymes and their inhibitors, but expression of the 0.1, 0.2, 0.4, and 0.6 
integrins is more variable, and may in part, be due to in vitro regulation. 
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Chapter 4: Transendothelial cell invasion Julia Woodward 
4.1. Introduction 
Various attempts have been made to develop a suitable animal model to more closely study the 
metastasis of uveal melanoma (reviewed by Grossniklaus et al., 2000). Cases have been reported 
occurring naturally in cats and dogs, but they are infrequent and the relationship to human disease is 
less apparent (Dubielzig, 1990). Induced models share some similarities with human uveal 
melanoma metastasis but each has unique advantages and disadvantages. Initial problems may 
arise when inducing chemically, or with radiation, as malignant pigmented neoplasms may not be 
melanocytic in origin (Patz et al., 1959; reviewed by Grossniklaus et al., 2000). Murine models have 
also been used, but metastases induced using the cutaneous B16 melanoma cell line can be 
pulmonary, and not hepatic (Grossniklaus et al., 1995). Rabbit models are possibly more suitable for 
study, due to the larger size of the rabbit eye and their longer life span, but again the development of 
hepatic metastases is dependent on the specific model used. In addition, successful implantation 
often requires immune suppression. Transgenic mice have also been utilised, but the origin of the 
tumours is again often unclear and the resulting metastatic spread is not hepatic (Bradl et al., 1991). 
Despite advances using animal models of uveal melanoma metastasis, the pattern of spread is 
therefore often dissimilar from that of human uveal melanoma and such models may not accurately 
represent the human situation in vivo. 
Aims of the study 
Due to the limitations associated with animal models of uveal melanoma, the purpose of this study 
was to develop a modified in vitro assay to assess uveal melanoma invasion across endothelial and 
basement membrane barriers, that is perhaps, more realistic than previous in vitro invasion models 
(Elshaw et al., 2001). In this model a microvascular endothelial cell monolayer has been included, in 
addition to an artificial basement membrane, and has been used to mimic invasion for a series of 16 
primary uveal melanomas and one cell line (SOM 196B). Levels of invasion were correlated with 
histe-pathological markers of prognosis. Cellular invasion through endothelial cells and basement 
membrane was also compared with invasion through the basement membrane alone. For one 
culture (SOM 196B), scanning electron microscopy was performed. In addition, for a small number of 
cultures, both cell populations were pre-labelled with fluorescent probes, to trace cell movement 
through the invasion assay. 
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4.2. Results 
4.2.1. Optimisation of the transendothelial cell model of invasion 
Prior to assessment of uveal melanoma STC transendothelial cell invasion, experimental parameters 
relating to the model had to be established. For this purpose, the cell line SOM 1968 was used, due 
to its known invasive characteristics through basement membrane barriers alone and continued 
availability of cellular material; most STCs die within ten passages or fail to produce adequate 
material. 
Membrane pore size 
To optimise the correct pore size for the model, maximising tumour cell migration, whilst minimising 
endothelial cell migration, SOM 1968 cells and HDMECAs were independently tested for their 
invasion through Transwell membranes with pore sizes of 3, 5 or 81!M, pre-coated with Matrigel. 
Results are illustrated in Figure 4.2.1.a. Movement of HDMECAs was minimal through all pore sizes, 
with a maximum of 2-3 cells/well (x400 magnification) only migrating. In these cases, it is probable 
that only passive migration of endothelial cells is occurring, as opposed to active invasion. In 
contrast, SOM 1968 cells invaded through all pore sizes tested. To therefore maximise tumour cell 
invasion, and in particular for low invading tumours, a pore size of 8J.lM was chosen. Figure 4.2.1.b.i 
shows an example of invaded cells on the underside of an 8J.lM pore membrane (all non-invaded 
cells had previously been removed from the top side of the membrane and thus all visible cells have 
invaded through the Matrigel-coated membrane); nuclei have been stained with Gill's haematoxylin. 
Invaded cells were also seen to be viable (Figure 4.2.1.b.ii; in this instance, cells had been pre-
labelled with CFDA-SE and observed under fluorescence). 
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Figure 4.2.1 .a. Invasion of SOM 1968 and HDMECAs, separately through Transwell 
membranes of varying pore size. Expressed as mean counts per field of view at x400 magnification. 
Mean (± SEM) invasion through 3, 5 and 8~M pores. The graph represents the mean of three experiments. 
The x-axis shows the membrane pore size and the y-axis shows the mean cell invasion per field through 
Matrigel under x400 magnification. 
Figure 4.2.1.b.i. Invaded tumour cells (T) (SOM 277) on the underside of the Transwell 
membrane (81lM pores) (x200 magnification). All non-invaded cells from the topside of the membrane 
have been removed. Nuclei are stained with Gill's haematoxylin, and an example of an invaded cell is 
indicated . ii. Viable Invaded tumour cells (SOM 196B) on the underside of the Transwell 
membrane (x1000 magnification). Cells are labelled with CFDA-SE (green), and were observed under 
fluorescence (492-517nm); areas of red staining are artefacts of the labelling process. 
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Endothelial cell seeding density 
To ensure that endothelial cells were forming a confluent monolayer, HDMECAs were seeded at 
densities of 20 ODD, 50 ODD, 100 000 and 150 000 cells/well and incubated for either 7 or 24 hours. 
When seeded at 100000 cells/well for 24 hours, a confluent monolayer was achieved (Figure 4.2.1.c) 
where few gaps between cells were seen, and cells did not form layers of more than one cell thick. 
Passive tumour cell migration between endothelial cells would therefore be reduced to a minimum. 
Figure 4.2.1.c. HDMECAs, seeded at 1X105, labelled with SNARF·1 and grown to confluence 
on the topside of an 8~M pore membrane, pre·coated with an artificial basement membrane 
(x100 magnification). Cells were observed under fluorescence at 580-640nm. 
Time course experiments 
In order to establish an appropriate incubation time for the assay, SOM 1968 and HDMECAs were 
independently tested for invasion through 8~M pore membranes, pre-coated with Matrigel. This was 
also repeated for transendothelial cell invasion of SOM 1968 through HDMECAs. Invasion levels 
were monitored over a period of 48 hours and results are represented in Figure 4.2.1.d. Subsequent 
to 24 hours, negligible increases in invasion of SOM 1968 cells through Matrigel alone were seen. 
Transendothelial cell invasion of SOM 1968 was minimal at all time points. HDMECA migration was 
also negligible at all time points. An incubation time of 24 hours was consequently chosen for 
transendothelial cell invasion. Time points subsequent to 24 hours were avoided, as tumour cell 
doubling times are likely to occur after th is point. It was not feasible to assess growth characteristics 
of each individual cu lture and hence by choosing a time point of 24 hours, direct comparison of 
invasion between cultures could be made. To ascertain whether any cells may have detached from 
- 88 -
Chapter 4: Transendothelial cell invasion Julia Woodward 
the membrane and further settled on the lower surface of the well , media from the lower chambers 
was observed and lower well surfaces were trypsinised; no cells were found to be present. 
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Figure 4.2.1.d. Time courses of independent invasion of SOM 196B and HDMECAs, and 
transendothelial cell invasion of SOM 1968 through HDMECAs through 8J.1M pores. Counts are 
expressed as mean counts per field of view under x400 magnification, and represent the mean of one 
experiment, set up in triplicate. For each well , ten fields of view were counted and a mean calculated. The x-
axis shows the time in hours and the y-axis shows the mean invasion through Matrigel under x400 
magnification. 
Comparing transendothelial cell invasion through HDMECAs and HULECs 
HDMECAs were used in all assays with STCs. As uveal melanomas primarily target the liver, 
microvascular endothelial cells derived from the liver would be appropriate for these studies, as 
differences potentially exist between dermal and liver endothelial cells . To validate the use of dermal 
endothelial cells, and to investigate this point, transendothelial cell invasion of SOM 1968 was 
assessed using both HULECs and HDMECAs. HULECs were freshly extracted and not commercially 
available making their use in all assays impractical. After repeating the experiment three times, no 
significant difference in levels of invasion through the two types of endothelium was observed 
(P>0.05) . Levels of transendothelial cell invasion of SOM 1968 cells were 5.45 (± 0.123) and 6.53 (± 
1.20) cells per field under x400 magnification, for invasion through HDMECAs and HULECs, 
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respectively. As dermal endothelial cells were more readily available the remaining assays were 
undertaken using these cells. 
Comparing Matrigel with an ECM solution 
Matrigel was used throughout the course of these studies, due to its commercial availability, ease of 
reproducibility and wide acceptance as an artificial basement membrane. The concentration at which 
it was used ensured that a thin barrier could be observed across the membrane, blocking the filter's 
pores. Matrigel is however a mouse derivative. The Humane Research Trust provided the funding 
for this investigation and the aim of this charity is to promote the reduction of the use of animals and 
animal products in experimentation. At the end of this investigation, with an aim of producing a 
comparable equivalent to Matrigel for future use, invasion of SOM 1968 through membranes pre-
coated with Matrigel or a freshly prepared ECM solution was compared (without an endothelial cell 
layer). The ECM solution was made up using equal concentrations of type IV collagen, fibronectin, 
and laminin. Comparable levels of invasion were seen between Matrigel and ECM-coated 
membranes (35.7 (± 2.92) and 34.6 (± 1.80) cells/field at x400 magnification, respectively) and no 
significant differences were found (P>O.05). Due to time constraints this assay was only repeated 
once, but another colleague in the laboratory (Ms Shona Elshaw) was able to reproduce similar 
results. 
4.2.2. Transendothelial cell invasion of uveal melanoma STCs 
Once all parameters had been established using the cell line SOM 1968, transendothelial cell 
invasion of a further 16 STCs was investigated. A description of the precise methodology is given in 
Methods 2.3.2. All STCs were used within five passages of being established in culture and assays 
were repeated once only due to insufficient cell numbers. The results of the transendothelial cell 
invasion studies on STCs are summarised in Figure 4.2.2.a and represent the mean invasion for 
tumours with and without the inclusion of a dermal endothelial barrier. Data is expressed in terms of 
mean number of cells invading per field of view at x400 magnification, after counting ten fields of view 
for triplicate wells. In all assays, appropriate positive and negative controls were included. Tumour 
cell invasion through basement membrane components only acted as positive controls (,standard 
invasion levels'), whilst endothelial cells alone acted as negative controls. 
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Figure 4.2.2.a. Invasion of primary uveal melanoma cultures through the transendothelial cell 
assay. Expressed as mean counts per field of view under x400 magnification after counting ten fields of view 
for triplicate wells. Mean (± SEM) invasion 8flM pores after 24 hours. For SOM 1968, counts represent the 
mean of three experiments; for STCs, counts represent the mean of one experiment, counting triplicate wells. 
The x-axis shows the short-term culture (SOM) and the y-axis shows the mean invasion under x400 
magnification. *, P<O.05 and H , P<O.001 when compared to positive controls (tumour cells alone). 
In wells with endothelial cells alone, maximum endothelial cell invasion was 2-3 cells/well and was 
considered negative. Using the ANOVA statistical test, inclusion of an endothelial layer resulted in a 
significant reduction in invasion (P<0.05) of SOM 1968, 262, 275, 277, 280, 281 , 282, 290, 295, 301 
and 305 when compared with invasion through the basement membrane alone. In relative terms, the 
invasive tumour cell populations of these cultures might therefore potentially be less capable of 
overcoming the endothelial cell barrier. Conversely, invasion of cultures that was not significantly 
reduced by the addition of an endothelial cell barrier (P>0.05) (SOM 263, 269, 272, 296, and 307) 
may infer the presence of invasive tumour cell populations that are more efficient at overcoming such 
barriers. Three tumours (SOM 269, 272 and 306) were considered non-invasive in both assays. For 
SOM 307 a higher number of cells invaded in the transendothelial cell assay, when compared with 
the number seen after invasion through the basement membrane only (25.3 ± 0.76 SEM and 22.4 ± 
2.53 SEM, respectively). This raised the possibility that both cell types could have been co-migrating 
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and to further assess this, a selection of tumours (SOM 196B, 295, 301, 306 and 30?) were labeled 
with fluorescent probes and tracked. The results from this are presented in 4.2.3.2. 
Most tumours had only recently been excised, so it was therefore not possible to correlate behaviour 
in vitro with the clinical course of the disease. When the 'control' invasion of cultures through the 
basement membrane alone was however compared with histo-pathological data (Appendix II), it was 
apparent that no correlation could be made between prognostic indicators and the relatively high 
invading melanomas (with invasion levels of over 20 cell counts per field [SOM 196B, 277, 280, 282, 
290, 295, 301, 305 and 30?]). However, when comparing invasion of all STCs through the 
transendothelial cell assay with the histo-pathological data, a closer correlation could be made with 
prognostic indicators. For example some of the invasive tumours, for which invasion levels were over 
50% of the control levels (SOM 280, 295, and 296), were on average larger tumours than the most 
invasive tumours through the control basement membrane only assays. These tumours were also 
more likely to be of a mixed cell type and with ciliary body involvement. Conversely other tumours 
(SOM 263, 290, and 307) reflecting these invasion patterns were nonetheless very small in volume, 
and one (SOM 295) was of spindle morphology; factors associated with good prognosis. The test 
sample was therefore too small to make reliable correlations. 
4.2.3. Monitoring tumour cell invasion 
4.2.3.1. Scanning Electron Microscopy 
To identity the invaded cells, scanning electron microscopy was initially used to visualise the process 
of transendothelial cell invasion process using SOM 196B and HDMECAs. Co-cultures were set up 
as previously described (Methods 2.3.2) but endothelial and non-invaded tumour cells were not 
removed prior to processing. Observations of the upper side of the membrane (non-invaded cells), in 
wells with endothelial cells alone or with co-cultures, confirmed the presence of a confluent layer of 
cells covering the surface on the membrane, uniformly coated with Matrigel, covering membrane 
pores. On the lower side of the membrane (invaded surface), occasional invaded cells were visible, 
but due to gross phenotypic similarities of tumour and endothelial cells (such as physical size), it was 
not possible to determine the nature of these cells. Figure 4.2.3.a illustrates a cell migrating from the 
upper surface towards the under side of the membrane. 
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Figure 4.2.3.a. Scanning electron micrograph from a co-cultured well. The under (invaded)-side 
of the Transwell membrane can be seen, with cellu lar projections through the 8J.1M pores (x1250 
magnification). 
4.2.3.2. Tracing cell movement 
In order to trace movement of both cell types in the transendothelial cell assay, in all cases tumour 
and endothelial cells were independently labelled with CFDA-SE and SNARF-1. This procedure was 
carried out on SOM 196B, and four STCs (SOM 295, 301 , 306 and 307), and compared with the 
cutaneous melanoma cell line, A375 and the lung carcinoma cell line, A549. Due to insufficient cell 
numbers in most STCs, only four cultures were pre-labelled. Experiments were set up in triplicate 
with appropriate controls (tumour cells invading the basement membrane alone or endothelial cells 
only) and non-invaded cells were again removed. By observing wells prior to the removal of non-
invaded cells, endothelial cell confluence could again by confirmed (Figure 4.2.1.c), whilst also 
allowing observation of tumour cell in teractions with the endothelium (Figures 4.2.3.b.i and ii). As this 
procedure was only used to identify invaded cell populations, no quantitative measurements were 
made. 
Cell lines 
When comparing SOM 196B with A375 it was evident from previous studies that levels of invasion 
through basement membranes alone were comparable (34.2 ± 3.08 SEM and 35.9 ± 3.49 SEM, 
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respectively). In the transendothelial cell assay, numbers of invaded cells were however 5.45 ± 0.12 
SEM and 33.3 ± 0.75 SEM (Figure 4.2.3.b.iii), respectively. By labelling cells, it was evident that a 
small number of endothelial cells were present on the invaded side of the membrane in the SOM 
196B assay (Figure 4.2.3.b.v). In contrast no endothelial cells were seen in the A375 assay, and 
A375 cells alone had invaded through the endothelial cell barrier (Figure 4.2.3.b.iii). Using A549 in 
this assay, it became clear that these cells are comparatively less invasive as few tumour cells were 
observed on the lower side of the membrane in both the standard and transendothelial cell invasion 
assays. Furthermore, no endothelial cell migration was seen when A549 cells were used in the 
transendothelial cell assay. 
STCs 
To substantiate the results using cell lines, four STCs were also pre-labelled and cell movement 
traced. In agreement with the pattern shown by A549, SOM 306 was non-invasive, with negligible 
numbers of tumour cells migrating (0.1 ± 0.1) and no endothelial cell movement. Phenotypically, 
SOM 306 varied from most cultures as cells appeared to lack any cellular projections and 
consequently few interactions with endothelial cells were evident (Figure 4.2.3.b.i). SOM 301 was 
invasive through basement membrane barriers alone, yet invasion was significantly reduced in the 
transendothelial cell assay (P<0.05) and no endothelial cell co-migration was observed. Both SOM 
295 and SOM 307 were considered invasive in the transendothelial cell assay, but similar to SOM 
196B, a small percentage of endothelial cells were seen to co-migrate (Figures 4.2.3.b.iv and vi). 
With regard to SOM 307, co-migration of tumour and endothelial cells might therefore explain the 
increased invaded cell number observed in the previous transendothelial cell assay in which no 
distinction was made between invaded cell types (4.2.2). 
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Figure 4.2.3.b. Photographic images of uveal melanoma and endothelial cells In the 
transendothelial cell invasion assay (for figure, see following page). Tumour cells were labelled 
with CFDA-SE (green) and endothelial cells were labelled with SNARF-1 (red) and observed under 
fluorescence at 492-517nm and 580-640nm, respectively. 
i} 
ii) 
iii} 
iv) 
v) 
vi) 
Tumour cell interactions (SOM 301) with the endothelium on the non-invaded (upper) side of the 
membrane (x100 magnification). 
Tumour cell interactions (SOM 306) with the endothelium on the non-invaded (upper) side of the 
membrane (x100 magnification). 
A375 cells on the invaded (under) side of the membrane after invasion through endothelial and 
basement membrane barriers, showing tumour cell invasion only (x100 magnification). 
Endothelial cells and non-invaded tumour cells had been previously removed from the non-
invaded surface. 
SOM 295 cells on the invaded (under) side of the membrane after invasion through endothelial 
and basement membrane barriers, showing co-migration of tumour (T) and endothelial cells (E) 
(x100 magnification) (indicated by the white arrows). Endothelial cells and non-invaded tumour 
cells had been previously removed from the non-invaded surface. 
SOM 1968 cells on the invaded (under) side of the membrane after invasion through endothelial 
and basement membrane barriers, showing co-migration of tumour and endothelial cells (x1000 
magnification). Endothelial cells and non-invaded tumour cells had been previously removed 
from the non-invaded surface. 
SOM 307 cells on the invaded (under) side of the membrane after invasion through endothelial 
and basement membrane barriers, showing co-migration of tumour and endothelial cells (x1000 
magnification). Endothelial cells and non-invaded tumour cells had been previously removed 
from the non-invaded surface. 
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Figure 4.2.3.b. For figure legend, see previous page. Tumour cells (T) are labelled green and 
endothelial cells (E) are labelled red . 
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4.3. Discussion 
4.3.1. The transendothelial cell model of invasion 
Figure 4.3. 1.a illustrates how the in vitro model of transendothelial cell invasion mimics the process in 
vivo. In its true sense the model is a model of extravasation, but mimicking intravasation also, would 
be impracticable in th is system, as addition of a basement membrane layer over the endothelium 
would be difficult to manipulate. 
Transwell insert Tumour cell 
Basement 
membrane 
Endothelial cell 
In vitro Basement 
membrane 
In vivo 
Figure 4.3.1.a. In vitro Transwell representation of transendothelial cell invasion in vivo. 
During extravastion, tumour cells must migrate between endothelial cells and invade through the underlying 
basement membrane. Tumour cells are shown in . Endothelial cell are shown in . A green line 
represents basement membranes. The ). areas represent normal tissue. 
Membrane pore size 
To model in vivo transendothelial cell invasion, tumour cells must invade through an intact endothelial 
cell barrier. Similar models of transendothelial migration for leucocytes have used membranes with 
3~M pores (Mahle et al., 1997). As endothelial cells are physically too large to migrate through pores 
of 3~M , when seeded at the correct density endothelial cells form a confluent monolayer and are 
unable to migrate. Leucocytes are smaller in size and thus are able to migrate through both the 
endothelial cell layer and the 3~M pores. Resu lts from this current study have however shown that 
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generally tumour cells are considerably larger in diameter and thus are unable to migrate through the 
3f.lM pores in any great number (Figure 4.2.1.a). In agreement with this study, other transendothelial 
cell models of tumour invasion have also used 8f.lM pore membranes (Li and Zhu, 1999; Laferriere et 
al., 2001). The obvious disadvantage with such models is the possibility of endothelial cell migration 
through pores of this size, and previous studies have often not considered this problem. In this study 
by tracing movement of labelled tumour and endothelial cells, co-migration of the two cell types was 
occasionally observed. This phenomenon of co-migration must therefore be taken into account in in 
vitro assays and will be discussed in further depth below. 
Artificial basement membranes 
Prior to invasion through the vessel endothelial cell layer, tumour cells must overcome the basement 
membrane, together with the surrounding ECM. Certain confusion exists regarding the distinction 
between migration and invasion assays with the definitions varying between groups. For the 
purposes of these studies, the difference was defined in accordance with previous reports relating to 
the barrier imposed (Youngs et al., 1997). Matrigel is widely used as an artificial basement 
membrane (Scott et al., 2001; Voura et al., 2001a and b) and is extracted from Engelbreth-Holm-
Swarm (EHS) mouse sarcoma as a solubilised basement membrane preparation. It was originally 
demonstrated the levels of tumour cell invasion in vitro, were inversely proportional to the 
concentration of Matrigel used as a barrier (Albini et al., 1987). However, other contradictory reports 
have demonstrated that invasion in vitro through Matrigel could not be correlated with invasion in vivo 
(Simon at al., 1992). 
Advantages of the use of Matrigel nevertheless include its ease of reproducibility and commercial 
availability. The concentration recommended by the manufacturers instructions ensured that the 
Matrigel layer formed a physical barrier for invasion coating the porous membrane, and uniformly 
covering the filter's pores. Matrigel does however have its disadvantages. For example, various 
growth factors have been identified in Matrigel (Taub at al., 1990; Vlodavsky at al., 1996) which are 
likely to differ from human basement membranes, and could have attracted invading tumour cells. To 
address this, the use of growth factor-reduced Matrigel may provide a more realistic representation. 
In addition, unlike human basement membranes, which have a high type IV collagen content, the 
major substrate in Matrigel is laminin (Kleinman et al., 1986; McGuire and Seeds, 1989). Matrigel 
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also does not possess cross-linked collagens nor does it have the ordered structure of the basement 
membrane. 
Due to the funding for this project, to establish a system less reliant on animal resources, an 
alternative ECM was constructed composed of equal concentrations of type IV collagen, fibronectin, 
and laminin. The advantages of such an ECM would be defined constituent concentration more in 
keeping with the in vivo state (Kleinman et al., 1986), and as human components were used, animal 
use was reduced. Using SOM 196B, no significant differences were observed between the invasion 
assays using Matrigel or ECM solution {P>0.05}, therefore validating its use for these purposes. 
There are however still limitations with this model, as in vivo the proportions of these substrates is 
unlikely to be 1:1:1 and other critical structural proteins and soluble factors are likely to be present. 
The ECM solution can nevertheless be further refined by the inclusion of additional substrates. 
As an alternative to Matrigel, invasion assays have been reported employing the use of intact human 
amniotic membranes {Gehlsen et al., 1992; Siegel et al., 1993; Singh et al., 1996}, and some 
correlation has been made with invasiveness in vivo {Yagel et al., 1989; Gehlsen et al., 1992}. 
Basement membranes are nevertheless known to vary in their composition between tissues, and 
even within different structures of the same tissue, and are also likely to differ between malignant and 
non-malignant tissue {Lang et al., 1999; Lang et al., 2000}. With regard to uveal melanoma invasion, 
even human amniotic membranes will therefore not fully represent the situation in vivo, besides 
which, such membranes would also be difficult to acquire. 
Endothelial cell layer 
Inclusion of an endothelial cell layer would make in vitro invasion assays more realistic and as no 
endothelial cell migration was seen in wells with endothelial cells alone, it was expected that cells 
would form a barrier through which tumour cells actively penetrated. Confluent endothelial cells 
would have also secreted additional basement membrane proteins, thus increasing the obstacle for 
the invading cells (Sage and Bomstein, 1982). A recent study reported the use of a similar 
transendothelial cell invasion system with bovine aortic endothelial cells (large vessel endothelial 
cells), assessing transendothelial migration of seven human malignant and non-malignant cell lines 
{Li and Zhu, 1999}. The authors however described the formation of confluent endothelial cell 
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monolayers on both the upper and lower surfaces of the membrane. This phenomenon was not 
observed in the in vitro model presented here (confirmed by fluorescent labelling), possibly due to the 
use of endothelial cells derived from a different source. In addition, comparable levels of 
transendothelial invasion through dermal and hepatic endothelial cells was observed (P>O.05), and 
thus a model using dermal endothelial cells as a barrier to uveal melanoma cells may therefore still 
be representative of the situation in vivo. Further data assessing potential differences between 
dermal and liver endothelial cells used in this study, is presented in Chapter 6. 
Monitoring cellular movement 
During angiogenesis, endothelial cells are known to migrate (reviewed by Folkman, 1995), and this 
had to be considered in the transendothelial model. Reports are scarce in which authors have 
assessed the possibility of endothelial co-migration, but limited evidence suggests that this 
phenomenon is not occurring in such assays (Okada et a/., 1994). In this present study, due to few 
phenotypic differences between the two cell types, no conclusions could be drawn regarding the 
nature of the invaded cells using scanning electron microscopy (Figure 4.2.3.a). Labelling cells with 
fluorescent probes however identified a degree of endothelial co-migration, but this was dependent 
upon the tumour type, and specifiC culture (Figure 4.3.2.b). These probes have been previously 
shown to have no effect on cellular adhesion to endothelial cells (Davenport et a/., 1995) and should 
thus have had little influence on the transmigration process. It is feasible that the co-migration of 
endothelial cells in these cases is a passive process, in which endothelial cells follow invading tumour 
cells through spaces in the basement membrane formed through tumour cell degradation. 
Alternatively, tumour cells could stimulate endothelial cell migration, involving either secreted tumour-
derived factors, or cell-cell interactions between aggressive tumour and endothelial cells, reflecting 
inherent properties of the particular invasive uveal melanoma cells. Due to time restrictions it was not 
possible to explore this further, but it would be of interest to study this phenomenon with a wider 
range of uveal melanoma STCs and other cell types. As only a relatively small degree of endothelial 
co-migration was observed limited associations could still be drawn. 
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4.3.2. Transendothelial cell invasion of uveal melanoma STes 
In general STC invasion in the transendothelial cell model, seemed to correlate more closely with a 
wider range of known prognostic indicators than invasion through the basement membrane alone 
(Elshaw at al., 2001). There were however some exceptions, which may reflect behaviour seen in 
vivo since not all tumours behave in accordance with prognostic indicators (Mooy at al., 1996). Long-
term follow-up is however required to draw more definite conclusions, as for most tumours studied, 
survival data was limited to an average of 12 months and correlation with long-term survival for 
tumours was not possible. In agreement with published data, suggesting a correlation between 
transendothelial invasion in vitro, with metastatic potential in vivo (Li and Zhu, 1999), it is 
nevertheless of interest that one tumour (SOM 1968), was resected 41 months previously, and the 
patient is known to still be alive and disease free. Once in culture, this tumour invaded well without 
the inclusion of an endothelial cell layer. Yet invasion was Significantly reduced (P<0.05) in the 
transendothelial cell invasion assay. 
It is widely understood that the metastatic process is highly inefficient (reviewed by Weiss, 1990). 
Only a small percentage of cells in the primary neoplasm will acquire the necessary phenotype 
required to facilitate successful extravasation. Once tumour cells have disseminated, only a fraction 
will reach the secondary site, and continue growth to become eventual metastatic foci. In vivo 
studies have shown that only 0.01 % of tumour cells injected into the circulation will progress to form 
metastatic colonies (Fidler, 1970). In previous invasion assays, tumour cells have been considered 
to be invasive if they are capable of traversing basement membrane barriers alone. In contrast, in 
the transendothelial model, cells have been considered to be invasive if they are able to overcome 
both the endothelial cell and basement membrane barriers together. Evidence from this study would 
suggest that tumours that are more effective at transendothelial invasion than others (for example 
SOM 280 and SOM 295) would equate more closely with highly aggressive tumours in which 
percentages of greater than 0.01 % have the propensities to metastasise. 
The in vitro model itself has limitations. In vivo during intravasation, tumour cells are separated from 
the endothelium with a basement membrane, whereas in this in vitro model, there is no segregation. 
Many factors also influence the establishment of metastases and thus although tumour cells may be 
capable of overcoming both barriers, aspects such as the effect of the host stroma, survival in the 
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bloodstream and proliferation in the target organ cannot be assessed by such a model. For example, 
surrounding stromal cells effect invasion of cutaneous melanoma and prostate cancer cells, as 
shown in recent reports using alternative in vitro invasion models (Eves et al., 2000; Hall et al., 2002). 
It has now been reported that tumour cells might not simply migrate through the endothelial cell lining 
of blood vessels. In colon cancer a small sub-population of tumour cells are present in newly formed 
blood vessels (Chang et al., 2000). The authors of this study suggest that these 'mosaic vessels' are 
formed during neovascularisation, where unstable junctions are formed between new endothelial 
cells allowing tumour cells to participate in the vessel wall formation. Tumour vascularisation is a 
dynamic process with ongoing migration and formation of capillaries that allows some tumour cells to 
take up temporary residence in the vessel wall prior to their transit into the lumen (reviewed by 
Folkman, 2001). The wider relevance of these 'mosaic vessels' in metastasis of other tumours 
remains to be established. 
As yet. mosaic vessels have not been reported in uveal melanoma but vascular channels conducting 
blood that are entirely lined by tumour cells have been recently reported (Timar and Toth, 2000); a 
phenomenon known as vasculogenic mimicry which is distinct from the significance of mosaic 
vessels (Maniotis et al., 1999). These authors concluded that aggressive uveal melanomas in vitro 
and in vivo, acquired the capability to form vascular channels that are not lined by endothelial cells 
providing a blood supply for growth and metastasis, functioning independently from angiogenic 
vessels. This evidence is however controversial and alternative reports have suggested that even in 
aggressive uveal melanomas, the majority of blood flow occurs via endothelial-lined vessels as 
opposed to vessels comprised of tumour cells (McDonald and Foss, 2000). It is nevertheless still 
feasible that uveal melanoma metastasis is more complex than originally thought, potentially utlising 
a number of mechanisms to successfully establish metastases. 
In conclusion, although a small number of uveal melanomas have been studied, invasion through the 
transendothelial model appears to correlate more closely with a wider range of prognostic indicators 
than invasion through the basement membrane alone. Long-term follow-up of the patients studied 
will elicit more relevant information. 
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5.1. Introduction 
The pattern of metastasis commonly observed in uveal melanoma raises the possibility that the 
hepatic environment attracts metastatic tumour cells, promoting secondary development. 
Conversely, such cells might not be attracted to other sites and their arrest may even be inhibited. In 
the rare instances where cells are seen to metastasise to organs other than the liver, a specific 
phenotype might allow successful arrest and growth at these sites. Alternatively, other organs could 
attract metastatic tumour cells, but instead tumour cells are less adept at growing elsewhere, and 
although the liver is commonly associated with ~econdary disease, it remains unclear as to whether 
metastatic uveal melanomas, given sufficient time, could also eventually grow elsewhere. 
The liver is the largest organ in the body fulfilling a variety of essential functions, including the 
metabolism of nutrients and drugs and the synthesis of a number of metabolites and proteins. 
Despite being the targets for many regulatory factors, cells of the liver have also been found to 
secrete a range of cytokines, growth factors, and chemokines, which may be imperative for 
metastatic development. Kupffer cells, stellate cells and infiltrating leukocytes have commonly been 
reported to be the major source of these, including IL-1, IL-8, and TNFa (reviewed by Ramadori and 
Armbrust, 2001) and have been associated with secondary growth of malignancies such as colorectal 
carcinomas (Gangopadhyay et al., 1996; Minami et al., 2001). Secretion of factors including HGF, 
IGF-I, and IGF-II, by the hepatic sinusoidal endothelium has also been reported (Rak et al., 1996), 
which whilst attracting tumour cells, could also ultimately promote attachment. Hepatocytes, which 
constitute the major cell type of the liver have generally been associated as target cells for regulators 
secreted by other cell types in the liver but evidence has nevertheless been published reporting 
synthesis of factors such as IGF-I, IGF-II, IL-8, GRO, RANTES and TNF-a (Rowell et al., 1997; Long 
et al., 1998a and b) .. The liver therefore represents an excellent 'soil' for many secondary cancers. 
Many inflammatory mediators regulate directional migration and invasion of both leucocytes and 
tumour cells (McKenzie, et al., 1994; Krasagakis, et al., 1995; Luan, et al., 1997; Kunz, et al., 1999). 
For example, both HGF and its receptor c-met, have been linked with cutaneous melanoma 
progression (Hamoen et al., 2001), whilst expression of specific chemokine receptors by both 
cutaneous melanoma and breast carcinoma cells has been shown to be potentially responsible for 
cells targeting specific sites (Muller et al., 2001). For uveal melanoma, both HGF and EGF increase 
-104 -
Chapter 5: Tissue targeting of metastatic uveal melanoma cells Julia Woodward 
invasion (Hendrix et al., 1998a and b; Ma and Niederkorn, 1998), and expression of EGF and IGF-I 
receptors has been correlated with death from metastatic liver disease (Monique at al., 2000; 
Ericsson at al., 2002). As metastatic uveal melanoma cells therefore appear to target the liver in 
most cases, further investigation into a wider range of factors that promote and inhibit uvaal 
melanoma migration and invasion is essential for the understanding of uveal melanoma metastasis. 
Aims of the study 
To determine if the liver favourably contributes to this specific pattern of metastasis through the 
production of stimulatory regulators, invasion of a series of uveal melanoma cultures was 
investigated in response to soluble factors secreted by cells derived from the liver. Results were 
compared with cells from sites less frequently colonised, to assess whether factors secreted by other 
tissues would have a similar effect on invasion. 
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5.2. Results 
5.2.1. The effect of HepG2 cells and eM on the invasion of uveal melanoma cell 
lines and STCs 
As metastatic uveal melanoma cells primarily target the liver, to assess the consequence of soluble 
factors secreted by cells derived from hepatocytes, the effect of HepG2 cells and CM on the invasion 
of SOM 1968, SOM 157d, and a series of seven STCs was investigated. SOM 1968 had already 
been established as an invasive cell line in standard assays through Matrigel barriers, whilst SOM 
157d was poorly invasive. Results of initial studies on the effect of HepG2 cells and CM on STC 
invasion are represented in Figure 5.2.1.a. 8asal levels of invasion in vitro (without any stimulation) 
th rough Matrigel barriers alone varied between STC. Cultures were broadly classified as 'non-
invasive' (SOM 157d, 269, 272 and 280); 'weakly invasive' (SOM 263 and 275) and 'highly invasive' 
(SOM 1968, 267 and 277). 
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Figure S.2.1.a. Effect of HepG2 cells and CM on STC invasion. Expressed as mean counts per field 
of view under x400 magnification. Mean (± SEM) invasion 8~M pores after 24 hours. Results with cell lines 
(SOM 157d and SOM 1968) representthe mea~ ~f three experiments; experi~ents with short-term cultures 
represent the mean of ten fields of view for triplicate wells from one experiment. The x-axis shows the 
Sheffield Ocular Melanoma (SOM) and the y-axis shows the mean invasion through Matrigel under x400 
magnification. *, P<0.05. when ~ompared w!th ,control invasion (without stimulation 0: invasion). SOM 1968, 
267 and 277 were considered highly Invasive ; SOM 263 and SOM 275 were considered 'weakly invasive'; 
SOM 157d, 269, 272, and 280 were considered 'non-invasive'. 
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Highly invasive cultures 
80th HepG2 cells and CM significantly increased invasion of SOM 1968 and SOM 267 (P<0.05) 
whilst HepG2 CM only significantly increased invasion of SOM 277 (P<0.05). Instead, invasion levels 
of SOM 277 decreased with the addition of HepG2 cells to the assay. The decrease seen was 
nevertheless negligible (P>0.05) when compared with control invasion of tumour cells without any 
stimulation and may have been a result of experimental error. Figure 5.2.1.b shows photographic 
images of the effect of HepG2 cells and CM on the invasion of SOM 267. 
Non- and weakly invasive cultures 
HepG2 cells but not CM significantly increased invasion of SOM 157d. This pattern was also 
observed for the non-invasive culture SOM 272, whilst for SOM 263, 275, and 280, both HepG2 cells 
and CM significantly increased invasion (P<0.05) (Figure 5.2.1.a). Neither HepG2 cells nor CM 
significantly increased invasion of SOM 269 (P>0.05) and under all experimental conditions, cells 
were still only weakly invasive (increasing from 0.433 ± 0.120 to 0.9 ± 5.75x10-5 and 1.5 ± 0.451, 
respectively). 
With the exception of SOM 269, non- and weakly invasive cultures (SOM 157d, 263, 272, 275, and 
280) presented proportionally higher responses, when compared with highly invasive cultures (SOM 
1968, 267 and 277). For example, when comparing the outcome observed with the two cell lines, the 
proportional effect seen of HepG2 cells on invasion levels of SOM 157d was nevertheless greater 
than for the invasive culture SOM 1968 (increasing invasion from 1.64 ± 0.754 to 6.32 ± 0.00167, 
and 37.S ± 1.66 to 53.2 ± 0.00306, respectively). This was in agreement with a comparable study by 
Ms Shona Elshaw, in which the effect of defined factors on invasion was investigated. Stimulatory 
factors were shown to cause a far greater response on non-invasive cells when compared with 
invasive cells. With regard to all of the non- and weakly invasive cultures described in this current 
study, even upon stimulation, only small numbers of cells were nevertheless seen to invade. In 
addition, no true associations could be made between these results, histe-pathological data, and 
clinical outcome (Appendix II). 
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Figure 5.2.1.b. Photomicrographs of the invasion of SOM 267 without stimulation (i), and after 
stimulation with HepG2 cells (ii), or CM (iii). Both HepG2 cells and CM stimulated SOM 267 invasion. 
All images show invaded cells on the underside of the BmM pore Transwell membrane (x100 magnification). 
Nuclei are stained with Gill's haematoxylin, and all non-invaded cells have been removed. 
Comparing the effect of HepG2 and A495 cells and CM on STC invasion 
To briefly assess whether the effect of HepG2 celis and CM on STC invasion was specific to celis of 
hepatic origin, the effect of celis from a site not commonly colonised by uveal melanoma celis was 
also assessed. For this purpose the consequence of A549 cells (a lung carcinoma celiline) and CM 
on the invasion of two STCs (SOM 277 and SOM 280) was investigated and the effect compared with 
that of HepG2 cells and CM (Figure 5.2.1 .c). Both STCs were used at passage four to enable a 
direct comparison to be made and were chosen due to their invasive abilities in vitro. The invasive 
nature of SOM 280 appeared to vary with increasing passage and this would account for differences 
in levels of invasion seen between this and the previous study (4.2.2) . 
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Invasion levels of SOM 277 significantly increased in response to HepG2 eM (P<0.05) (Figures 
5.2. 1.a and c). As described previously, in contrast, in response to HepG2 cells a slight decrease in 
invasion of SOM 277 cells was seen, but this result was not significant (P>0.05), and may have been 
as a result of slight experimental variation. This pattern was nevertheless reflected with the inclusion 
of A549 cells and CM in the assay, but the decrease in invasion seen by SOM 277 cells in response 
to A549 cells was highly significant, decreasing from 40.6 ± 1.07 to 26.5 ± 2.00 (P<0.05). In 
comparison, A549 CM slightly increased invasion of SOM 277, but the increase was negligible 
(P>0.05) (Figure 5.2.1.c) . 
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Figure 5.2.1.c. Effect of HepG2IA549 cells and eM on the invasion of SOM 196B, 277 and 280. 
Expressed as mean counts per field of view under x400 magnification. Mean (± SEM) invasion 81-lM pores 
after 24 hours. Results with SOM 1968 represent the mean of three experiments, and are included as positive 
controls; experiments with SOM 277 and 280 represent the mean of triplicate wells from one experiment. The 
x-axis shows the short-term cu lture (SOM) used with either HepG2 or A549 cells or eM. The y-axis shows the 
mean invasion through Matrigel under x400 magnification. ., P<0.05 when compared with control invasion 
(without stimulation of invasion). 
For SOM 280, a non-invasive culture in vitro, eM from and the cells of both HepG2 and A549 cells, 
significantly increased invasion (P<0.05) (Figures 5.2.1.a and c) . In contrast to SOM 277, for both 
HepG2 and A549, responses seen by the inclusion of cells in the lower chamber of the assays, were 
considerably greater when compared with the inclusion of CM. Similar to other STCs, responses of 
the non-invasive cu lture SOM 280 were proportionally higher, when compared with the invasive 
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culture SOM 277. With regard to histo-pathological data (Appendix II), both patients presented with 
tumours with similar characteristics, and thus no association could be made between the behaviour in 
vitro in response to HepG2 or A549 cells or CM, and prognostic indicators. 
5.2.2. The effect of cells and eM from alternative cell types on the invasion of 
SOM 1968 
In addition to hepatocytes, alternative cells of the liver such as hepatic endothelial cells may also 
influence invasion. As primary liver endothelial cells (HULECs) were obtainable for study, such cells 
were chosen. Other cell types present in the liver, such as Kupffer cells, were not used due to a lack 
of an available source. To therefore establish if chemoattractants specifically associated with the 
endothelium of the liver may contribute to the specific pattern of spread seen in uveal melanoma, the 
study was extended to assess the effect of the HULECs and the respective CM on invasion of SOM 
1968. As cell numbers were limited with STCs, invasion of this cell line only was assessed at this 
stage. Results of this study are represented in Figure 5.2.2.a and represent the mean data of three 
experiments. Similar to HepG2 cells and CM, HULECs significantly increased invasion of SOM 1968 
(P<O.05). 
As it is a feasible possibility that cells from other tissues less commonly associated with uveal 
melanoma metastasis could also stimulate invasion, the effects of cells and CM from primary dermal 
keratinocytes (NAK 3.2) and fibroblasts (JFF), and the lung carcinoma cell line A549 on SOM 1968 
invasion was assessed. Uveal melanomas have occasionally been seen to metastasise to sub-
cutaneous and pulmonary tissue (Char, 1978), and thus cells derived from these tissues were chosen 
for study. In addition, to investigate potential autocrine responses, the effects of SOM 1968 cells and 
CM on the invasion of the same cell type was also studied. With the exception of A549 cells, all other 
cell types, together with respective CM significantly increased invasion of SOM 1968 (P<O.05) 
(Figure 5.2.2.a). A549 cells stimulated a slight increase in invasion (P>O.05) whilst A549 CM 
significantly increased invasion (P<0.05). Cells derived from primary cultures (NAK 3.2, SOM 1968, 
JFF, and HULECs), were also generally seen to have a stronger stimulatory effect on invasion than 
the established cell lines HepG2 and A549. The effect of SOM 1968 cells and eM on invasion of the 
same cell type, further implied possible autocrine stimulation. 
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Figure 5.2.2.a. Effect of cells and eM from a series of cell types on invasion of SOM 196B. 
Expressed as mean counts per field of view under x400 magnification. Mean (± SEM) invasion 811M pores 
after 24 hours. Results represent the mean of three experiments. The x-axis shows the different cell types 
used to assess the effect on invasion and the y-axis shows the mean invasion through Matrigel under x400 
magnification . • , P<O.05 when compared with control invasion (without stimulation of invasion). 
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5.3. Discussion 
5.3.1. Paracrine stimulation of invasion by HepG2 cells 
As the liver is largely composed of hepatocytes, the effects of cells derived from hepatocytes on 
uveal melanoma invasion in vitro were initially assessed. Hepatocytes produce a number of factors 
(Rak et al., 1996; Rowell et al., 1997; Long et al., 1998a and b), which may potentially attract 
circulating tumour cells through paracrine stimulation. Due to the constraints of long-term culturing of 
human hepatocytes (Runge et al., 1999), HepG2 cells were used to provide an approximation. As 
these cells were derived from a malignant hepatoma cell line, functional differences between such 
cells and native hepatocytes are likely to exist (Lin et al., 1997; Stonans et al., 1999; Liu et al., 2000). 
Cells should have however retained some characteristic features of hepatocytes providing an 
indication of whether uveal melanoma cells are favourably attracted to the liver in preference for other 
sites. 
In this present study, HepG2 cells and CM nevertheless increased uveal melanoma STC invasion 
and the extent of the effect appeared to depend upon the individual culture (Figure 5.2.1.a). In 
support, in the comparable study by Ms Elshaw, stimulatory factors, and in particular HGF, had the 
most overt effect on non-invasive cultures. HepG2 cells may have thus produced amongst other 
factors HGF to cause the responses seen, but as yet there is no published evidence to support this. 
As tumours were surgically resected, all cases were already classified as large tumours and thus 
associated with a poor prognosiS (reviewed by Singh et al., 2001). With the exception of SOM 269, 
no correlation could be made with other prognostic indicators. The non-invasive culture SOM 269 
showed little response to either HepG2 cells or CM, and morphologically was composed of spindle B 
cells, and as such, associated with a better prognosis. Other tumours that responded positively to 
HepG2 cells and CM were however of a similar morphology and thus no connections can realistically 
be made. The number of tumours studied was therefore too small to draw reliable conclusions and 
could have been biased towards the specific tumours studied. 
With the exception of SOM 157d and SOM 196B, all tumours had been recently excised and thus no 
association could be made with the clinical course of the disease. Most reports of established uveal 
melanoma cell lines indicate that they do not possess the characteristic chromosomal abnormalities 
of chromosomes 3 and 8 associated with primary uveal melanoma tumours (Aubert et al., 1993; De 
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Waard-Siebinga et al., 1995; 810m et al., 1997; Sisley et al., 1997; Guan et al., 1998; White et al., 
1998). As detailed in Chapter 3 (3.3.1), this has similarly been shown for SOM 157d and SOM 1968, 
yet samples from the original tumours displayed these characteristic changes. Other chromosomal 
markers have however been consistently retained, suggesting that these cell lines are still 
representative of the original tumour. Although the cell line SOM 157d was classified as non-
invasive, the patient from whom the tumour originated has died of metastatic disease, indicating that 
the tumour itself was highly invasive; thus suggesting a degree of pre-selection in culture. High 
levels of invasion in response to HepG2 CM could therefore have been as a result of specific 
metastatic characteristics that have been retained from the original tumour. By using STCs within 
five passages, it was consequently hoped that cells more closely resemble the original tumour in 
vivo, and close follow-up of these patients will elicit more information regarding responses in vitro and 
in vivo. 
5.3.2. Paracrine stimulation of invasion by hepatic endothelial cells 
As the liver is comprised of a number of cell types, including hepatocytes, sinusoidal endothelial and 
Kupffer cells and infiltrating leucocytes, cells in addition to hepatocytes are also likely to attract 
tumour cells. Brief assessment of the paracrine effects of primary hepatic endothelial cells indicated 
that these cells could also stimulate invasion of SOM 196B (Figure 5.2.2.a). Endothelial cells have 
been reported to produce a number of factors including HGF, IGF-I, IGF-II, TGF-j3, GRO, RANTES 
and IL-1 (Matsumoto et al., 1992; Rak et al., 1996; Krishnaswamy et al., 1999); each of which could 
have stimulated invasion. Similarly, capillaries have been shown to attract cutaneous melanoma 
cells (Rak et al., 1996; von Bulow et al., 2001). Murine lung endothelial cells, but not hepatic 
sinsusoidal endothelial cells, have furthermore been shown to release MCP-1 which stimulated the 
migration of lung-metastasising RA W117 -L 17 cells in vitro (Wakabayashi et al., 1995). This raises 
the possibility that factors secreted by hepatic endothelial cells may contribute to attracting circulating 
uveal melanoma cells, but assessment of a wider range of tumour and endothelial cell types is 
required to confirm this hypothesis. 
5.3.3. Paracrine stimulation of invasion by cells from tissues of different origins 
As uveal melanomas occasionally metastasise to sites other than the liver (Char, 1978), study of the 
stimulatory effects of primary keratinocytes (NAK 3.2) and dermal fibroblasts (JFF), and a lung 
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carcinoma cell line (A549), also identified that with the exception of A549, factors secreted by these 
cells could also stimulate invasion of SaM 1968 (P<O.05) (Figure 5.2.2.a). The effect of A459 cells 
and CM was however more variable, and after analysis of two further STCs, it became evident that 
that the effect was dependent upon the individual culture, either stimulating or inhibiting invasion 
(Figure 5.2.1.b). Throughout all experiments in this investigation, exact effects on stimulation (or 
inhibition) were seen to vary between inclusion of cells or CM in assays (Figures 5.2.1.a and b, and 
5.2.2.a). As variation was not large, experimental error could explain the apparent differences, whilst 
production of eM may show more inherent variability between individual flasks of cells than 
incorporation of cells in the assay. An alternative explanation could however relate to differences in 
concentrations or activities of factors secreted by the cells or present in the CM. 
These results nevertheless raise the question as to why uveal melanoma cells are not frequently 
seen to metastasise to alternative sites. It could be speculated that although other tissues may 
attract uveal melanoma cells, as patients rapidly die as a result of liver metastases, secondary 
disease may have established elsewhere, but to lesser degree than that in the liver. Metastasis 
might as a consequence, be primarily associated with the liver and not other sites where disease is 
less evident. Alternatively, as metastatic development involves a number of stages, despite other 
tissues attracting metastatic uveal melanoma cells, subsequent metastatic development may not be 
supported, relating to both the microenvironment of non-hepatic sites, and inherent properties of the 
tumour, resulting in the cells being inefficient at metastasising elsewhere. The liver may therefore be 
the main organ providing the optimum micro-environmental conditions to promote all stages of uveal 
melanoma metastatic development. For those tumours that are seen to metastasise elsewhere, 
these cells could be more effective 'metastasisers' than those disseminating to the liver alone. As 
however, this aspect was carried out on SaM 1968 alone, results will be specific for this culture, and 
thus by assessing the effect on a wider range of uveal melanoma cultures more precise conclusions 
could be drawn. 
5.3.4. Autocrine stimulation of invasion 
During tumour progression, in addition to paracrine stimulation from host cells, autocrine stimulation 
is often also evident, and this was reflected for SaM 1968 (Figure 5.2.2.a). Similar observations 
have been seen previously, using metastatic variants of RAW117 large-cell lymphoma cells 
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(Wakabayashi at al., 1994). In further support, cutaneous melanoma cells secrete a number of 
autocrine growth factors (Lazar-Molnar et al., 2000; reviewed by Ruiter et al., 2002), whilst autocrine 
expression of high levels of IL-8 by metastatic cells associates with increased in vitro invasion 
through MMP-2 up-regulation (Luca et al., 1997; Wang et al., 1998a). As this present investigation 
was similarly only carried out on one culture, results could again have been biased towards these 
cells, and analysis of a wider range of cultures would elicit more precise results. 
Growth factors produced by melanoma cells have however also been shown to have paracrine 
effects on other cell types in the surrounding stroma (Lazar-Molnar et al., 2000; reviewed by Ruiter et 
al., 2002). In response, endothelial cells, fibroblasts, keratinocytes, monocytes, lymphocytes and 
granulocytes secrete either activating or inhibitory factors affecting processes such as tumour growth, 
angiogenesis, adhesion and migration. In this current investigation cell types were initially separated 
with an artificial basement membrane, thus allowing diffusion of soluble mediators, but direct cell-cell 
interactions between the two cell types were theoretically not possible. Cross talk between the co-
cultures could therefore have had an effect on invasion, which was not present in wells with CM 
alone, whereby soluble factors secreted by tumour cells in the upper chamber diffused into the lower 
chamber, stimulating cells grown in the chamber to secrete further paracrine factors. In support of 
this premise, primary uveal melanomas, co-cultured with endothelial cells in a similar experimental 
system, have been shown to produce bFGF and VEGF, which subsequently supported endothelial 
cell growth (Boyd et al., 2002). 
When considering the results presented in this chapter, as checkerboard analysis was not carried 
out, it was not possible to distinguish between intrinsic motility and chemotactic responses to 
autocrine and paracrine factors. To fully validate this data, it would therefore be necessary to assess 
the effect of the addition of CM or cells to upper well only, the lower well only, or to both wells. 
Chemotactic responses could be confirmed if movement occurred only in the presence of a 
concentration gradient. This is nevertheless impracticable when considering the effect of viable cells, 
and would only be of use to assess CM. Blocking tumour cell receptors in the invasion assays, and 
using procedures such as ELiSAs and mRNA studies such as RT-PCR or in situ hybridisation, could 
aid to identify the specific regulatory factors produced by these cells. 
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In summary, these results confirm that cells associated with the liver are capable of stimulating uveal 
melanoma invasion. As alternative cell types also stimulated invasion of one culture, it is possible 
that other sites similarly attract uveal melanomas, but it remains unclear as to whether secondary 
disease could develop at these sites. As cells of pulmonary origin had diverse effects on uveal 
melanoma cultures, in some instances, arrest may be inhibited in such tissues. 
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6.1. Introduction 
As detailed in the Introduction (Section A), following Paget's theory, inherent properties of the 
microvasculature of the target organ could playa pivotal role in determining the pattern of spread 
seen for many tumours (Paget, 1889). In support, endothelial cells from different organs are known 
to display diverse structural and biochemical characteristics (Rymaszewski et al., 1992), but cells 
used in vitro may not always reflect their in vivo heterogeneity (Swerlick et al., 1992; reviewed by 
Thorin and Shreeve, 1998). A number of endothelial cell molecules are constitutively expressed 
including PECAM-1 (CD31) and the factor VIII-related antigen, allowing identification of most 
endothelial cell types (reviewed by Garlanda and Dejana, 1997). As again highlighted in the 
Introduction (Section A, 1.5), a number of specialised endothelial cell molecules have also been 
identified in specific vascular regions, which might further aid site-specific metastasis for some 
tumours (Zhu et al., 1991; Abdel-Ghany et al., 2001). Expression of other endothelial cell molecules 
such as E-selectin, ICAM and VCAM, are further activated by inflammatory cytokines or growth 
factors in the local environment, and the relevance of these markers has been widely reported in 
tumour cell adhesion to the endothelium (Scherbarth and Orr, 1997; Vidal-Vanaclocha et al., 2000; 
Minami et al., 2001). 
Aims of the study 
For uveal melanoma, it is possible that characteristics of the adhesion molecule profiles of the 
microvascular endothelial cells of the liver influence the metastatic spread of uveal melanoma. In 
Chapter 4 (4.2.1), in a preliminary experiment, no Significant differences in the level of invasion were 
seen between the transendothelial invasion through dermal and liver endothelium for one uveal 
melanoma culture (SOM 1968) (P>0.05) (n=3). As differences are nevertheless likely to exist 
between these endothelial cell types, the purpose of this investigation was to further examine 
potential variation between HDMECAs and HULECs in vitro. For this study, adhesion of uveal 
melanoma cells to both endothelial cell types was assessed. In addition flow cytometric analysiS of 
the two-endothelial cell types before and after culture with cytokines, or uveal melanoma cells and 
their conditioned media (CM), was investigated. 
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6.2. Results 
6.2.1. Adhesion of tumour cells to HDMECAs and HULECs 
Figure 6.2.1.a represents the levels of adhesion of melanoma cell lines to fibronectin, HDMECAs and 
HULECs. Figure 6.2.1.b represents the levels of melanoma cell adhesion to HDMECAs and 
HULECs, expressed as a percentage of the total cell number adhering to fibronectin. 8y assessing 
both sets of data, the efficiency of attachment to the fibronectin and endothelial cells could be 
compared between tumour cell types. This was reflected in this investigation for a" melanoma types, 
in which the highest levels of adhesion were seen to fibronectin (Figure 6.2.1.a). When comparing 
the ability of individual cell lines to adhere to either HDMECAs or HULECs, no significant difference 
was found in levels of adhesion compared to that of fibronectin (P>O.05). 
There were however significant differences in adhesion levels between invasive and non-invasive cell 
lines. When comparing adhesion of SOM 1968, SOM 157d and A375 to each endothelial cell type 
and fibronectin, highly significant variation was seen between the two uveal melanoma cell lines to 
both HDMECAs and HULECs (P<O.001) (Figures 6.2.1.a and b). SOM 1968 cells adhered at the 
highest levels to both endothelial cell types and fibronectin, whilst A375 and SOM 157d cells adhered 
less we", with SOM 157d cells adhering in the lowest numbers. Significant variation between levels 
of adhesion of A375 cells and uveal melanoma cells to either endothelial cell type or to fibronectin 
was only seen when comparing attachment of SOM 1968 and A375 cells to HDMECAs (P<O.05). It 
would thus appear that relative adhesion to fibronectin, HDMECAs and HULECs bears some 
relationship to the invasive properties of the cells in vitro through Matrigel barriers. 
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Figure 6.2.1 .a. Adhesion of the uveal melanoma cell lines SOM 196B and SOM 157d and the 
cutaneous melanoma cell line A375 to fibronectin (Fn), HDMECAs and HULECs. Mean (± SEM) 
number of tumour cells adhering to Fn or different endothelial cell types. Results represent the mean of three 
experiments. Units of fluorescence at 530nm are measured on the y-axis. No significant differences in 
adhesion of SOM 1968, SOM 157d and A375 cells to fibronectin were observed (P>O.05) when compared with 
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tumour cell types, significantly higher levels of SOM 1968 cells adhered to both HDMECAs and HULECs, 
when compared with SOM 157d (P<O.001 ). 
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Although no significant difference was found in the adhesion of SOM 1968 to endothelial cells when 
compared with attachment to fibronectin (P>O.05), when the relative adhesion of SOM 1968 to the 
two endothelial cell types was compared, using adherence to fibronectin as a baseline, significantly 
higher levels of SOM 1968 cells adhered to HDMECAs than to HULECs (Figure 6.2.1.b) (P<O.05). 
Negligible differences were shown with adhesion of A375 cells and SOM 157d to HDMECAs and 
HULECs (P>O.05). A slight preference by A375 cells for HDMECAs and by SOM 157d cells for 
HULECs was nevertheless seen . In all cases, it must however be taken into consideration that some 
the adherent tumour cells detected, may have been adhering to one another and not to the 
endothelium. 
As tumour-endothelial interactions could occur at several locations, to briefly assess which sites 
might be implicated; scanning electron microscopy was performed on a co-culture of SOM 1968 cells 
and HDMECAs. Figure 6.2.1.c shows a scanning electron micrograph of SOM 1968 cells adhering 
to HDMECAs. From th is image it was not possible to identify precise locations of adhesive 
interactions, but SOM 1968 cells did appear to attach to the upper surface of the HDMECA cells, as 
opposed to docking at intercellular junctions. The SOM 1968 cell indicated can be seen to be 
projecting pseudopodia between the endothelial cells. 
Figure 6.2.1.c. A scanning electron micrograph of SOM 1.968 cells (T) adhering to HDMECAs 
(E) (x640 magnification). ~OM 1968 cells can beseen adhering to the upper surface of the HDMECA 
cells and projecting pseudopodia between the endothelial cells. 
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6.2.2. FACS analysis of adhesion molecule expression by HDMECAs and 
HULECs 
When grown in culture no gross morphological differences could be seen between HDMECAs and 
HULECs and both cell types exhibited characteristic cobblestone morphology (Figure 6.2.2.a). 
Figure 6.2.2.a. Photographic images of HDMECAs (i) and HULECs (ii) grown in culture, taken 
by light microscope, under phase-contrast (x100 and x200, respectively), illustrating similar 
morphological features in culture. 
Adhesion molecule expression of HDMECAs and HULECs 
Initial studies to characterise HDMECA and HULEC expression of a selection of adhesion molecules 
using FACS, identified that both cell types without stimulation, expressed ICAM-1 , a1, a2, a3, and 
a5, and no significant differences were shown in the levels of expression between the two 
endothelial cell types (P>O.Q5). The only significant difference was shown for a4 (P<Q.05); 
HDMECAs expressed this subunit at significantly higher levels than HULECs, which were considered 
negative for a4. With regard to adhesion molecules typically involved in tumour cell adhesion, both 
HDMECAs and HULECs therefore expressed high levels of ICAM-1, but did not express E-selectin or 
VCAM-1. 
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6.2.2.1. Effect of cytokine modulation (TNFa and IL·1 (3) on endothelial adhesion molecule 
expression 
As previously mentioned, inflammatory mediators secreted by either tumour or host cells up-regulate 
E-selectin, ICAM, and VCAM expression (Tamaki et al., 1995; Steinbach et al., 1996; Vidal-
Vanaclocha et al., 2000; Minami et al., 2001), and therefore to initially assess whether this could be 
reproduced in HDMECAs and HULECs, increases in expression of these adhesion molecules was 
assessed by stimulating cells with TNFa or IL-1 (3. Both cytokines significantly stimulated expression 
of E-selectin and VCAM-1 on both endothelial cell types (P<O.05), whilst also significantly increasing 
ICAM-1 expression (P<0.05) (Figure 6.2.2.b and Tables 6.2.2.a-c). The stimulatory effect was also 
greatest for ICAM-1 (Figure 6.2.2.b and Tables 6.2.2.a-c). There was however, no significant 
difference in the increase in levels of expression of these adhesion molecules between the two-
endothelial cell types (P>0.05). 
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6.2.2.2. Ability of tumour cells to stimulate endothelial cell adhesion molecule expression 
As tumour cells may therefore directly effect endothelial adhesion molecule expression, the study 
was extended to investigate the effect of uveal melanoma cells on HDMECA and HULEC adhesion 
molecule expression. As this could be in response to soluble secreted factors or direct cell contact, 
HDMECAs and HULECs were grown in tumour cell CM or co-cultured with tumour cells for 24 hours. 
In all cases, the effect of SOM 1968 and SOM 157d cells were assessed, and compared with the 
effect of A375. Results from these studies are presented in sections below under the sub-headings 
'changes to endothelial E-selectin ', 'changes to endothelial VCAM-1 ' and 'changes to endothelial 
ICAM-1 ' and are summarised in Figure 6.2 .2.e and Tables 6.2.2.a-c. Data regarding stimulation of 
expression by TNFa and IL-1 f3 is also included in these tables to illustrate levels of up-regulation. 
Figure 6.2.2.c shows an image of HDMECAs cultured with SOM 157d, taken by light microscope, 
under phase-contrast (x200 magnification). 
Figure 6.2.2.c. Photographic images of HDMECAs cultured with SOM 157d taken by light 
microscope, under phase-contrast (x200 magnification). A spindle SOM 157d cell (T) can be 
visualised adhering to the endothelium (E) beneath. 
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Changes to endothelial E-selectin 
Results regarding E-selectin expression are summarised in Table 6.2.2.a and Figure 6.2.2.e. No 
significant increases in E-selectin expression by either endothelial cell type were shown after culture 
with CM from each of the melanoma cell lines (P>O.05). In contrast, co-culturing HULECs with SOM 
1968 cells resulted in a significant increase in expression of E-selectin, when compared with 
corresponding control endothelial cells (control cells) (P<O.05), (an increase from 1.22 ±O.0441 MFI 
to 1.62 ±O.0715 MFI). This result was not reflected when culturing HULECs with either SOM 157d or 
A375. Similarly culturing HDMECAs with each melanoma cell type did not result in a significant 
increase in expression of E-selectin (P>O.05). 
TNFa IL-1~ SOM 1968 SOM 157d (non- A375 (invasive cell line) invasive cell line) 
CM Ca- CM Ca- CM Co-
culture culture culture 
HDMECAs 1.49 2.02 0.901 0.986 1.05 0.875 0.940 1.19 
+0.538 ±1.00 ±0.103 ±0.0219 ±0.0107 ±0.0228 +0.109 +0.0709 
HULECs 4.97 9.61 0.868 1.33 1.01 1.12 0.948 0.954 
+0.556 ±1.04 ±0.0618 ±0.0355 ±0.0438 +0.0576 ±0.0306 ±0.0766 
Table 6.2.2.a. Mean (± SEM) relative increase in expression of E-selectin by HDMECAs and 
HULECs after treatment with TNF-a, IL-1~, tumour-cell conditioned media (CM) and after 
culture with tumour cells. Results represent the mean of three experiments. A significant increase in 
expression was shown by HDMECAs and HULECs after culturing with TNFa and IL-1 p and by HULECs are 
culturing with SOM 196B for 24 hours (P<O.05) and these results in highlighted in blue. 
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Changes to endothelial VCAM-1 
Results regarding VCAM-1 expression are summarised in Table 6.2.2.b and Figure 6.2.2.e. Growing 
either HDMECAs or HULECs in the CM produced by all of the melanoma cell lines did not 
significantly increase VCAM-1 expression, when compared with corresponding control endothelial 
cells (without CM) (P>0.05). Similarly co-culturing HDMECAs or HULECs with each melanoma cell 
line did not significantly increase VCAM-1 expression (P>0.05). Culturing HULECs with SOM 1968 
nevertheless increased expression of VCAM-1 (an increase from 1.36 ±O.0333 MFI to 1.94 ±0.217 
MFI), whilst culturing HDMECAs with A375 increased VCAM-1 expression (an increase from 0.983 
±O.198 MFI to 1.35 ±O.0903 MFI) but neither of these results was significant (P>0.05). In these 
instances, experiments would need to be repeated further to draw more exact conclusions. Limited 
conclusions were nonetheless possible. 
TNFa IL-1 (3 SOM 1968 SOM 157d A375 
CM Co- CM Co- CM Co-
culture culture culture 
HDMECAs 4.76 2.40 0.972 1.158 0.853 0.963 0.886 1.477 
±2.21 ±0.578 ±0.117 ±0.205 ±O.062 ±0.080 ±0.204 ±0.265 
HULECs 12.2 6.12 0.780 1.416 0.937 1.10 0.903 0.941 
+3.33 +0.853 ±0.0913 ±0.131 ±0.0465 +0.0456 ±0.0237 ±0.129 
Table 6.2.2.b. Mean (± SEM) relative increase in expression of by HDMECAs and 
HULECs after treatment with TNF-a, IL-1 (3, tumour-cell conditioned media (CM) and after 
culture with tumour cells. Results represent the mean of three experiments. A significant increase in 
expression was shown by HDMECAs and HULECs after culturing with TNFa and IL-1 p for 24 hours (P<O.05) 
and these results are highlighted in blue. Increases were observed after co-culture of SOM 1968 with 
HULECs, and with A375 and HDMECAs, but these results were not significant (P>O.05) and are shown in red . 
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Changes to endotheliallCAM-1 
Results regarding ICAM-1 expression are summarised in Table 6.2.2.c and Figure 6.2.2.e. CM from 
each melanoma line did not significantly increase ICAM-1 expression by HDMECAs or HULECs, 
when compared with corresponding control endothelial cells (without CM) (P>0.05). However, CM 
from SOM 157d increased ICAM-1 expression levels by both endothelial cell types. For HDMECAs, 
an increase from 14.9 ±2.09 MFI to 23.7 ±2.44 MFI was seen whilst for HU LECs, an increase from 
4.63 ±O.270 MFI to 7.74 ±2.78 MFI was seen. CM from SOM 1968 also increased HDMECA ICAM-
1 expression but this increase was to a lesser extent (from 7.36 ±1 .55 MFI to 10.1 ±2.81 MFI). 
TN Fa IL·1 B SOM 1968 SOM 157d A375 
CM Co- CM Co- CM Co-
culture culture culture 
HDMECAs 25.9 11 .0 1.38 0.941 1.70 2.19 0.993 2.46 
+6.95 ±2.92 ±0.191 ±0.231 ±0.403 ±0.241 ±0.289 ±0.389 
HULECs 16.0 12.5 0.800 3.25 1.62 1.58 1.14 0.871 
+0.560 +3.23 +0.141 ±0.454 +0.485 +0.141 +0.124 +0.151 
Table 6.2.2.c. Mean (± SEM) relative increase in expression of ICAM·1 by HDMECAs and 
HULECs after treatment with TNF·a, IL·1 r3, tumour-cell conditioned media (CM) and after 
culture with tumour cells. Results represent the mean of three experiments. Significant increases in 
ICAM-1 expression were seen by HDMECAs and HULECs after culture with TNFu, IL-1 ~ and SOM 157d cells 
for 24 hours (P<O.05) and these results are highlighted in blue. Increases were observed after culture of 
HDMECAs with SOM 196B CM, co-culturing SOM 1968 cells with HULECs, culturing HULECs and HDMECAs 
with SOM 157d CM, and after co-culturing A375 celis with HDMECAs, but these results were not significant 
(P>O.05) and are shown in red . 
Significant increases in ICAM-1 expression by HDMECAs and HULECs were shown when cells were 
cultured with SOM 157d cells for 24 hours when compared with corresponding control endothelial 
cells (control cells) (P<0.05). Levels increased from 13.2 ±O.484 MFI to 28.7 ±2.34 MFI and 13.4 
±O.669 MFI to 21 .0 ±1.10 MFI , respectively. Flow cytometry dot plots and histograms illustrating 
ICAM-1 expression by HDMECAs cultured alone (controls) and after co-culture with SOM 157d are 
shown in Figure 6.2.2.d. As illustrated, cell populations could be easily distinguished due to 
differences in fluorescence between SNARF-1 and FITC. Culture of both endothelial cell types with 
SOM 1968 and A375 did not significantly increase ICAM-1 expression (P>0.05). Increases were 
nevertheless still shown after culturing HULECs with SOM 196B cells (from 12.6 ±3.96 MFI to 44.3 
±20.1 MFI) and HDMECAs with A375 cells (from 7.18 ±1.81 MFI to 16.3 ±2.38 MFI). In these 
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instances, the experiments would again need to be repeated further to draw more precise 
conclusions. Similarly, limited conclusions have nevertheless been described. 
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Figure 6.2.2.d. Flow cytometry dot plots and histograms illustrating ICAM-1 expression by (i) 
HDMECAs cultured alone (controls) and (ii) after co-culture with SOM 157d. HDMECA ICAM-1 
expression has been inc~eased after culture with SOM 157d cells. Endoth~l ia l cells were labelled with 
SNARF-1 prior to co-culturing with SOM 157 d cells for 24 hours and are shown In blue. Tumour cells were 
selectively disaggregated from the endothelial cells and are shown in red. Cells were then stained with avidin-
FITC conjugates and analysed with flow cytometry. Gate G 1 refers to cells in the region R1 of the dot plot 
(SOM 157d cells) and gate G2 refers to cells in the region R2 (HDMECAs). 
- 129 -
Chapter 6: Adhesion to the endothelium Julia Woodward 
i. HDMECAs 
35 o E-selectin 
~ 30 . ICAM-1 OVCAM-1 c: 
.- 25 
(1) 
II) 
fa 20 (1) 
~ 
0 15 c: 
(1) 10 > 
.. 
~ 5 
* (1) ~ 
• 0 I ---, 
196BCM A375CM 157dCM 196B co- A375 co- 157d co-
culture culture culture 
treatment 
ii. HULECs 
35 
30 o E-selectin u.. 
~ . ICAM-1 
c: 25 OVCAM-1 (1) 
II) 20 fa 
(1) 
~ 15 0 
c: 
(1) 10 
> 
.. 
~ 5 (1) 
~ 
0 
196BCM A375CM 157dCM 196B co- A375 co- 157d co-
culture culture culture 
treatment 
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HDMECAs and ii) HULECs, after treatment with conditioned media from uveal melanoma cell 
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expression after treatment with control levels of expression (untreated cells) . 
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6.2.3. FACS analysis of adhesion molecule expression by tumour cells 
6.2.3.1. Ability of endothelial cells to stimulate tumour adhesion molecule expression 
As described previously, tumour cell a4 (the VCAM-1 ligand) is commonly involved in tumour-
endothelial interactions. As expression of a4 had been previously seen to vary between uveal 
melanoma cultures (3.2.2), it is possible that this integnn plays a role in uveal melanoma metastasis. 
After co-culture with endothelial cells, expression of this subunit was assessed in tumour cell samples 
selectively disaggregated from the co-cultures, for the three-melanoma cell lines. In addition, as 
other f31-integrins and ICAM molecules have been reported to be involved in tumour-endothelial 
interactions (Price et al., 1996; Papadimitriou et al., 1999), for one co-culture arrangement, the effect 
on a wider range of tumour cell adhesion molecules was also investigated. Due to time restrictions, 
this could not be extended to all co-culture systems. Prior to co-culture, FACS analysis revealed that 
SOM 1968 and A375 cells expressed a 1, a2, a3, a5, and a6. A375 cells also strongly expressed 
a4 and ICAM-1, whilst SOM 1968 cells only weakly expressed a4 and were negative for ICAM-1. 
SOM 157d cells similarly expressed a2, a3, a5, and a6 and like SOM 1968, only weakly expressed 
a4 and did not express ICAM-1 . None of the cells studied expressed the f34 subunit. 
Changes to tumour cell a4 expression 
a4 may be associated with either the 131 or 137 subunits. Due to the specificity of the antibody for the 
a4-subunit alone, no distinction could be made between a4(31 and a4137 expression. Figure 6.2.3.a 
and Table 6.2.3.a represent the increase in expression of the a4-subunit by SOM 1968, SOM 157d 
and A375, after co-culture with HDMECAs or HULECs, when compared with control samples (tumour 
cells cultured alone). As time was a limiting factor, the effect of endothelial CM on tumour cell a4 
expression was not assessed. 
When cultured alone, both SOM 1968 and SOM 157d weakly expressed the a4-subunit whilst A375 
cells expressed the subunit at higher levels. Culturing SOM 1968 and SOM 157d cells with HULECs 
resulted in a significant increase in a4 expression by SOM 1968 and SOM 157d cells, when 
compared with control cells (P<O.05). This result was however not reflected for A375. Meanwhile 
culturing each melanoma line with HDMECAs did not result in significant increases in a4 expression 
(p>O.05). The highest increase in expression of a4 after culture with HDMECAs was nevertheless 
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shown after culturing with A375 (from 3.7 ±D.0710 MFI to 4.93 ±D.606 MFI). Figure 6.2.3.b shows 
flow cytometry dot plots and histograms illustrating u4-subunit expression by SOM 1968 when 
cultured alone or after co-culture with HULECs. 
HDMECA HULEC 
SOM 1968 1.18 ±0.172 1.47 +0.0149 
SOM 157d 1.07 ±0.0313 1.13 ±0.0114 
A375 1.34 ±0.185 0.900 +0.105 
Table 6.2.3.a. Mean (± SEM) relative increase in expression of a4 by SOM 1968, SOM 157d 
and A375 after culture with HDMECAs and HULECs, assessed by FACS analysis. Results 
represent the mean of three experiments. A significant increase in a4 expression by SOM 1968 and SOM 
157d cells was shown after culture with HULECs for 24 hours (P<O.05) and this result is highlighted in blue. 
Increases in a4 expression by A375 cells was also seen after co-culture with HDMECAs, but this result was 
not significant, and is highlighted in red . 
Figure 6.2.3.a Relative increase in expression of a4 by SOM 1968, SOM 157d and A375, after 
co-culture with HDMECAs and HULECs, assessed by FACS analysis. The x-axis shows the tumour 
cell type and the y-axis shows the increase in MFI after co-culture, when compared with tumour cells cultured 
alone. Mean (± SEM) relative increase in expression. Results represent the mean of three experiments; the * 
indicates a significant (p<O.05) difference in a4-subunit expression by SOM 1968 and SOM 157d after culture 
with HULECs. 
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Figure 6.2.3.b. Flow cytometry dot plots and histograms illustrating a4-subunit expression by 
SOM 1968 when cultured alone (i) or after co-culture with HULECs (ii). SOM 1968 0.4 expression 
has been increased after cu lture with HULECs. Endothelial cells were labelled with SNARF-1 prior to co-
culturing with SOM 1968 cells for 24 hours and are shown in blue. SOM 1968 cells were selectively 
disaggregated from the endothelial cells and are shown in red. Cells were then stained with avidin-
FITC conjugates and analysed with flow cytometry. Gate G1 refers to cells in the region R1 of the 
dot plot (SOM 1968 cells) and gate G2 refers to cells in the region R2 (HULECs) . 
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Changes to tumour cell integrins and ICAM-1 expression 
The effect on expression of tumour cell adhesion molecules previously assessed was additionally 
investigated after SOM 1968 cells were cultured with HDMECAs (Figure 6.2.3.c). As increased 
ICAM-1 expression by invasive cutaneous melanomas is related to poor prognosis (Johnson et a/., 
1989; Natali et a/., 1997; Johnson, 1999), the invasive uveal melanoma cell line SOM 1968 was 
chosen for study. As SOM 1968 had been previously shown to preferentially adhere to HDMECAs 
(6.2.1), co-culture with these endothelial cells was chosen for investigation. 
After culture with HDMECAs for 24 hours, no significant changes in expression of any of the integrin 
subunits or ICAM-1 were shown when compared with control cells (p>0.05). Of note however, a3 
expression increased by 1.67 ±O.908 MFI, whilst a6 expression decreased proportionally by 0.441 
±O.0212 MFI. 
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Figure 6.2.3.c. Relative increase in expression of mtegrin subunits and ICAM-1 by SOM 196B, 
after co-culture with HDMECAs when compared with expression by cells cultured alone, 
assessed by FACS analysis. Mean (± SEM) relative increase in expression. Results represent the mean 
of three experiments. The x-axis shows the adhesion molecule or subunit and the y-axis shows the increase 
in expression after co-culture. No significant changes in expression were shown (P>O.05). Increased a3 
expression was observed whilst a6 expression was reduced, but these results were not significant (P>O.05). 
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6.3. Discussion 
6.3.1. Adhesion of tumour cells to HDMECAs and HULECs 
Despite evidence presenting alternative mechanisms of arrest and extravasation (AI-Mehdi et al., 
2001), there are still many published reports to suggest that different types of adhesion molecules are 
involved in the site-specificity of adhesive interactions between circulating tumour cells and the target 
endothelium. For uveal melanoma this may be of relevance in liver targeting. To investigate this 
further, interactions of invasive and non-invasive uveal melanoma cells with hepatic and dermal 
endothelial cells were studied. As described in Chapter 5 (5.3.1), invasive characteristics were 
defined upon the behaviour of the selected clones in vitro, which could not necessarily be related to 
the corresponding behaviour in the patient. This had to be taken into consideration when speculating 
conclusions. 
Adhesion levels of prostate carcinoma cells have been shown to differ between primary bone marrow 
endothelium and HUVECs, reflecting preferential binding to the former (Scott et al., 2001). In this 
present study, invasive cell lines (SOM 196B and A375) adhered in greater numbers to both 
endothelial cell types, when compared with the non-invasive cell line (SOM 157d). In support of 
these results, highly metastatic lymphoma cells adhere to endothelial cells in greater numbers than 
their poorly metastatic counterparts (Yun et al., 1997). Uveal melanoma cells did not however show 
a significant preference for HULECs and instead the invasive uveal melanoma cell line, SOM 196B 
preferentially adhered to HOMECAs (Figures 6.2.1.a and b). A direct explanation for this preference 
remains uncertain but did indicate differential attachment to the two-endothelial cell types. 
When observing adhesion, a degree of tumour cell clumping could be seen, and despite attempts to 
overcome this, tumour cells still appeared to bind to one another easily, inferring an inherent 
cohesive property of these cells (analogous to 'piggy backing'). When assays were analysed, cell 
clumping therefore had to be taken into consideration, and could provide an explanation for the 
higher levels of adhesion of SOM 196B to HOME CAs when compared with HULECs. Washing less 
adherent cells from the endothelial layer might have also removed loosely adhered cells and thus 
only tumour cells tightly bound to the endothelial cells would have been assessed. 
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The assay system has additional limitations, primarily as it is static, and therefore cannot be expected 
to reflect all aspects of the continuously changing hydrodynamic conditions in vivo, whilst the input of 
host cells cannot also be assessed. As adhesion molecules involved in tumour-endothelial 
interactions can vary depending upon static or hydrodynamic conditions in vivo (Mogiri at al., 1995; 
Yoshida et al., 1999), using a more sophisticated system under flow conditions would provide a 
closer approximation. 
6.3.2. The effect of TNFa and IL·1 ~ on endothelial adhesion molecule expression 
As described in Chapter 5 (5.1), In the liver, Kupffer cells are one of the major sources of cytokine 
production, including both TNFa. and IL-1J3 (Gangopadhyay et al., 1996). Both of these cytokines up-
regulate endothelial E-selectin, VCAM and ICAM expression, increasing tumour cell adhesion 
(Tamaki et al., 1995; Steinbach at al., 1996; Vidal-Vanaclocha at al., 2000; Minami at al., 2001), 
whilst promoting a.4-expressing B16 melanoma cell metastasis to the lung and liver via a VCAM-1-
mediated process (Garofalo at al., 1995; Vidal-Vanaclocha et al., 1996). Similarly in this present 
study, both TNF-a. and IL-1J3 up-regulated expression of E-selectin, ICAM-1 and VCAM-1, but no 
significant differences in the increases in expression were seen between endothelial cell types 
(Figure 6.2.2.b). 
6.3.3. The effect of culturing with tumour cells and tumour cell eM on adhesion 
molecule expression 
Although direct functions of the endothelial adhesion molecules typically involved in metastasis (E-
selectin, VCAM-1 and ICAM-1) were not assessed with regard to adhesion, the different patterns of 
up-regulation seen after culture with tumour cell types and CM studied, would infer dissimilar 
mechanisms of binding. The levels of up-regulation were however far less than those seen after 
exogenous stimulation with TNFa. and IL-1 J3 (Figures 6.2.2.b and e), suggesting either different 
mechanisms of up-regulation, that tumour cells were releasing factors at lower concentrations, or that 
factors were secreted over a different time scale. When directly comparing results from adhesion 
and flow cytometry experiments, it must also be taken into consideration that adhesion assays were 
performed over a period of four hours, whereas the flow cytometry experiments were carried out over 
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24 hours. To draw more accurate conclusions, it would be necessary to run assays under the same 
experimental parameters. 
Analysis of both endothelial cell types identified differences in the expression of the a4-subunit only, 
which could be of relevance when considering uveal melanoma metastasis to the liver. Similarly, co-
up-regulation of invasive tumour cell (SOM 1968) a4 expression and its ligand VCAM-1 on the 
endothelial cells after culture with hepatic endothelial cells may further imply that this integrin subunit 
is involved in liver targeting (Tables 6.2.2.b and 6.2.3.a and Figures 6.2.2.e and 6.2.3.a and b). In 
support of this premise, a4j31 and a4j37 playa role in tumour cell and lymphocyte trafficking to 
specific sites (Hamann et al., 1994; Matsuura et al., 1996; Holzmann et al., 1998), whilst the VCAM-
1-a4 interaction is involved in liver metastasis of other tumour types including 816 cutaneous 
melanoma cells, lymphoma and myeloma (Papadimitriou et al., 1999; Okada et al., 1999; Vidal-
Vanaclocha et al., 2000; Langley et al., 2001). Furthermore as uveal melanocytes do not express 
a4j31 (Elshaw et al., 2001), whilst uveal melanomas variably express this integrin (3.2.2), it is 
possible that this receptor is involved in malignant progression. As the non-invasive cell line SOM 
157d showed an increase in tumour cell a4 after culture with HULECs, without corresponding 
increases in endothelial VCAM-1, the a4-VCAM-1 interaction might further be required for invasion 
through the endothelium. As up-regulation by SOM 1968 cells was specific to HULECs, with regard 
to endothelial a4-expression, it could be speculated that upon direct cell contact, the VCAM-1-a4 
interaction is required, but is only be stimulated in the absence of endothelial a4 expression. 
Conversely as dermal endothelial cells express a4, by negative feedback, up-regulation of VCAM-1 
by SOM 1968 is not permitted. 
Cutaneous melanomas metastasise to a wider range of organs than uveal melanomas. This could 
be reflected by the observation of similar co-up-regulation of both VCAM-1 and a4, after co-culture of 
A375 with dermal but not hepatic endothelial cells (Tables 6.2.2.b and 6.2.3.a and Figures 6.2.2.e 
and 6.2.3.a). With regard to the possible relevance of endothelial a4 in this process, it is possible 
that HDMECA a4 plays a lesser important role in endothelial VCAM regulation by A375 cells. 
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Comparable increases in hepatic endothelial E-selectin expression after culture with SOM 196B cells 
(Table 6.2.2.a and Figure 6.2.2.e), suggested that this interaction is also being utilised by the invasive 
uveal melanoma cells, possibly increasing attachment. In support, strong evidence exists regarding 
the importance of the E-selectin in colon and breast cancer metastasis {Renkonen et al., 1997; 
Kitayama, et al., 2000; Moss et al., 1999; Moss et al., 2000; Minami et al., 2001} and the colonisation 
of Lewis lung carcinoma cells to the liver (Brodt et al., 1997; Khatib et al., 1999). Incubation with 
SOM 196B CM did not affect the same result, and similar increases were not seen with other co-
culture systems, suggesting that similar to the VCAM-a4 interaction, direct cell contact between SOM 
196B and HULECs was required to influence the apparent up-regulation. As unlike VCAM-1, 
increases in E-selectin were specifically induced by SOM 196B cells, it is possible that this receptor is 
not utilised by SOM 157d or A375 cells in adhesion to the endothelium. Blocking these receptors in 
adhesion assays would provide further information regarding the preCise interactions occurring. 
For the non-invasive uveal melanoma cell line (SOM 157d), increased endothelial ICAM-1 in 
response to potentially soluble tumour-derived factors was most evident {Table 6.2.2.c and Figures 
6.2.2.d and e}. As lack of endothelial ICAM-1 has been associated with increased B16 melanoma 
liver metastasis (Marvin at al., 1998), up-regUlation of endothelial ICAM-1 by SOM 157d cells may 
therefore associate with a less invasive phenotype. As both dermal and liver endothelial cells ware 
affected, the effect was less specific for the individual endothelial cell type. Similar increases were 
not seen with E-selectin and VCAM-1, and it could therefore be speculated that an ICAM-1-mediated 
but not an E-selectin or VCAM-1 interaction may be assisting SOM 157d binding to these endothelial 
cell types. Non-metastatic breast carcinoma cells have been shown to bind to the endothelium using 
an ICAM-1 mechanism whereas metastatic cells utilised E-selectin- and VCAM-mediated interactions 
(Moss at al., 1999; Moss et aI., 2000), supporting results for both SOM 157d and 196B. Such 
interactions for SOM 196B could potentate a stronger adhesive interaction with the endothelium, as 
reflected by adhesion assays (Figures 6.2.1.a and b). 
Conflicting evidence exists regarding uveal melanoma ICAM-1 expression (Natali at al .• 1997; Lawry 
at al" 1999). but a recent report has correlated loss of tumour ceIiICAM-1 expression with increased 
risk of metastasis within the first five years (Anastassiou at al .• 20oob). In this present study. A375 
cells expressed high levels of ICAM-1, whilst both uveal melanoma cell types did not. As detailed 
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previously in Chapters 4 and 5 (4.3 and 5.3.1), patient SOM 157d died of metastatic disease, 
whereas patient SOM 1968 is alive to date, and thus expression of ICAM-1 represents an example 
whereby responses seen in vitro, are not fully representative of the tumour in vivo. Adhesion to the 
endothelium nevertheless only represents one stage of the metastatic process. Therefore with 
regard to SOM 1968, despite cells being adept at adhering to the endothelium, tumour cells may not 
be effective at completing all other processes of the metastatic cascade (as reflected by the 
inefficiency of these cells at traversing the endothelium, as presented in Chapter 4 (4.3)). 
Previous evidence for uveal melanoma has reported a potential association between expression of 
a6~1 and poor prognosis (Rohrbach et al., 1994; Elshaw et a/., 2001), but this could not be 
supported by results from Chapter 3 (3.3.2.1). Although data was not significant, a decrease in a6 
expression by SOM 1968 cells after culture with dermal endothelial cells (Figure 6.2.3.c) could 
therefore relate to the lack of secondary disease currently seen in this patient. Stimulated decreases 
in tumour a6 expression by dermal endothelial cells could therefore inhibit uveal melanoma 
extravasation at dermal sites. From study of only one culture system, it is however not possible to 
draw reliable conclusions. 
Alternative endothelial adhesion molecules should also be considered for uveal melanoma adhesion 
to the endothelium. For example uveal melanoma cell lines express CD44 (Creyghton et al., 1995), 
and expression by colon cancer cells plays a pivotal role in increasing adhesion to endothelium and 
transendothelial cell migration (Fujisaki et al., 1999). In cutaneous melanoma, expression of N-
cadherin has also been shown to assist adhesion to the endothelium, whilst similarly being involved 
in transendothelial migration (Sandig et al., 1997; Voura et aI., 1998b; Li et al., 2001). Adhesion is 
therefore likely to utilise a far greater range of adhesion molecules than those studied in this 
investigation. 
In summary, invasive and non-invasive uveal melanoma cells varied in their levels of adhesion to the 
endothelium, but no preference for hepatic endothelial cells was shown. The different patterns of 
adhesion molecule up-regulation after co-culture would further suggest that different systems are 
involved in adhesion of these tumour cell types to the endothelial cells studied, which could be 
implicated in site-specific metastasis. As cell lines have been used in this study, the use of STCs 
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may provide a closer approximation to interactions occurring in vivo, allowing potential correlation 
with clinical details. Due to time constraints and a lack of sufficient cell numbers, this could not be 
undertaken at this stage. 
-140 -
Chapter 7: Final discussion and conclusions Julia Woodward 
Chapter 7 
Final Discussion and Conclusions 
7.1. Uveal melanoma and liver targeting 142 
- 141 -
Chapter 7: Final discussion and conclusions Julia Woodward 
7.1. Uveal melanoma and liver targeting 
Figure 7.1.a illustrates the processes studied by this investigation, and summarises brief conclusions 
made. 
An efficient method for culturing primary uveal melanomas has been established within the Academic 
Unit of Ophthalmology and Orthoptics, and as such allowed analysis of a wide range of primary 
tumours with potentially different metastatic properties. As all of the primary tumours studied were 
obtained by surgical means, they were of necessity, a biased sample, as their large size precluded 
the use of more conservative treatments. On this basis, all tumours could be classified as having a 
poor prognosis. Since most tumours were only recently resected, in the majority of cases 
metastases have, as yet not been detected. It therefore remained unclear whether cells from these 
primary tumours would remain confined within the boundaries of the eye (Le. behave as relatively 
benign tumours, similar to iris melanomas), or invade into the circulation, potentially metastasising to 
a secondary tissue. Iris involvement was however limited to one tumour alone, and thus the samples 
studied were further prejudiced towards tumours originating either in the choroid or ciliary body. 
Although cell lines alone were investigated for most aspects of these studies, by assessing STCs and 
relating patterns of expression and responses to histo-pathological data, the results suggest that 
certain observations are valid. 
For five of the patients of the studied (SOM 157d, 250, 255, 262, and 272) hepatic metastases had 
been detected, suggesting that cells had disseminated rapidly and successfully established 
secondary foci. Factors associated with these cells may therefore have been associated with a 
poorer prognosis, allowing certain conclusions to be drawn relating to the metastatic phenotype. 
Consistent with classic prognostic indicators, these tumours were all considerably larger than other 
tumours studied, and were more likely to have ciliary body involvement and characteristic 
chromosomal abnormalities, and an epithelioid or mixed morphology; all factors associated with a 
worse prognosis. 
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Chapter 3 
The ability of tumour cells to invade through the ECM is 
important in metastasis, and required at both the primary 
and secondary sites. For tumours to accomplish this, a 
number of adhesive and degradative interactions are 
undertaken. Results from this study demonstrate that 
uveal melanomas ubiquitously express some integrins 
and degradative enzymes associated with these 
processes, whilst for others (a1, a2, a4, and ( 6). 
expression is more variable, potentially affected by in 
vitro stimulation. 
Primary 
site 
Chapter 5 
Once in the 
circulation, tumour 
cells are 
transported to the 
target site. For 
some tumours this 
may be the first 
vascular bed 
encountered , 
whilst others show 
some site-
specificity. 
Results have 
indicated that 
factors secreted 
by cells derived 
from hepatocytes 
and the hepatic 
endothelium 
stimulate invasion, 
whilst invasion 
may be inhibited 
by cells derived 
from the lung, but 
the effect is 
dependent upon 
the individual 
tumour. 
Julia Woodward 
Chapter 4 
Once invaded through the ECM and BM, tumour cells 
must migrate through the endothelium into the 
circulation. Many in vitro studies of invasion have 
employed models assessing invasion through the BM 
alone. In this present study, a model of 
transendothelial migration was established, and 
results showed that for uveal melanoma, invasion 
seemed to correlate with a wider range of prognostic 
indicators than through the BM alone. 
Chapter 6 
At the target site, tumour 
cells must attach to the 
endothelium. Adhesion 
molecules expressed by 
the endothelial and tumour 
cells may further 
determine the site of 
arrest. Hepatic endothelial 
cells in this study differed 
from dermal endothelial 
cells in their expression of 
a4 alone and differences 
in levels of adhesion 
between invasive and non-
invasive cells were seen. 
Invasive tumour cell lines, 
lacked ICAM-1, and co-
cultures stimulated 
increases in hepatic 
endothelial ICAM-1, 
VCAM-1 , and E-selectin, 
and tumour a4, and this 
may have been regulated 
by an absence of 
endothelial a4 expression. 
Non-invasive cell lines 
lacked expression of 
ICAM-1 and co-cultures 
stimulated increases in 
endotheliallCAM-1 only. 
Secondary 
site 
Figure 7.1.a. Diagrammatic representation of the metastatic cascade, identifying the 
processes studi.ed in this investiga~ion and brief conclus.ions drawn (adapted from 
Introduction A Figure 1.a). Representative normal cells are shown In and the light blue areas 
represent surrounding tissue. Metastatic tumour cells are shown in , the basement membrane is shown in 
green, and the endothelium is shown in . 
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From this present study, those aspects potentially associated with more advanced malignancies may 
therefore hold true for these cases. For example, with regard to adhesion molecule expression, 
results from previous investigations have associated a6 expression, involved in laminin binding {and 
hence primarily basement membrane adhesion} with the invasive epithelioid phenotype and worse 
prognosis {Rohrbach et al., 1994; Elshaw et al., 2001}. In support of these observations, SOM 157d, 
250 and 255 all expressed this integrin, and correspondingly were more likely to be of an epithelioid 
cell type. In addition, these tumours also expressed the a4 integrin subunit, known to be involved 
with liver metastasis of a number of other tumour types {Papadimitriou et al., 1999; Okada at al., 
1999; Vidal-Vanaclocha et al., 2000; Langley at al., 2001}. Conclusions drawn from this present 
study have similarly speculated that expression of a4 by uveal melanoma cells {in conjunction with 
increases hepatic endothelial VCAM-1 expression} could be involved in liver targeting, and as these 
tumours have disseminated to the liver, it is possible that these tumours reflect this. Of the 
metastatic tumours, ICAM-1 expression, also previously associated with poor prognosis 
{Anasatassiou et al., 2000b}, was additionally investigated for SOM 157d, and in support of published 
data, this tumour lacked expression of this receptor. 
Once migrated through the ECM and basement membrane, the ability to traverse the endothelium is 
a further important aspect of metastasis. Of those tumours known to have already metastasised, 
transendothelial invasion was only assessed for SOM 262 and SOM 272 (Figure 4.2.2.a). Although 
SOM 262 invaded well through basement membrane barriers alone, levels were significantly reduced 
by the inclusion of an endothelial layer to the assay. Conversely, despite SOM 272 behaving 
relatively non-invasively through both the basement membrane only and transendothelial invasion 
assays, it is however of interest, that a high proportion of these cells were able to overcome the 
additional endothelial barrier. As such, these cells which possess the ability to invade through both 
the basement membrane and endothelium might reflect the invasive population of cells, which in vivo 
have the ability to traverse the endothelium, potentially validating the model's use. 
In contrast to those patients known to have developed secondary disease, for the majority of patients 
studied, metastases had however as yet not been detected. It is feasible that a number of these 
tumours will remain benign and never invade from the primary site. Contrary to those properties 
associated with a poor prognosis, an absence of such factors would therefore correlate with a better 
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prognosis. For example, with regard to adhesion molecules, if expression of a4 and a6 is be 
involved in liver metastasis and poor prognosis, conversely, lack of expression may be correlated 
with a better prognosis. Consistent with this hypothesis, SOM 239 lacked expression of both of these 
subunits, and originated in the choroid, a location associated with a better prognosis (Table 3.2.2.a). 
In the remaining eight of these nine cases studied for adhesion molecule expression, in which 
metastases were absent, expression of the a4 and a6 subunits was observed. Fo"owing the 
theories regarding association of a4 and a6 expression with secondary disease and poor prognosis, 
such tumours could therefore ultimately have the propensity to metastasise. As uveal melanomas 
have been detected up to 42 years after initial diagnosis (Egan et al., 1988), and due to the time 
scale of this investigation, it seems possible that cells from these tumours could have already 
disseminated but as yet secondary metastatic growth has not been stimulated. No correlation could 
however be made between expression of a4 and a6 by these tumours and known prognostic 
indicators to support this proposal. 
A further selection of these tumours were analysed for their ability to overcome the basement 
membrane and endothelium. Those tumours more likely to metastasise would therefore, by 
necessity, be required to overcome both of these barriers. In support of this, those tumours that were 
more proficient at invading through both basement membrane and endothelial cell barriers were on 
average more likely to be larger tumours with mixed cell morphology and ciliary body involvement 
(factors a" associated with poor prognosis) (SOM 280, 290 and 296) (Figure 4.2.2.a). Similarly 
tumours that were less efficient at overcoming both of these barriers were in general of choroidal 
origin, a factor linked with better prognosis (SOM 1968, 262, 275, 277, 281, 301, and 306). In further 
support, SOM 1968, the only tumour resected over four years ago, has as yet not developed 
metastases. This tumour invaded we" through basement membrane barriers alone, yet was poorly 
invasive through the transendothelial cell assay. Similar to metastatic SOM 272, the behaviour of 
SOM 1968 in this model could therefore confirms its use, identifying those tumours more likely to 
disseminate. 
The inclusion of an endothelial layer in the invasion assay nevertheless reduced invasion for most 
tumours studied (Figure 4.2.2.a). It is therefore plausible that uveal melanomas are in general, 
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relatively inefficient at crossing the endothelium. In support of this speculation, detection of low levels 
of uveal melanocytes and melanoma cells in the circulation has been reported (Tobal et al., 1993; 
Foss et al., 1995; Hanekom et al., 1999). Authors however concluded that the presence of circulating 
cells is not a predictive indicator of metastatic disease, and leads to the possibility that although 
tumours cells are circulated around the body, metastatic disease might not be a consequence. In 
agreement with this, micrometastatic uveal melanoma cells have been detected in the bone marrow 
of 33.9% of patients (Eide et al., unpublished data), yet metastases rarely grow at this site. 
The two theories of metastasis may therefore each be partially correct for uveal melanoma. 
Following the mechanical entrapment theory, uveal melanoma cells could therefore circulate widely, 
becoming physically trapped at a variety of sites. Once lodged in capillaries, cells may consequently 
grow to a minimal size, or alternatively reside at certain locations until they die. The work by Eide at 
a/., (1999) would further support this hypothesis, as micrometastases may develop in locations such 
as the bone marrow, but without an angiogenic stimulus, cells would remain dormant. Metastatic 
progression at sites such as the liver would therefore only be a consequence once the balance 
between angiogenic inhibitors and stimulators, favours promotion of the latter, ultimately stimulating 
secondary growth. Successful metastatic development subsequently only results due to specific 
properties of both the tumour and microenvironment of the liver, promoting secondary disease, 
essentially following Paget's theory also (Paget, 1889). In further support of this, expression of the 
receptors for HGF, EGF, and IGF-I have all been previously associated with liver targeting and 
metastasis of uveal melanoma (Hendrix at al., 1998a and b; Ma and Niederkorn, 1998; Ericsson at 
al., 2002). A combination of factors produced by hepatic and inflammatory cells and a possible lack 
of angiogeniC inhibitors would therefore assist in creating the favourable environment required to 
promote metastatic growth. 
In this present study, most tumours studied responded Significantly to factors secreted by cells 
derived from hepatocytes (Figure 5.2.1.a), but no direct association with known prognostic indicators 
could be made. Conversely, invasion of one of these tumours (SOM 277), whilst being attracted by 
hepatic cells, was in contrast, inhibited by cells of pulmonary origin, further supporting an argument 
for attraction to the liver, in preference to other organs. It is of interest however, that one tumour 
(SOM 269) did not react positively to factors secreted by the HepG2 cells. This tumour was 
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considerably larger than most studied, and was also of ciliary body origin, and as such associated 
with a worse prognosis. It could therefore be speculated that this tumour instead is capable of 
autocrine regulation, not necessarily requiring the same degree of support from other cell types for 
survival. In support of this hypothesis, SOM 1968 also responded significantly to factors secreted by 
the same cell type (Figure 5.2.2.a), inferring that these cells have the propensity to produce a number 
of autocrine factors. 
In contrast to cells derived from the lung, keratinocytes and fibroblasts were however also seen to 
stimulate invasion of SOM 1968 (Figure 5.2.2.a), supporting theories suggesting that uveal 
melanoma cells circulate widely. It is nevertheless likely that sites elsewhere do not provide the ideal 
'soil' requirements to promote metastatic growth. Consistent with this argument, after culture of SOM 
1968 cells with dermal or hepatic endothelial cells, notable changes in adhesion molecule expression 
only resulted after interactions between tumour and hepatic endothelial cells (Figures 6.2.2.e and 
6.2.3.a and b, and Tables 6.2.2.a-c and 6.2.3.a). Dermal endothelial cells further expressed a4, 
whilst co-culture with uveal melanoma cells did not up-regulate tumour a4 expression. As it has 
been hypothesised from this study that a4 expression is involved with liver targeting, it is feasible that 
such patterns may therefore not promote arrest at dermal sites. In addition, dermal endothelial cells 
were observed to down-regulate SOM 1968 a6 expression, which following association of a6 
expression with poor prognosis (Rohrbach et al., 1994; Elshaw et al., 2001) could aid in preventing 
attachment and extravasation. As a consequence, despite attraction to other organs, successful 
adhesion to the endothelium would potentially only be initiated at the liver. Investigation of the 
regulation of tumour a6 expression by hepatic endothelial cells will provide additional information 
regarding the importance of this observation. 
In most instances, metastatic disease may therefore only result if Circulating uveal melanoma cells 
arrest in the hepatic vasculature, successfully extravasate, and ultimately are promoted to develop 
into secondary metastases. In reflection of this, invasive SOM 1968 cells adhered to endothelial 
cells in significantly higher levels than non-invasive SOM 157d cells (Figures 6.2.1.a and b). Hepatic 
endothelial cells correspondingly also attracted SOM 1968 cells in invasion assays (Figure 5.2.2.a). 
In contrast to dermal endothelial cells, hepatic endothelial cells (lacking a4 expression), up-regulated 
invasive SOM 1968 a4 expression. This factor might be particularly important in view of the fact that 
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the ligand for a4, VCAM-1 was shown to be up-regulated concurrently. 8y extrapolation, this may 
suggest that increased tumour a4 was directly related to increased endothelial VCAM, ultimately 
effecting increases in adhesion. In addition, as these uveal melanoma cells also stimulated an 
increase in hepatic endothelial E-selectin expression, it seems feasible that this receptor was utilised 
in the adhesive interaction. Such patterns were not a consequence after culture of the non-invasive 
cell line SOM 157d with either endothelial cell type, and could in part infer that different interactions 
were being utilised for adhesion. 
Although this aspect only assessed changes in response to two uveal melanoma cultures, it could be 
hypothesised that as, in particular the VCAM-1-a4 interaction has been associated with liver 
metastases of a number of other tumour types (Papadimitriou et al., 1999; Okada et al., 1999; Vidal-
Vanaclocha et al., 2000; Langley et al., 2001), this interaction is primarily implicated in hepatic 
metastases of uveal melanoma also. This may further be regulated by an absence of endothelial a4 
expression, whilst an E-selectin-mediated process might further strengthen this interaction. As 
endothelial ICAM-1 was up-regulated by both invasive and non-invasive cells, the involvement of this 
receptor might be less relevant with regard to the invasive phenotype. As however loss of ICAM-1 by 
uveal melanoma cells has been associated with poor prognosis (Anasatassiou et al., 2000b), and 
due to a similar lack of expression by the uveal melanoma cells studied, a combination of all of these 
factors would ultimately be required for determining adhesion to the hepatic endothelium. To further 
confirm these speculations, it would be necessary to expand the study to a wider range of uveal 
melanoma cultures, whilst in light of the apparent differences in endothelial a4 expression, analysis 
of expression of ligands for this subunit by the uveal melanoma cultures studied will elicit further 
information regarding the precise involvement in adhesion to the endothelium. Additional study 
should also focus of the factors potentially regulating changes in expression of these adhesion 
molecules. Aspects of this work however also focused on SOM 1968 cells. In culture these cells 
behaved invasively, whilst in vivo, metastases have yet to be detected. The observations in vitro 
therefore reflect an invasive capacity, but as metastatic disease has not yet been observed, the 
behaviour in vivo, may ultimately relate more closely to the poor ability of the cells at traversing the 
endothelium. More accurate conclusions could therefore be drawn through study of a highly invasive 
and metastatic uveal melanoma. It is still nevertheless possible that SOM 1968 cells in vivo will 
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eventually successfully metastasise, and thus close observation of this patient is required to elicit 
more long-term conclusions. 
In conclusion, if we are to consider the two theories of metastatic spread (,mechanical dissemination' 
and the 'seed and soil' hypothesis), the work of this current investigation has in some way, clarified 
aspects of the particular targeting of the liver by uveal melanomas. Despite physical entrapment of 
circulating uveal melanoma cells in the liver assisting metastasis, ultimately more specific 'seed and 
soil' factors, may playa more vital role. Factors determined by both the hepatic vasculature and 
microenvironment, together with the properties of the tumour cells themselves, might thus facilitate 
the ultimate fate of the malignancy. Only tumour cells expressing the required phenotype may 
eventually accomplish all of the necessary processes required to establish secondary growth. The 
investigation has nevertheless only examined a certain number of processes involved in metastasis 
for a limited number of tumours. In particular, although cells have been shown to traverse the hepatic 
endothelium, it is still ultimately unknown as to whether these cells may survive and proliferate in the 
hepatic tissue. To build a more complete picture of the process in its entirety, further research into 
factors promoting metastatic development for a wider range of uveal melanomas, is therefore 
imperative in conjunction with on-going cytogenetic analysis. 
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Appendix I 
Names and Addresses of Suppliers 
Anachem Limited, 
Anachem House, 20 Charles Street, Luton, Bedfordshire, LU2 OEB. 
Ansell Medical, 
Ansell House, 119 Ewell Road, Surbiton, Surrey, KT66AY. 
Antec International Limited, 
Windham Road, Sudbury, Suffolk. 
Beckton Dickenson (BD), 
Between Towers Road, Cowley, Oxford, OX43LY. 
Bibby Sterilin Limited, 
Tilling Drive, Stone, Staffordshire, ST15 OSA. 
Boots Company PLC, 
Nottingham. 
British Oxygen Company (SOC), 
10 Priestly Road, Guildford, Surrey. 
Chemicon International, Limited, 
2 Admirals House, Cardinal Way, Harrow, HA3 5UT. 
Corning Incorporated, 
HP-AB-03, Corning, NY 14831, USA. 
Costar (UK) Limited, 
10 The Valley Centre, Gordon Road, High Wycombe, Buckinghamshire, HP13 6EQ. 
DAKO Limited, 
Denmark House, Angel Drive, Ely, Cambridgeshire, CB74ET. 
Denley, 
Stevenage, London 
ECACC, 
Julia Woodward 
Division of Biologies, Centre for Applied Microbiology and Research, Parton Down, Salisbury, 
Wiltshire, SP4 OJG. 
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Gelman Sciences! Walker Limited, 
Brackmills Business Park, Caswell Road, Northamptonshire, NN4 7EZ. 
Genetic Research Instrumentation, 
Gene House, Dunmow Road, Felsted, Dunmow, Essex, CM6 3LD. 
Grant Instruments (Cambridge) Limited, 
Cambridge, CB2 5QZ. 
Helena Biosciences, 
Julia Woodward 
Colima Avenue, Sunderland Enterprise Pari, High Wycombe, Buckinghamshire, HP13 7DL. 
Heraeus Equipment Limited, 
Unit 9, Wates Way, Brentwood, Essex, CM15 9TB. 
Invitrogen (formerly Life Technologies), 
3 Fountain Drive, Inchinnan Business Park, Paisley, PA 4 9RF. 
Merck/SOH, 
Merck House, Poole, Dorset, BH151TD. 
Millipore UK Limited, 
The Boulevard, Blackmore Lane, Watford, Hertfordshire, WD1 BTW. 
Molecular Probes Europe, 
Cambridge BioScience, 24-25 Signet Court, Newmarket Road, Cambridge, CS5 8LA. 
Nalge Nunc Company, 
Rochester, NY-14602-0365, USA. 
Nalgene, 
75 Panorama Creek Drive, PO Box 20365m, Rochester, New York, 14602-0365, USA. 
Novocastra Laboratories, 
Balliol Business Park West, Benton Lane, Newcastle upon Tyne, NE12 SEW. 
Olympus Optical Company Limited, 
2-8 Honduras Street, London, EC17 OTX. 
Purite Limited, 
Bandet Way, Thame, Oxon, OX9 3SJ. 
R&D Systems Europe Limited, 
4-10 The Quadrant, Barton Lane, Abingdon, Oxon, OX14 3YS. 
Sanyo, 
Sanyo Scientific, 600 Suprime Drive, Bensenville, IL 60106, USA. 
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Scientific Laboratory Supplies limited (SLS), 
Wilford Industrial Estate, Nottingham, NG11 7eP. 
Scotsman Ice Systems limited, 
20010 Bettolino di Pogliano, Milan, Italy. 
Seratec limited, 
22 Bankside, Station Approach, Kidlington, Oxford, OX5 1JE. 
Sigma-Aldrich Company limited, 
Fancy Road, Poole, Dorset, BH12 4QH. 
Starstedt limited, 
68 Bosteon Road, Beaumont Leys, Leicester, LE41AW. 
Swann Morton Limited, 
Owlerton Green, Sheffield, S6 2BJ. 
T MB Laboratories Equipment limited, 
Aldermaston, Berks, RG7 8NA. 
TCS CeliWorks Limited, 
Botolph Claydon, Buckingham, MK18 2LR. 
Unipath Limited, 
Wade Road, Basigstoke, Hants, RG24 OPW. 
Vector Laboratories Limited, 
Peterborough. 
Vernon carus, 
Preston, Lanes. 
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Appendix II 
Histo-pathological details of patients treated for posterior uveal melanoma by 
enucleation. (Volume = 7tl6 x length x height x width) 
Short-term Age Sex Location Metastatic Volumel Cell type Status 
culture disease mm3 
(STC) 
S.O.M 157d 73 M Choroid Yes 3647 E~thelioid Dead 
S.O.M. 80 M Choroid No 885 Mixed Alive 
1966 
S.O.M.200 42 M Choroid No 922 Mixed Alive 
S.O.M.210 64 M Ciliary Body No 974 Mixed Alive 
S.O.M.238 23 F Choroid No 754 ~indle Alive 
S.O.M.239 44 F Choroid No 1016 Mixed Alive 
S.O.M.248 78 M Ciliary Body No 1705 Mixed Alive 
S.O.M.250 61 F Choroid Yes 2205 Mixed Dead (liver 
metastases) 
(26-5-00) 
S.O.M.253 51 M Ciliary No 847 Spindle B Alive 
Body/ 
Choroid 
S.O.M.255 63 F Ciliary Yes 1138 Spindle B Terminally ill 
Body/ (liver 
Choroid metastases) 
S.O.M.256 80 F Choroid No 481 Spindle B Alive 
S.O.M.260 58 F Choroid - - Spindle A Alive 
and 6 
S.O.M.262 73 M Choroid Yes Too large Mixed (50% Alive 
to scale epithelioid) 
S.O.M.263 71 M Choroid No 725 Mixed Alive 
S.O.M.266 62 F Choroid No - Spindle 6 Alive 
S.O.M.267 50 F Choroid No 1395 Spindle Alive 
S.O.M.269 72 M Ciliary Body No 2273 S~ndleB Alive 
S.O.M.272 71 F Choroid Yes 1795 Spindle 8 Alive 
S.O.M.273 70 F (Iris) Ciliary No - Mixed (50% Alive 
Body epithelioid) 
S.O.M.274 82 F Choroid - 511 Spindle Alive 
S.O.M.275 71 M Choroid No 1070 ~ndleB Alive 
S.O.M.277 74 M Choroid No 1476 
-
Alive 
S.O.M.279 72 M Choroid No 1263 Spindle 6 Alive 
S.O.M.280 85 M Choroid No 2621 Mixed Alive 
S.O.M.281 54 M Choroid No 1273 ~ndleB Alive 
S.O.M.282 64 M Cili~Bod1 No 1141 Mixed Alive 
S.O.M.286 79 F Choroid! No 677 Spindle 8 Dead 
Ciliary Body (unknown 
cause) 
S.O.M.288 59 M Choroid! No 1158 Mixed Alive 
Ciliary Body 
S.O.M.289 88 F Choroid No 1477 Mixed Alive 
S.O.M.290 53 M Choroid No 754 Mixed Alive 
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S.O.M.295 13 F Choroidl No Too large Spindle B Alive 
Ciliary Body to scale 
S.O.M.296 55 M Ciliary Body No 1270 Mixed Alive 
S.O.M.301 28 M Choroid No 1829 Spindle B Alive 
S.O.M.302 66 M Choroid - 272 Mixed Alive 
S.O.M.304 70 M Choroid - 171 Spindle B Alive (lung 
primary 
tumour also) 
S.O.M.305 67 M Ciliary Body No 1166 SpindleB Alive 
S.0.M.306 81 M Choroid No 730 Mixed (10% Alive 
epithelioid) 
S.O.M 307 65 M Choroid No 764 Spindle B Alive 
S.O.M.308 72 M Choroid - - SpindleB Alive 
S.O.M.311 60 F Ciliary Body - - Spindle A Alive 
and B 
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